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The introduction of automation in carbohydrate synthesis has paved the way towards 
getting faster access to complex, immunologically relevant glycans. Automated 
assembly enables the synthesis of oligomers and polymers (as long as 50 mers) to be 
accomplished in weeks, compared to months or even years when performed via 
conventional solution phase synthesis. However, the optimization of the entire process 
still lies in its infancy, and standard protocols for the automated synthesis of 
oligosaccharides are not yet available. The work in this thesis aims to develop 
optimized protocols for the automated assembly of complex glycans using the 
Glyconeer synthesizer, which was accomplished by firstly, optimizing the synthesis of 
building blocks. Since building block synthesis is very often the most laborious and 
time consuming step in the entire process of automation, ready availability of standard 
protocols for procuring multi-gram quantities of these monomers further reduces the 
time required to synthesize complex glycans via automated synthesis.  
Thereafter, with multi-gram quantities of building blocks in hand, the automated 
synthesis of glycans using the Glyconeer synthesizer were streamlined. Optimized 
protocols for automated glycan assembly of complex glycans were established by 
streamlining the variables associated with the glycosylation reaction, namely, 
temperature, number of glycosylation cycles and concentration of donor (in this case 
building blocks). Therefore, the AGA of Lewisx epitope was optimized to establish 
optimal glycosylation conditions for the building blocks (Chapter 3) on a 0.0125 mmol 
scale. With these optimized protocols, the synthesis was then scaled up to a 0.025 
mmol scale to procure milligram quantities of the Lex epitope.  
Secondly, in order to establish the reproducibility of these protocols, the optimized 
synthetic protocols were applied to procure a library of Lewis antigens, namely, Lewisa, 
Lewisy and Lewisb antigens (Chapter 4). The successful synthesis of these antigens 
further confirmed the reproducibility of the established synthetic protocols. Thereafter, 
these synthetic protocols were then validated for synthesizing longer structures, which 
was achieved by synthesizing a library of poly-N-acetyl glucosamine oligomers, such 
as, tetramer, pentamer and hexamer (Chapter 5). The oligomers synthesized were 
then used to determine the substrate specificity of the glucosamine hydrolase from 
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Pseudomonas aeruginosa. Finally, the boundaries of AGA were further pushed by 
synthesizing one of the most difficult linkage, namely, the beta mannose linkage via 
automation (Chapter 6), which makes the synthesis of complex N-glycans possible by 
automated synthesis.  
In a nutshell, the work performed in this thesis aims to overcome the challenge of 
gaining quick access to pure oligosaccharides by establishing standard protocols for 
synthesizing immunologically relevant glycans via automated glycan assembly, 




























Die Einführung von automatisierten Prozessen in die Kohlenhydratsynthese hat den 
Weg für einen schnelleren Zugang zu komplexen, immunologisch relevanten 
Glykanen geebnet. Automatisierte Festphasensynthese (automated glycan assembly, 
AGA) ermöglicht die Synthese von Oligo- und Polymeren (bis zu einer Länge von 50 
Zuckerbausteinen) innerhalb weniger Wochen, während die entsprechenden 
konventionellen Flüssigphasen-Synthesen Monate oder sogar Jahre in Anspruch 
nehmen. Jedoch steckt die Optimierung des gesamten Prozesses noch in den 
Kinderschuhen und es gibt keine standardisierten Protokolle für die automatisierte 
Synthese von Oligosacchariden. Das Ziel dieser Arbeit ist es, optimierte Protokolle für 
die automatisierte Festphasensynthese komplexer Glykane unter Benutzung des 
Glyconeers zu entwickeln. Der erste Schritt dahin war die Optimierung der Baustein-
Synthesen. Da die Synthese der Bausteine meist der arbeitsintensivste und 
zeitbestimmende Schritt während der gesamten Automation ist, ist das 
Vorhandensein von Standardprotokollen für die Herstellung von mehreren Gramm 
dieser Monomere entscheidend, um den Zeitaufwand für die Synthese komplexer 
Glykane mittels automatisierter Festphasensynthese weiter zu reduzieren.  
Mit mehreren Gramm der Bausteine in der Hand, wurde nun die automatisierte 
Festphasensynthese der Glykane mittels Glyconeer optimiert. Durch die 
Rationalisierung aller Variablen, die während der Glykosylierung eine Rolle spielen, 
namentlich Temperatur, Anzahl der Glykosylierungszyklen und Konzentration des 
Donors (in diesem Fall der Bausteine), wurden optimierte Protokolle für die 
automatisierte Festphasensynthese komplexer Glykane entwickelt. Für das Lewisx-
Epitop wurden optimale Glykosylierungsbedingungen für die einzelnen Bausteine bei 
einer Ansatzgröße von 0.0125 mmol ermittelt (Kapitel 3). Mithilfe dieser optimierten 
Protokolle wurde die Synthese dann in einer Ansatzgröße von 0.025 mmol 
durchgeführt, um mehrere Milligramm Lewisx-Epitop zu produzieren.  
Im nächsten Schritt, um die Reproduzierbarkeit dieser Ergebnisse zu zeigen, wurde 
unter Anwendung der optimierten synthetischen Protokolle eine Reihe von Lewis-
Antigenen dargestellt, darunter Lewisa, Lewisy und Lewisb (Kapitel 4). Die erfolgreiche 
Synthese dieser Antigene belegt weiter die Reproduzierbarkeit der entwickelten 
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Synthese-Protokolle. Darauffolgend wurden die Protokolle für die Synthese längerer 
Strukturen validiert, was durch die Darstellung mehrerer poly-N-acetyl-glucosamin-
Oligomere, namentlich einem Tetramer, einem Pentamer und einem Hexamer, erfolgt 
ist. The synthetischen Oligemere wurden dann eingesetzt, um die Substrat-Spezifität 
der Glucosamin-Hydrolase aus Pseudomonas aeruginosa zu bestimmen. Durch die 
Darstellung einer synthetisch sehr komplexen beta-Mannose-Verbindung mittels 
Automation (Kapitel 6), wurden die Anwendungsmöglichkeiten des AGA noch einmal 
erweitert und die Synthese von komplexen N-Glykanen in der Automation ermöglicht.  
Zusammenfassend ist das Ziel der vorgelegten Arbeit, das Problem des schnellen 
Zugangs zu reinen Oligosacchariden durch die Einführung von standardisierten 
Protokollen für die Synthese von immunlogisch-relevanten Glykanen via AGA zu lösen 
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Automation in carbohydrate synthesis: Developments 
made so far 
 
1.1   Brief account of developments made in carbohydrate 
chemistry 
Carbohydrates are one of the most diverse and abundant biomolecules on earth. They 
play important roles in various biological processes, such as cell growth, facilitating 
joint lubrication, inflammatory and immune responses.8 Decades of research has also 
revealed the involvement of carbohydrates in pathogen-host interactions. The 
pathogenesis of diabetes, septicemia, cancer, pneumonia, malaria, AIDS, and 
hepatitis are all mediated by carbohydrates.8  Therefore, understanding the role of 
carbohydrates in these processes has prompted the investigation of carbohydrate 
composition, conformation, and their interaction with other molecules and with 
themselves. Although, isolation of carbohydrates from natural sources is a plausible 
approach for providing samples for the biological testing of these molecules, it is 
chemical synthesis that allows access to both natural carbohydrates and their 
mimetics, which are often of interest because of their therapeutic and diagnostic 
potential.8 
A majority of complex sugars are oligomers in which the monomer units are connected 
via glycosidic linkages. These linkages are obtained by glycosylation, a reaction of the 
nucleophilic displacement of an anomeric leaving group (LG) on the glycosyl donor by 
a hydroxyl group of the glycosyl acceptor. The remaining groups on the donor and 
acceptor are modified with different functional groups in order to minimize the 
formation of by-products. A general outline of the chemical glycosylation reaction is 








The earliest reactions performed by Michael, Fischer and Koenigs and Knorr at the 
turn of the twentieth century showed the complexity of glycosylation reaction.6 At this 
stage, the glycosylation of sugar acceptors was quite inefficient and the synthesis of 
even a disaccharide was extremely challenging.  
 
 
Scheme 1: General outline of the chemical glycosylation reaction31 
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The improvements thereon led to the expansion of leaving groups beyond the halides, 
and hemiacetals. Thus, in the 1970’s to early 1980’s, new classes of glycosyl donors 
were introduced, namely, thioglycosides, O-imidates, thioimidates and glycosyl 
fluorides.31 The list of new leaving groups grew further in the late 1980’s, with the 
introduction of glycosyl carbonates, thiocyanates, glycals, sulfoxides, and heteroaryl 
glycosides. Apart from studying the anomeric leaving groups, protecting group effects 
were also investigated. The crucial findings of Lemeiux and Fletcher led to the 
recognition that the stereoselectivity of glycosylation is directly correlated to the nature 
of protecting groups, especially at the neighbouring C2 position.9,31 For instance, 2-O-
acyl substituents typically lead to the formation of 1,2-trans glycosidic linkages, albeit 
with the formation of 1,2-cis glycosides or 1,2-orthoesters as by-products. Demchenko 
and co-workers introduced donors equipped with a 2-O-picolinyl ether participating 
group that ensures complete 1,2-trans stereoselectivity. The presence of a non-
participating group at C2 such as benzyl ether is necessary for the synthesis of 1,2-
cis glycosides. In order to achieve more stereocontrol for the formation of cis 
glycosides, Boon et.al. introduced chiral auxiliaries capable of producing trans-decalin 
like intermediates, promoting “opposite face of the ring” type participation, thereby 
enabling higher 1,2-cis stereoselectivity.9 The work of Crich et. al. on the synthesis of 
β-mannosides explored the deactivating and stereodirecting effect of 4,6-O-
benzylidene substituent on the stereoselectivity of glycosylation.30 
Several other factors, such as temperature, solvent, and type of promoter used were 
found to influence the outcome of glycosylation by affecting its stereoselectivity and 
yield. The solvent effect on the stereoselectivity of glycosylation has been widely 
studied. While nitrile solvents favour the formation of β-glycosides by forming axial 
nitrilium cation intermediates, diethyl ether, THF and dioxane have a tendency to form 
α-linked glycosides by forming the equatorial O-linked intermediate.9  
The developments made in the glycosylation methods were followed by advances in 
the strategies used to assemble oligosaccharides. The synthesis of oligosaccharides 
are multistep reactions, which are repeated again and again until the desired 
oligosaccharide is obtained. Many advance strategies that streamline the 
oligosaccharide assembly are based on chemoselective or on selective activation of 
leaving groups. One-pot strategies have expedited oligosaccharide synthesis further. 
In this method, all the sequential reactions are performed in a single flask, and 
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purification is only performed at the stage of the final product and purification of 
intermediates is not performed. Demchenko et.al. reported the synthesis of the blood 
group determinant H-type II pentasaccharide using the one-pot glycosylation strategy, 
which afforded the target oligosaccharide in 60% overall yield.5 The convergent block 
synthesis strategy enables accessing complex oligosaccharides faster by pre-
synthesizing the oligosaccharide fragments and then converging them by means of a 
glycosylation reaction. A relevant example was the synthesis of ganglioside GP3, 
developed by Kiso and co-workers,13 wherein the target octasaccharide was 
synthesized by glycosylating pre-synthesized tetrasaccharide building blocks. Further 
breakthroughs in carbohydrate chemistry came with the development of supported 
synthesis techniques. Solid phase synthesis using insoluble polymer supports has 
been extensively used to synthesize various classes of biomolecules. Merrifield was 
the first to report the synthesis of polypeptides using polystyrene beads.31 The 
introduction of solid phase synthesis to carbohydrates is credited to Frechet and 
Schuerch who reported the first oligosaccharide synthesis on solid support.31 One of 
the examples for the synthesis of oligosaccharides on solid support was reported by 
Schmidt et. al. of a branched saccharide.5,31  
 














1.2   Automated synthesis of carbohydrates 
 
The developments made over the course of conventional synthesis of 
oligosaccharides, wherein all the protecting group manipulations were performed 
manually, have laid the basis for considering their automation in a bid to quicken 
synthesis manipulations. Automation enables operational simplicity, development of 
accessible methods for glycan synthesis. It offers a potential to revolutionize the way 
glycans are synthesized.17  
Many automation platforms utilize a computer interface and a liquid handling 
equipment, which helps in minimizing human error and therefore, increases the 
reproducibility of results. The underlying idea of automation is that the synthesis is 
recorded as a computer program, which is then executed with a “click of a button”. 
Takahashi et. al.18 investigated a number of platforms for the automation of solution-
based synthesis of oligosaccharides In 2000, they adapted a semi-automated 
instrument Quest 210 to synthesize a trisaccharide (Figure1) by selective activation of 
leaving groups.18 They further extended their efforts to a number of automated 
platforms, such as L-COS by Moritex, that allows to automate temperature control, 
stirring and rate of reagent addition for glycosylation and deprotection steps.17,18  
Thereafter, Seeberger and co-workers21 introduced the first, fully automated 
oligosaccharide synthesizer by re-engineering a peptide synthesizer. To begin with, a 
7-mer oligomannoside (Figure 1) was synthesized with 42% overall yield using 
Merrifield resin as solid support and an olefin type linker. The high promise of the 
automated approach was evident with the successful synthesis of the oligomannoside 
in a considerably short time compared to conventional synthesis. After this first 
milestone, the subsequent efforts made by Seeberger et. al.21,22 focused on the 
synthesis of oligosaccharides containing various challenging linkages, which included 





























Trisaccharide synthesized by solution phase 
automation of the oligosaccharide synthesis in one 
pot using Sythesizer Quest 21018 
Oligomannoside synthesized using a modified 
peptide syntheizer  
Automated synthesis of Globo H hexasaccharide using home-built synthesizer 




1.3    History of the synthesizer 
 
The earliest version of the automated oligosaccharide synthesizer was developed by 
Seeberger and co-workers in 2001 by re-engineering an automated peptide 
synthesizer.22 The custom-made reaction vessel was constructed of jacketed glass to 
allow for cooling. The building blocks were placed in cartridges to be delivered 
sequentially. The synthesizer allowed for use of nine different solvents and reagents. 
A systematic study was then carried out to ascertain the performance of the modified 
synthesizer by synthesizing a series of α-mannosides. With the successful synthesis 
of the mannosides, a more complicated phytoalexin elicitor (PE) fungal β-glucan was 
synthesized successfully synthesized using the synthesizer.24 A series of complex 
glycans, such as tumor associated carbohydrate antigens, hexasaccharide malarial 
toxin, core N-linked pentasaccharide, common to all N-linked glycoproteins were 
successfully synthesized using the modified synthesizer.  
Thereafter, a new, more versatile and less expensive platform based on syringe 
pumps was developed by Seeberger and co-workers.21 The programming of the 
instrument could be modified easily to accommodate different cycles of glycosylations, 
deprotections as well as different washing procedures.  Several complex glycans such 
as Tumor-Associated Carbohydrate Antigens Gb-3 and Globo-H, lipomannan 
backbone α-(1-6) oligomannoside, and a 50-mer polymannoside were synthesized 
with satisfactory yields.21,22 Finally, a commercial version of the automated glycan 
assembly synthesizer, called the “Glyconeer” was developed.31 The delivery of 
reagents/solvents are performed under argon atmosphere, and is equipped with 
flexible hardware and software to allow for complex glycosylation reaction to be 



























 Modified peptide synthesizer used for automated synthesis of oligosaccharides24 
Home-built synthesizer for automated glycan assembly of complex glycans21  
Figure 2: Different versions of the automated oligosaccharide synthesizers24,21  
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1.4    Glyconeer 2.1 
 
 
Glyconeer 2.1 is a commercially available, automated solid phase oligosaccharide 
synthesizer. It is designed with flexible hardware and software to accommodate the 
complexities of synthesizing complex glycans. In order to maintain an inert 
atmosphere for glycosylation, the entire synthesizer is kept under argon pressure. The 
synthesizer consists of separate “chambers” for solvents and reagents. The solvent 
chamber consists of eight positions, providing the flexibility to use eight different 
solvents for automation. The reagent chamber, on the other hand, is further divided 
into three blocks, namely, deprotection block, consisting of five positions to place the 
reagents to cleave the temporary protecting group, namely, FMOC, followed by the 
activator block (including the pre-cooled positions on a Peltier cooling block), further 
consisting of six positions to place the reagents needed to activate the building blocks, 
and finally, the aqueous block, containing five positions for miscellaneous reagents. 
Each of these blocks have a dedicated manifold through which the solvents/reagents 
flow before they reach the reaction vessel via the central manifold. The argon block 
situated on the right side of the Glyconeer synthesizer (Figure 3) distributes argon to 




each of these manifolds, which further distributes argon on each of the solvent 
/reagent bottles.   
 
1.4.1 Components of the Glyconeer 
 
The Glyconeer is equipped with different hardware units to accomplish complex 
glycosylation reactions. These hardware units allow for accurate and precise delivery 
of reagents as well as temperature control, which is essential for successful 
glycosylation reactions.  









The reaction vessel is triple jacketed to allow for accurate temperature control, which 
is a prerequisite for an efficient glycosylation reaction. It is fitted with a frit at the bottom 
to ensure efficient washing and filtration during automation.  
 











The building block carousel consists of 64 BB vial positions, which can be rotated to 
add the building blocks sequentially via a needle under argon pressure. Each BB vial 
can hold 3 mL of BB solution, and the BB needle can be programmed to take up the 
desired volume of BB solution to be delivered into the reaction vessel.  
 








The cryostat is a commercial, table top cooling unit which is used to control the 
temperature for different processes in the Glyconeer. It is connected to the reaction 
vessel via specialized metal hoses to ensure uniform circulation of cooling fluid.  
 














The Glyconeer synthesizer is also equipped with a fraction collector consisting of 26 
test tube positions. It can be rotated under argon pressure to the next position. The 












The UV lamp fitted in the Glyconeer measures the transmittance of the discharge 
solution upon FMOC cleavage, thus providing a real time feedback regarding the 
coupling efficiencies of the building blocks. The increasing amount of dibenzofulvene 
in the discharge solution leads to a sharp decrease in the transmittance values (see 
section 1.4.4 for more details), thereby giving a semi-quantitative estimate of the 




1.4.2   Operating the Glyconeer 
 
The software used to operate the Glyconeer synthesizer is known as Glycosoft. It 
enables the user to program synthetic cycles in order to assemble complex glycans 
via automation. The software is equipped with crucial, user-friendly features that allow 
for smooth operation of the Glyconeer. For instance, the software provides a 
description of the different solvents and reagents which are placed in different 













This information provided by the software prevents any ambiguity regarding the 
solvents and reagents which occupy specific positions.  
The synthetic cycles used to assemble complex glycans are programmed in the 
“Prepare synthesis” tab, which consists of the synthetic modules. These modules in 
turn comprise of “variables”, or reaction parameters which enable the users to define 











Figure 4: Description of solvents and reagents occupying different positions in the 
Gyconeer 








These modules can then be dragged and dropped to the right panel according to the 
desired coupling cycles required to assemble the target molecule. This tab also enlists 
building blocks that the users can choose, and define the parameters for glycosylation 
(activation temperatures, reaction times etc.).  These synthetic cycles then act as a 
set of instructions that are executed by the synthesizer. Once the synthesis is 
executed by the synthesizer, the completed runs can be viewed in the “Completed 
Runs” tab. This tab enables the user to also generate a report highlighting the details 
of the synthesis performed by the synthesizer. Additionally, the FMOC traces can also 












Next, the software also enables the user to monitor the argon pressure on the various 
“chambers”, or “blocks”, namely, the solvent, activator, deprotection and aqueous 
blocks, which provides an advantage of detecting pressure leaks while the synthesizer 





















1.4.3   Synthetic modules  
 
The automated assembly of glycans using the Glyconeer synthesizer is accomplished 
by using a set of commands (more details in supplementary information) programmed 
to allow for the glycosylation of building blocks to the solid support. Each command is 
comprised of a set of variables, also known as parameters, which are used to define 
the reaction conditions, such as temperature, reaction times, volume of reagents or 
solvents to be added during reaction, and the number of times a particular reaction 
needs to be performed. These parameters provide flexibility to the users to define the 
reaction conditions required for automated glycan assembly. The arrangement of 
these commands to accomplish each of the reaction steps are known as synthetic 







Figure 7: Argon Pressure reading on various blocks, namely, solvent, deprotection, 




Each module begins by setting the desired temperature, followed by washing the resin 
with DCM or DMF to ensure that the resin is sufficiently swollen for effective diffusion 
on the solid support. This is followed by adding the reagent, and then incubating the 
resin with the reagent for a specified amount of time depending on the reaction being 
performed. After the incubation period is over, the reagent is drained out of the reaction 
vessel, and the resin is further washed with the desired solvent. With the design of 
synthetic modules in hand, they are then arranged stepwise in order to accomplish a 
coupling cycle (Figure 8).  













All automated synthesis commenced by swelling the resin with dichloromethane, to 
allow for effective diffusion of reagents on the solid support, which is followed by 
washing the resin with trimethylsilyl trifluoromenthane sulfonate (TMSOTf) in order to 
coat the reaction vessel in a bid to prevent the resin from sticking to the walls of the 
reaction vessel. The building block is then glycosylated, which is followed by capping 
the deletion sequences, to render the by-products unreactive and prevent them from 
interfering in further reactions. Finally, the temporary protecting groups are cleaved in 
















Figure 8: Step-wise arrangement of synthetic modules to accomplish a coupling cycle  
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1.4.4   FMOC trace: a semi-quantitative handle to assess the 
coupling efficiencies 
 
With the synthetic modules in hand, a test synthesis was performed in order to validate 
the synthetic modules described in section 1.4.3. The test system chosen was a 
tetramer of α-1,6-Man. The parameters which were studied to validate the synthetic 
modules as well as the performance of the Glyconeer were the yield of the target 
oligomer, time required for assembling it on the solid phase as well as the HPLC purity 
of the oligosaccharide obtained upon automation. 
 
 
In order to perform the test synthesis, the building blocks were glycosylated one by 
one to the solid phase, followed by capping the deletion sequences. The temporary 
protecting group, such as the FMOC was then cleaved to propagate the chain. Upon 
removal of the FMOC carbonate, the discharge solution passes through the UV lamp 
(see section 1.4.1 for more details), which measures the transmittance of the solution 
containing the 9-methylenefluorene (formed during cleavage of FMOC carbonate with 
a base) intermediate. As the amount of 9-methylenefluorene passing through the UV 
lamp increases, a sharp decrease in the transmittance value is observed. The 
decrease in the transmittance value over a period of time is indicative of the increase 
in the coupling efficiencies of the building blocks. Therefore, higher is the coupling 
efficiency of the building block, the bigger is the dip in the transmittance curve. In other 
Figure 9: Transmission curve of discharge solution upon FMOC cleavage  
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words, the direct feedback provided by the FMOC sensor provides the advantage of 
assessing coupling efficiencies “real time”, and thereby identify weak or inefficient 
glycosylations. Additionally, the real time monitoring further reduces time and 
resources by identifying inefficient couplings at the stage of automated assembly itself, 



















The data in Table 1a indicates that the FMOC traces obtained showed excellent 
correlation with the HPLC traces. In other words, the excellent coupling efficiencies 
shown by the FMOC traces are confirmed by the clean HPLC traces obtained. These 
results further established the reliability of the data obtained from the FMOC traces, 
which could be used for “preliminary analysis” of the target structures obtained upon 
automation, which in turn implies that the inefficient couplings could be identified 
during automated synthesis using the Glyconeer, and HPLC analysis could be avoided 














Glycosylation Conditions: Man (I-IV): -20oC (5 min) to 0oC (20 min), 6.5 eq, 1x 
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1.5   Solid support and linkers used for automated glycan assembly  
 
A wide variety of resins have been utilized successfully in solid phase peptide 
synthesis to synthesize a plethora of peptides and proteins, such as polystyrene based 
resins, and PEG based resins.31 Taking inspiration from solid phase peptide synthesis, 
Merrifield resin and Controlled pore glass type resin have been most extensively used 
for automated glycan assembly. Since the assembly of glycans involves a series of 
complex reactions using harsh conditions, the Merrifield resin was reported to be the 
most suitable choice as a solid support due to its resistance to the conditions used for 
assembling complex glycans.21 Additionally, it has reasonable swelling properties in 
the most commonly used solvents for automated glycan assembly such as DCM, DMF 
and THF, which further allows for efficient diffusion of reagents and solvents at the 
solid phase.  
In order to anchor the growing oligosaccharide chain to the solid support, different 
linkers (which can also be viewed as a protecting group for the solid support) have 
been developed over the last decade. The choice of the linker is crucial, since it is 
required to be orthogonal to the reaction conditions used for the entire synthesis, and 
also to the cleavage conditions to cleave the final product off the solid support.  
The earliest linker developed for automated glycan assembly is the octenediol linker, 
which is linked to the solid support via an ester or ether linkage. With this linker, the 
final oligosaccharide is released by Grubb’s metathesis in the presence of ethylene or 
other alkenes, to afford an n-pentenyl moiety at the reducing end of the 
oligosaccharide upon cleavage from the resin.24 
 
Among the other linkers used is Lenz linker, which is attached to the resin via an ester 
linkage.31 It can be cleaved off the solid support by methanolysis to afford a pentenyl 
amine at the reducing end. The most recent and one of the most widely used linker for 
automated glycan assembly is the photocleavable linker. It is linked to the resin via an 
ether linkage. It is removed off the solid support by light induced cleavage. Similar to 






































Octenediol  Linker 
Figure 10: Most commonly used linkers for automated glycan assembly of complex glycans 
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1.6   Stability of linkers towards acid wash 
 
The linkers used to anchor the growing oligosaccharide chain to the solid support are 
required to be stable to all the conditions used for assembling complex glycans using 
AGA. As mentioned in section 1.4.3, every glycosylation step is preceded by an acid 
wash using TMSOTf. Therefore, it was hypothesized that the repeated use of acid 
wash might lead to the cleavage of the linkers during automated synthesis. Therefore, 
in order to prove the hypothesis, the linkers most commonly used, such as Lenz linker 
and photocleavable linker were subjected to successive acid washes, in order to study 
the stability of the linkers towards acid wash. The HMBA linker was used as a control 
to test whether the aromatic ester would survive the acid wash.  FMOC carbonate was 
attached to the linkers, and upon each acid wash, the loading of the linker, or the 
number of active sites on the solid support occupied by the linker was determined 





Linker Number of acid 
washes 
Loading 













Table 1b: Determining the stability of linkers towards successive acid washes with TMSOTf by 





The data shown in Table 1b indicates a decreasing trend in the loading of the linkers 
upon increasing number of acid washes. These results further confirmed the 
speculation that successive acid washes lead to cleavage of the linker. More 
specifically, the Lenz linker was found to be particularly susceptible to cleavage upon 
acid wash compared to the photoclevable and HMBA linkers, which deemed it unfit to 
be used for automated glycan assembly involving extensive acid washes.  
 
 
1.7   Aims of the Thesis 
 
The objective of this work was to develop optimized synthetic protocols for the 
automated glycan assembly of complex, immunologically relevant glycans using the 
Glyconeer synthesizer. Firstly, building block synthesis was optimized in order to 
overcome the roadblock towards automated glycan assembly (Chapter 2). Thereafter, 
the established protocols were used to scale up the synthesis of these monomers to 
40g batch size in order to procure multi-gram quantities of diverse, differentially 
protected building blocks. The ready availability of bulk quantities of building blocks 
further reduced the time required to access complex glycans via automation.  
With the BBs in hand, efforts were then turned towards developing optimized protocols 
for the automated glycan assembly of the Lewisx epitope using the Glyconeer 
synthesizer (Chapter 3). The reproducibility of the established synthetic protocols was 
then ascertained by synthesizing a library of Lewis antigens, such as Lewisa, Lewisy 
and Lewisb antigens (Chapter4).  
With the optimized protocols in hand, the Glyconeer was then validated to synthesize 
longer structures by synthesizing a library of Poly-N-acetyl-Glucosamine oligomers, 
such as tetramer, pentamer and hexamer. The rapid access to these oligomers helped 
to study their involvement in biofilm formation in Pseudomonas aeruginosa. Finally, 
the beta mannose linkage, considered to be one of the most challenging linkages to 
establish via synthetic carbohydrate chemistry was attempted via automation using 
the Glyconeer synthesizer, which opened up the possibility of synthesizing the 
































Streamlining Building Block Synthesis: Overcoming the 
Roadblock Towards Automated Glycan Assembly 
 
2.1   Introduction 
 
Recent attempts towards automating the synthesis of oligosachharides21-24 have 
paved the way towards fast and efficient synthesis of biologically relevant, complex 
oligosaccharides. However, the success of automated synthesis relies heavily on the 
ready availability of a set of diverse differentially protected building blocks.3 Therefore, 
it is of utmost importance to procure these building blocks in multi-gram quantities, 
which in turn necessitates the need to establish streamlined protocols for the synthesis 
of these building blocks.  
The “approved building blocks” highlighted by Seeberger21 in 2015 have laid the 
foundation towards overcoming the tedious task of synthesizing BBs for automation. 
This chapter highlights the strategies used to establish optimized protocols for the 
synthesis of these building blocks, which not only helps in procuring them in multi-
gram quantities, but also helps in establishing a routine on the Glyconeer while 
synthesizing complex glycans. Additionally, having faster access to the differentially 
protected building blocks allows to forego the laborious and time consuming step of 
synthesizing the BBs, thereby further speeding up the automated glycan assembly of 
complex glycans using the Glyconeer.  
 
This chapter is divided into three sections. The first section describes the selection of 
the most suitable aglycon to mask the anomeric centre, followed by identifying the 
most suitable thioglycoside derivative for GlcNac, Fuc, Man and Gal. The second 
section highlights the optimization of building block synthesis, with particular attention 
to the common synthetic steps required for the synthesis of all the building blocks. 
Finally, the third section establishes the scalability of the synthetic protocols developed 
for the GlcNAc BB to a 40g batch size.   
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2.1.1   Exploring the variability in building block synthesis 
 
Carbohydrates are composed of monosaccharide building blocks joined together via 
a glycosidic linkage. Most commonly, the glycosylation reactions follow an SN1 type 
mechanism,4 wherein the leaving group at the anomeric centre of the glycosyl donor 
is substituted by the nucleophile (glycosyl acceptor) to establish the glycosidic linkage. 
The stereochemical outcome of the glycosylation reaction is influenced by the 
protecting group at the C2 position of the glycosyl donor as well as the solvent used 
for performing the glycosylation reaction. The participating protecting groups, such as 
acetyl (OAc) and benzoyl (OBz) esters promote the formation of 1,2-trans glycosidic 
linkages by forming an acyloxonium ion intermediate that blocks the α face of the 
oxocarbenium ion, thereby forcing the nucleophile to attack from the top face as 
depicted in Scheme1.  
 
 





As indicated by the structures in Figure 1, the presence of several hydroxyl groups 
with similar reactivity (O2, O3 and O4) necessitate the need to differentially modify 
them in order to achieve the desired linkage and stereochemistry in the final 
oligosaccharide structure.  
Scheme 1: General reaction mechanism of Glycosylation and the plausible intermediates formed 
Figure 1: Symbolic representation of the most commonly used monosaccharides 
D-GlcNAc D-Glc D-Gal D-Man L-Fuc 
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Most commonly, the hydroxyl groups are modified as esters, ethers or acetals. While 
the ester protecting groups such as acetates, benzoates, chloroacetates and 
pivaloates can be installed under mild acidic/basic or neutral conditions using acid 
anhydrides, or acid chlorides, the ether groups such as benzyl, silyl, allyl are installed 
under acidic, basic and neutral conditions using benzyl bromide, silyl chloride and allyl 







Since the ester type protecting groups can be easily cleaved under mild basic or acidic 
conditions, they are used as “temporary protecting groups”, which can be cleaved 
during automation in order to extend the oligosachharide chain. The ether protecting 
groups, on the other hand, are quite robust to the conditions of glycosylation, and can 








Scheme 2: Modifying the hydroxyl groups with ester and ether functional groups (i) Introduction 
of acetyl functional groups under acidic, basic and neutral conditions. (ii) Introduction of benzyl 
functional group  
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The most commonly used acetal protecting groups are the benzylidene and 
isopropylidene acetals (cyclic acetals of benzaldehyde and acetone, 2,2-
dimethoxyropane respectively). These acetal protecting groups simultaneously mask 
two hydroxyl groups (cis or trans). Additionally, the 4,6-O benzylidene modification 
provides a conformational advantage in establishing a cis glycosidic linkage, 
especially in the case of mannose. Crich et.al.30 reported that the 4,6-O benzylidene 

























Scheme 3: Masking two hydroxyl groups via cyclic acetals (iii) Benzylidene and isopropylidene acetals to 
protect the O4 and O6 positions. (iv) Conformational advantage provided by benzylidene acetals in the 
generation of 1,2-cis linkage in mannose 
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2.1.2    Choosing an appropriate leaving group to mask the anomeric centre 
 
The earliest class of glycosyl donor, such as the glycosyl halides were developed by 
Koenigs and Knorr in the nineteenth century.31 These halides could be reacted with 
alcohols in the presence of Ag2CO3, Ag2O or heavy salts of Hg2+. Since then, there 
have been tremendous advancements towards developing new anomeric leaving 
groups. In the 1970s and 1980s, new classes of glycosyl donors such as 
thioglycosides, O-imidates and thioimidates were developed.29 These developments 
were followed by the use of glycosyl phosphates, selenium-glycosides as well as 
tellurium-glycosides in the last decade.29  
Among the various classes of glycosyl donors, the thioglycosides, phosphates and O- 
imidates remain the most popular choices to modify the anomeric centre. The glycosyl 
imidates and phosphates most often result in a mixture of stereoisomers that are 
difficult to separate. On the other hand, the introduction of the thiol moiety proceeds 
with excellent stereoselectivity. Additionally, the thioglycoside derivatives are highly 
stable and can be stored for long periods of time, unlike the O-imidate and phosphate 
derivatives, which degrade readily. Therefore, keeping all these factors in mind, the 
thiolate was chosen as the anomeric leaving group of choice for all the building blocks 
synthesized.    









There are three most commonly used thioglycoside leaving groups reported in the 
literature, namely, the ethanethiol (-SEt), p-toluylthiol (-STol) and the 5-tert-butyl-2-
Scheme 5: General reaction scheme for synthesizing thioglycoside derivatives for GlcNAc, Man, Fuc and 
Gal monosaccharides  
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methyl-phenyl thiol (-SAr). However, the rationale behind choosing a particular 
thioglycoside leaving group for a specific monosaccharide remains unclear. Therefore, 
in order to reduce the ambiguity, the three thioglycosides were synthesized for 




















The most suitable thioglycoside derivative was chosen by taking into account, firstly, 
the ease of purification and secondly, the toxicity of the respective thiol. The 
derivatives that crystallized were preferred over the ones that needed column 
Glucosamine series:  
 
Galactose series:  
Fucose series:  
GlcN 1 GlcN 2 GlcN 3 
Gal 1 Gal 2 Gal 3 
Fuc 1 Fuc 2 Fuc 3 
Mannose series:  
Man 1 Man 2 
Man 3 
Figure 2: Library of thioglycoside derivatives synthesized for GlcNAc, Gal, Fuc, Man and Gal in order to 
select the most suitable derivative 
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purification, because of ease in scaling up the synthesis to a 40g batch size. This is 
because, crystalline derivatives prevented the use of column chromatography for 








Table 2a indicates that the ethanethiol and p-toluyl thiol afford the respective 
thioglycoside derivatives in excellent yields. On the other hand, the 5-tert-butyl-2-
methyl-phenyl thiol gives the product in poor yields. Therefore, based on the results in 
Table 2a, the ethanethiol protecting group was found to be the most suitable thiol 




From Table 2b, it is evident that only the p-toluyl thiol derivative for Fuc affords a 
crystalline derivative. Although the yield for this particular derivative was observed to 
be the lowest of the three thioglycosides, the low yield was compensated by firstly, the 
Thioglycoside Thiol moiety (R) % Yield Crystallization 
 








Thioglycoside Thiol moiety(R) Stereoselectivity %Yield Crystallization 
 
 
α/β, 1:1* 60% × 
 
Exclusively β*  
50% 









Table 2a: Thioglycoside derivatives synthesized for GlcNAc, and the yields and crystallinity 
of the derivatives  
Table 2b: Yield and crystallinity of the Fucose thioglycoside derivatives synthesized 
Note - *ratio determined by NMR  
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time saved in getting access to the thioglycoside, and also by the excellent 





The results obtained in Table 2c confirm the p-toluyl thiol derivative as the obvious 
choice, since it is a crystalline derivative, provides excellent stereoselectivity and 
affords the respective thioglycoside in satisfactory yield.  On the other hand, the 
ethanethiol and 5-tert-butyl-2-methyl-phenyl thiol derivatives result in poor 










Monosaccharide Thiol moiety(R) Stereoselectivity % Yield Crystallization 
 
 














Table 2c: Thioglycoside derivatives synthesized for Gal 












Since mannose did not pose any challenge with regards to stereoselectivity because 
of no participation from C2 position, the only criteria which governed the choice of a 
suitable thiol moiety were the yield and crystallinity of the thioglycoside. The results 
(Table 2c) proved that the ethanethiol moiety afforded a crystalline derivative, thereby 
making it the preferred choice.  
In a nutshell, the different thioglycoside derivatives, ethanethiol, p-toluyl as well as 5-
tert-butyl-2-methyl-phenyl thiol synthesized for GlcNAc, Fuc, Man and Gal helped in 
determining the optimal thioglycoside for each of these monosachharides.  Therefore, 
from the results obtained, it could be concluded that while intermediate GlcN1 and 
Man1 were found to be the favoured thioglycoside derivative for GlcNAc as well as 
Man, Fuc2 and Gal2 was the preferred derivative for Fuc and Gal. With the most 
suitable thioglycoside derivative in hand, efforts were then turned towards optimizing 
the individual synthetic steps leading to the synthesis of the differentially protected 






Thioglycoside Thiol moiety(R) %Yield Crystallization 
 










Table 2d: the different thioglycoside derivatives synthesized for Mannose to select the most 
suitable derivative  
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2.3   Optimizing building block synthesis: Establishing streamlined 
synthetic protocols  
 
The success of automated glycan assembly heavily relies on the availability of 
differentially protected building blocks. Therefore, in order to procure multi-gram 
quantities of BBs, it is of utmost importance to optimize their synthesis. Additionally, 
having easy access to multi-gram quantities of building blocks is also helpful in 
establishing a routine on the Glyconeer. This is further highlighted in Chapters 3, 4 
and 5, wherein procuring multi-gram quantities of building blocks proved to be 
advantageous in gaining rapid access to the target glycan structure. Also, it assisted 
in conducting multiple synthetic trials using the Glyconeer synthesizer in order to 
obtain optimized protocols for automated glycan assembly of the target structure, 
thereby establishing a streamlined protocol.  
The first step towards achieving streamlined synthetic protocols was to design the 
differentially protected building blocks required to assemble the target glycans using 
the Glyconeer synthesizer. In other words, the protecting group manipulations needed 
in the monosachharides were chosen upon retrosynthetic analysis of the target 
structures.  
Firstly, the positions that required to be extended during automation were modified 
with temporary protecting groups, such as levulinate ester (Lev) and  and 9-
fluorenylmethyl carbonate (FMOC), because they are stable to the glycosylation 
conditions for thioglycosides, and are orthogonal to each other, which enables them 
to be removed selectively during automation. Secondly, the remaining positions that 
didn’t need to be extended were modified with permanent protecting groups, namely, 
benzyl ether (OBn).  
Another very important factor that needs to be taken into account while designing 
building blocks is the desired stereoselectivity in the target oligosaccharide structure. 
For instance, in order to establish trans glycosidic linkages, participating protecting 
groups such as benzoyl (OBz) and trichloacetamide (TCA) were installed in the C2 
positions. The design of all building blocks required to assemble the target structures 
using the Glyconeer is further highlighted in the following chapters using this strategy.  
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With the design of building blocks, as well as the optimal thioglycoside derivative for 
each of them in hand, efforts were then turned towards establishing optimized reaction 
conditions for each synthetic step, affording satisfactory yields, and  ensuring minimum 
loss of material along the synthetic scheme. Thus, for each reaction step, parameters 
such as concentration of reagents, temperature and time were studied to establish 
optimized protocols, and obtain satisfactory yields.  
The synthesis of building blocks commenced from the free sugar, except in the case 
of glucosamine, wherein, the synthesis started from commercially available 
intermediate 1a. The first four synthetic steps for synthesis of Gal and GlcNAc are 




The reactions in Scheme 5 further highlight that the first four synthetic steps, such as 
peracetylation, introduction of the thiol moiety, removal of acetyl groups as well as 
installation of the benzylidene protecting group serve as the reaction steps involved in 
the synthesis of all the building blocks. Therefore, efforts were turned towards 
Scheme 5: The first four steps of the synthetic scheme for synthesizing (v) Gal intermediate 2a (vi) 






streamlining these four synthetic steps, to help in establishing standard operating 
protocols to get faster access to differentially protected building blocks.  
The peracetylation of the monosaccharides was optimized by establishing the most 
suitable method among the procedures reported in the literature.3 Thus, based on the 
experiments conducted for galactose, fucose, and glucose, it was observed that the 
NaOAc in Ac2O method of peracetylation afforded the pentaaacetate intermediate in 
satisfactory yields, as well as the more reactive β anomer. Additionally, the reaction 
time for this method is the minimum, ranging from 1h - 2h, thereby providing faster 




Monosaccharide Stereoselectivity % Yield 
 
NaOAc, Ac2O, reflux 
D-Glucose Exclusively β 72% 
D-Galactose Exclusively β 77% 
L-Fucose Exclusively β Quant. 
 
The next step, which is the introduction of the thiol moiety to afford a thioglycoside was 
optimized as described in section 2.4. Thereafter, particular attention was paid to 
streamline the crystallization or precipitation of these thioglycoside derivatives. This 
was achieved by studying the most suitable solvent mixtures and precipitation 
conditions (temperature), to afford thioglycoside derivative with excellent yields. The 
solvent system chosen for precipitation of the product was governed by the polarity of 
the product as well as impurities present in the crude mixture. It was observed that 
ethyl acetate (EA) was the most suitable solvent. However, no precipitation was 
observed with only EA as the solvent. Therefore, it was speculated that because of 
the presence of unreacted thiol moieties, such as ethanethiol and p-toluylthiol as 
impurities, a co-solvent might be required to dissolve these impurities, and thereby 
help in precipitating the product.  
Thus, precipitation of the thioglycoside derivatives was performed with a mixture of 
Hex/EA. This afforded the product in excellent yields, which in turn proved the 
hypothesis of using a solvent mixture instead of only one solvent. The detailed 
conditions of the solvent mixtures are indicated in Table 2f.  
Table 2e: Peracetylation of Glc, Gal and Fuc, using the NaOAc method and the 









The results obtained in Table 2f confirm that the temperature played a pivotal role in 
achieving successful precipitation of the product, which is proved by the excellent yield 
obtained for the thioglycoside derivatives at higher temperatures. With the optimized 
reaction and purification conditions for the synthesis of thioglycoside derivatives in 
hand, the next step, the removal of the acetate groups, was found to be 
straightforward, and the deacetylated derivative 1d (Scheme 5) did not require to be 
purified and used for further steps without any purification.  
 Next, the optimization of the introduction of the benzylidene protecting group was of 
particular interest. The benzylidene intermediates 1e, 2a (Scheme 5) could be 
selectively decorated with various protecting groups to provide access to a plethora of 
differentially protected building blocks for automation. An example to further highlight 




Thioglycoside Precipitation conditions % Yield 
 Hex/EA, 4:1, room 
temperature 
56% 
Hex/EA, 4:1, 35oC 72% 
Hex/EA, 4:1, 50oC 88% 






The scheme depicted in Figure 4 further confirms the versatility of the benzylidene 
intermediate 1e.The benzylidene intermediates 1e, 2a will be referred to as a “common 
intermediate” in the succeeding chapters, since they could be adorned with various 
protecting group patterns affording diverse building blocks as depicted in Figure 4. 
Intermediate 1e also ensured faster access to the differentially protected building 
blocks in fewer synthetic steps. In a nutshell, this intermediate provided twofold 
advantage, since firstly, it provided access to a repertoire of diverse building blocks, 
and secondly, it expedited the synthesis of diverse building blocks BB1, BB9, BB10, 











Literature reports8 indicate that N,N-dimethylformamide and tetrahydrofuran are most 
commonly used  to synthesize the benzylidene intermediate. Since DMF is known to 
be carcinogenic as well as mutagenic, THF was opted as the solvent of choice in order 
to synthesize the benzylidene derivatives. Secondly, the concentration of the reagents, 
namely, benzaldehyde dimethyl acetal PhCH(OMe)2 and camphorsulfonic acid were 
optimized. To begin with, the reaction conditions reported in literature were used, and 
the reproducibility of these conditions was studied by conducting a series of reaction 










The reaction conditions were reproducible (Table 2g), which was confirmed by the 
consistent yields obtained for the successive trials conducted for the synthesis of 
intermediate 2a. With the optimized conditions in hand, these protocols were then 








(Eq. based on 
starting material) 
CSA 



















The reaction conditions established for the synthesis of the benzylidene intermediate 
were reproducible, and afforded the product 1e in consistent as well was satisfactory 
yields (Table 2h). Similar to the intermediate 2a, the glucosamine intermediate 1e 
could be recrystallized using the same solvent system and temperature, such as 
DCM/Hexane, 4:1 at 50oC. Next, with these reproducible reaction conditions in hand, 











The results obtained in Table 2i indicate that the reaction conditions for synthesizing 
intermediate 4b required further optimization. Therefore, the focus was now shifted 
towards other solvents that are reported in literature in order to synthesize the 
intermediate 4b.  The reaction was then performed in acetonitrile, which resulted in 
the formation of product in 76% yield. 
 
Reaction Conditions 









Reaction Conditions % Yield 
PhCH(OMe)2 (2.0 eq), Camphorsulfonic 
acid (0.175 eq) 
No Product 
PhCH(OMe)2 (2.0 eq), p-toluenesulfonic 
acid (0.175 eq) 
No Product 
Table 2h: Optimizing the introduction of the benzylidene intermediate for synthesizing 
intermediate 1e  





In a nutshell, the reaction conditions for the synthesis of the benzylidene intermediates 
2a, 1e and 4b were optimized and the reproducibility of these conditions were 
established. Additionally, the purification of these intermediates was streamlined, 
thereby affording the products in excellent yields.  
 
2.4   Establishing the robustness and scalability of established 
synthetic protocols  
 
With the optimized reaction conditions for the common synthetic steps in hand, the 
next step was to establish their robustness and applying these protocols to the 40g 
batch sizes. The aim for performing the synthetic steps in a large batch size was to 
procure multi-gram quantities of the differentially protected building blocks in order to 
establish a routine on the Glyconeer synthesizer. The first step towards achieving 
robust and scalable protocols was to determine the impact of the various reaction 
parameters, such as concentration of reagents, temperature, mixing, and rate or order 
of addition of reagents on the 40g batch size reactions.  
Another important factor which required optimization was the purification of the 
intermediates. In this regard, the glucosamine intermediates (Figure 4) posed an 
advantage since these derivatives could either be precipitated or used for further 
synthetic steps without any purification. A particular observation made while inducing 
precipitation in the 40g batch sizes was the formation of large agglomerates. The NMR 
of these lumps confirmed that they trapped impurities and solvents, thereby reducing 
the purity of the products. Therefore, in order to avoid the formation of these 
macroscopic structures, the stirring speed was increased gradually with increasing 
precipitate formation, which led to the precipitate being finely suspended in the solvent, 
thereby affording a highly pure product. For example, in case of the intermediate 2a, 
the formation of agglomerates could be avoided by gradually increasing the stirring 
speed upon adding hexane to induce precipitation giving a highly pure product. 
Secondly, the solvent system used for washing the precipitated product was optimized 
to minimize loss of product during filtration.  
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Since the glucosamine building blocks (BB1, BB9 and BB10) were utilized to procure  
the target oligosaccharides mentioned in the succeeding chapters, the synthetic steps 
leading to these building blocks were optimized and scaled up to 40g batch sizes in 
order to obtain multi-gram quantities of these differentially protected building blocks. 
As a result, standard operating protocols could be established for the synthesis of 
these BBs which enabled batch production of the final building blocks. A reaction 
scheme depicting the synthesis of all the GlcNAc BBs synthesized is shown in Scheme 




















Scheme 6: Reaction scheme for the synthesis of diverse differentially protected GlcNAc BBs for 
automation, also highlighting the versatility of intermediate 1e 
BB8 BB 10 
43 
 
The scalability of the protocols to synthesize the glucosamine building blocks was 
established by performing the synthesis on 10g, 20g and 40g batch sizes. The yields 




Reaction Step %Yield 



























































Table 2j: Establishing the scalability of each synthetic step leading to the common intermediates 1e, 
5a by applying the established protocols in a 40g batch size 
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The results in Table 2j indicate that the protocols established for each of the synthetic 
steps are scalable, as confirmed by the excellent yields obtained for the 40g batch 
size.  
A particular step which needs mention is the introduction of the Lev protecting group 
to obtain intermediate 1f. As shown in Table 2j, the yields in the 10g and 20g batch 
sizes were low, which necessitated the need to further optimize the synthetic protocol. 
Therefore, taking inspiration from the procedure used to introduce the Lev protecting 
group in peptides, the DCC and intermediate 1e were pre-mixed, followed by adding 
a solution of levulinic acid in DCM. A marked increase in yield was observed in the 
40g batch size using the altered procedure. This improved yield could be attributed to 
the fact that by changing the order of reagent addition, the rate of reaction was faster 
owing to better mass transfer.  
With the optimized and scalable protocols for each synthetic step in hand, the building 
blocks could then be procured in multi-gram quantities, and the benzylidene 
intermediates 1e, 2a could be stocked up and used to synthesize a library of 
differentially protected building blocks for automation, which is highlighted in the 
subsequent chapters. Additionally, the ready availability of these building blocks also 


















2.5   Conclusion 
  
The synthesis of building blocks was optimized by firstly, selecting the thioglycosides 
as the most suitable aglycon to mask the anomeric centre owing to their stability and 
excellent stereoselectivity. Thereafter, the most suitable thioglycoside derivative was 
chosen for GlcNAc, Fuc, Man and Gal. The results obtained indicated that while GlcN 
1, Fuc2 were found to be the most suitable derivatives for GlcNAc and Fuc, Man1 and 
Gal 1 were the optimal derivatives for Man and Gal. With these results in hand, the 
common synthetic steps leading to the synthesis of the building blocks, such as 
peracetylation, introduction of the thiol moiety, removal of the acetate groups , followed 
by formation of the benzylidene intermediate (Scheme 5) were optimized to obtain 
excellent yields.  
Thereafter, the benzylidene intermediates 1e, 2a were identified as common 
intermediates which provided access to a plethora of differentially protected building 
blocks (Figure 4). Therefore, this intermediate was procured in multi-gram quantities 
in order to get quicker access to diverse building blocks.  
Finally, the scalability of the protocols developed for the synthetic steps leading to the 
GlcNAc BBs (BB1, BB9, BB10) were established by performing the synthesis in 10g, 
20g and 40g batch sizes. The results indicated that the synthesis in the 40g batch 
sizes afforded the intermediates in excellent yield, thereby confirming the scalability of 
the protocols established. The availability of the optimized protocols established pave 
the way for developing standard operating protocols, which also enable the batch 
production of the building blocks, and represent one step further to overcome the 






































Combining Automated Glycan Assembly and Enzymatic 
Sialylation to prepare a Lewisx epitope 
 
3.1   Introduction 
 
Lewisx is a tumor associated carbohydrate antigen TACA, that is overexpressed on 
the surface of several types of cancers.1 As a result, it has been an attractive target 
for developing an anti-cancer vaccine.1 The biological relevance of Lewisx has turned 
it into a subject of thorough examination.24 Therefore, there have been several 
attempts to synthesize the Lewisx antigen by solution phase synthesis.32-34 The solid 
phase synthesis of Lewisx was reported by Seeberger in 2004,23 wherein the Lewisx 
antigen was assembled via automation to get rapid access to the target 
oligosaccharide. This work paved the way for further optimizations in order to improve 
the yield as well further reduce the time required to access the final oligosaccharide. 
The work in this chapter highlights the step-by-step approach adopted to establish 
optimized protocols for automated glycan assembly of Lewisx on the Glyconeer 
synthesizer to obtain satisfactory yields of the target oligosaccharide.  
This chapter is divided into four sections. The first section describes the identification 
of building blocks required for automated glycan assembly of the Lewisx epitope 
structure followed by optimization of the building block synthesis, as well as scaling 
them up to a 40g batch to procure multi-gram quantities of the building block. The 
second section describes the assembly of these building blocks on the Glyconeer, as 
well as the strategy adopted to establish an optimized protocol for automated solid 
phase synthesis of Lewisx epitope structure, followed by synthesis on the larger scale 
(0.025 mmol). The third section details the optimization of global deprotection of the 
Lewisx epitope. Finally, the fourth section focusses on the enzymatic sialylation of the 
fully deprotected Lewisx using bacterial α-2,3 sialyltransferases which was performed 
in collaboration with Prof. Sabine Flistch at University of Manchester, as part of the EU 
ITN Immunoshape.    
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The first step towards obtaining the target structure was the identification of building 
blocks upon retrosynthetic analysis of the Lewisx epitope structure. This was achieved 
by taking into account the specific positions to be glycosylated and the stereochemistry 
required in the target structure. Therefore, the C3 and C4 hydroxyl groups of GlcNAc 
(BB1) were modified as Levulinic ester (Lev) and 9-fluorenylmethoxycarbonyl (Fmoc) 
carbonates respectively, in order to extend the chain during automated synthesis. 
Secondly, in order to establish β-glycosidic linkages, the GlcNAc (BB1) and Gal (BB2) 
building blocks were modified at C2 position with N-trichloroacetyl (TCA) and benzoyl 
(OBz) functional groups respectively. These functional groups, also known as 
participating protecting groups promote the formation of 1,2-trans linkages by 
selectively blocking the  bottom face of the oxocarbenium ion intermediate formed 
during glycosylation, thus prompting the incoming nucleophile to approach via the top 
face, thus forming β-glycosidic linkage.4 On the contrary, the benzyl ether (OBn) type 
protecting groups do not provide such a participation, thereby allowing for α 
connectivity. Therefore, the Fuc BB (BB 3) was synthesized as a perbenzylated 









3.3    Optimization and bulk synthesis of building blocks 
 
With the design of building blocks in hand, efforts were turned towards developing 
optimized synthetic protocols and scale up synthesis. The ready availability of 
differentially protected building blocks is a prerequisite for the success of automated 
glycan assembly, and required to establish a routine on the Glyconeer.1,3 
In the process of optimizing the synthesis of building blocks, particular attention was 
paid to minimize the column chromatography purifications required after each 
synthetic step. Firstly, it ensured faster access to the final building block, because, 
column chromatography purification is time consuming. Secondly, reducing the 
column purifications avoids the use of enormous amounts of solvents on large scale, 
thereby reducing the waste and saving resources.  
The synthetic intermediates shown below could either be crystallized, or used for the 
next synthetic step without any purification. For example, the synthesis of GlcNAc BB 
(BB1) and Fuc BB (BB3) as shown below, could be synthesized without any column 
purification, thereby allowing the synthesis to be completed in 2 weeks. Finally, 
GlcNAc (13g), Fuc (9g) and Gal (8g) building blocks were obtained respectively, which 






















The synthesis commenced from commercially available intermediate 1a. The amine 
group was then modified as the trichloroacetamide (TCA) 1b, followed by introduction 
of the thiol moiety in order to obtain thioglycoside 1c. Subsequently, the acetate 
groups were hydrolysed 1d and the C4 and C6 positions were functionalized as the 
benzylidene intermediate 1e. The 3-OH group was then modified as the levulinic 
ester (1f). Thereafter, the benzylidene ring was regioselectively opened to obtain the 
C4 hydroxyl group 1g, which was finally converted to an FMOC carbonate 1h. Upon 
scale-up synthesis (40g batch size) for this building block, 13g of the final building 










The synthesis of this building block commenced from the common intermediate 2a, 
synthesized in bulk quantities in-house, and the 3-OH was selectively modified as a 
silyl ether 2b, followed by the introduction of a benzoyl ester at C2 position 2c, in order 
to serve as a participating protecting group, thereby favouring the formation of the β-
glycosidic linkage.  Thereafter, the benzylidene ring was regioselectively opened to 
afford a free hydroxyl at C6 position 2d, which was then modified as a benzyl ether 
(2e). Subsequently, the silyl group was selectively cleaved (2f), which was then 
modified as an FMOC carbonate to obtain the target building block (2g). Scale up 













The building block synthesis started from commercially available L-fucose 3a, which 
was then converted into the peracetylated derivative 3b. Thereafter, the p-toluyl thiol 
moiety was used to convert it into a thioglycoside 3c. The acetate groups were 
subsequently removed (3d), followed by perbenzylation to afford the final building 
block. The final building block was obtained in 9g upon scale-up synthesis starting 















3.4   Assembly of building blocks to obtain target structure 
 
With multi-gram quantities of BBs in hand, efforts were turned towards assembling 
them on the Glyconeer, and establish optimized glycosylation conditions for each of 
them in order to obtain maximum purity of the final oligosaccharide. The first step 
towards achieving this was to develop a workflow on the synthesizer to tether the 
building blocks one-by-one on to the solid phase depending on the linkage and the 
compatibility of the temporary protecting groups, the synthetic modules on the 
Glyconeer (see Chapter 1 for more details) were programmed accordingly (Table 3a, 
3b). Therefore, for the Lewisx epitope structure, the synthesis was started by first 
attaching the GlcNAc Building Block to the linker loaded resin, followed by cleaving the 
levulinoyl ester protecting group. Any deletion sequences were then capped,12 and the 
fucose moiety was glycosylated to the C3-OH position of GlcNAc. Thereafter, the 
FMOC protecting group was removed from the C4-OH of GlcNAc, and the galactose 
unit was attached, followed by capping of deletion sequences, and finally removing the 
FMOC protecting group from galactose to obtain the final Lewisx trisaccharide. 
 
 
S.No. Module Conditions 
1. Resin preparation 
for synthesis 

















NIS/TfOH in DCM 
(anhydrous) 
:Dioxane 
(anhydrous)  2:1 
 
GlcNAc in DCM (anhydrous) 
GlcNAc-20oC 
(5 min) , 0o C 
(20 min) 
       
      4. 
Ac2O acidic 
capping, preceded 
by Pyridine wash 
10% Ac2O , 
2% 
Methanesulfo
nic acid in 
DCM 
(anhydrous) 
(v/v), 25oC  






Module 1, 2,3, 4 
Module 5 
Table 3a: Synthetic modules required to 









Post-automation steps  
Cleavage from solid support  
After  automated  synthesis,  the  oligosaccharides  were  cleaved  from  the solid  
support  using  a continuous flow photoreactor.12 (See SI for detailed procedure) 
Purification and HPLC analysis   
The crudes were dissolved in 1:1 Hex:EA and  analysed  using Analytical HPLC (YMC-
Diol-300 column, 150 X 4.6 mm, ELSD Detector and DAAD, 280 nm). The product 
was then isolated using Preparative HPLC. The detailed solvent gradients used for 
analysis as well as purification of the Lewisx epitope is shown in Table 3c. 
 
 
S.No. Module Conditions 














Fuc  in DCM 
(anhydrous): -40oC 
(5 min) , -20o C (20 
min), 
Gal  in DCM 
(anhydrous): -20oC 
(5 min) , 0oC (20 
min) 





10% Ac2O , 2% 
Methanesulfonic 
acid in DCM 
(anhydrous) (v/v), 
25oC 
 6. FMOC 
Deprotection 
20% Piperidine in 
DMF (v/v), 25oC 
          
Module 2,3,4,6 
Module 2,3,4,6 














3.5   Establishing optimized glycosylation conditions 
 
Glycosylation reactions usually follow an SN1 type mechanism, wherein the glycosyl 
donor upon activation by a promotor/activator forms an oxocarbenium ion 
intermediate. The nucleophile, in this case, the glycosyl acceptor then attacks to form 
the glycosidic linkage.4 Therefore, the glycosylation efficiencies are governed by the 
concentration of the glycosyl donor, in this case, the BBs. Thus, in order to obtain 
optimized conditions of glycosylation, these parameters were studied, and their impact 
on the yield and the purity of the reaction was thereby ascertained.  
Number of Glycosylation Cycles – The glycosylation efficiencies of building blocks 
for each coupling cycle are dependent on the amount of BB added. Therefore, the 
number of glycosylation cycles, or the number of times a BB is added per coupling 
cycle, were varied to obtain the most optimized value to achieve maximum 
glycosylation efficiency. The standard conditions reported by Delbianco7 (6.5 
equivalents of BB) were implemented for the BBs 1-3, and the number of glycosylation 










%Hexane Flow rate  
(mL/min) 
0.00 20 80 1.000 
5.00 20 80 1.000 
40.00 55 45 1.000 
45.00 100 0 1.000 
50.00 100 0 1.000 
Table 3c: Description of solvent gradient used to analyse crude 

























    21% 
Table 3d: Establishing optimized glycosylation conditions for AGA of Lewisx on the Glyconeer 
synthesizer 
Glycosylation Conditions: GlcNAc: -20
o
C (5 min) to 0
o
C (20 min), 6.5 eq, 3x, Fuc:  -40
o
C 
(5 min) to -20
o
C (20 min), 6.5 eq, 2x, Gal:  -20
o
C (5 min) to 0
o
C (20 min), 6.5 eq, 2x 
Glycosylation Conditions: GlcNAc: -20
o
C (5 min) to 0
o





C (20 min), 6.5 eq, 1x, Gal:  -20
o
C (5 min) to 0
o
C (20 min), 6.5 eq, 1x 
Product 
-Fuc 
Table 3d: Establishing optimized glycosylation conditions for BBs 1-3 









Structure of LacNAc deletion sequence (-Fuc):  
 
 
When single glycosylation cycle was used for all the three building blocks, there was 
No product formation observed in the first trial (Lewisx_T1) (Tables 3d and 3e). Adding 
the GlcNAc, Gal and Fuc BBs once was not sufficient to perform a successful 
synthesis. Taking inspiration from solid phase peptide chemistry where the first 
building block coupling is the most difficult glycosylation step, the number of coupling 
cycles were increased to three for GlcNAc, and two for Gal as well as Fuc BBs. 
However, the second trial (Lewisx_T2) indicated the formation of a by-product, which 
was identified as LacNAc (structure shown above), in addition to the product. This trial 
also confirmed that the GlcNAc coupling was efficient, which was confirmed by the 
absence of capped linker. Hence, the number of cycles for this BB were then reduced 
to two, in a bid to use the GlcNAc BB judiciously, and thereby reduce the cost, while 
maintaining the same number of cycles for Fuc and Gal. HPLC analysis of the 3rd trial 
(Lewisx _T3) indicated formation of product, and an identical deletion sequence as 





   22% 
Glycosylation Conditions: GlcNAc: -20
o
C (5 min) to 0
o





C (20 min), 6.5 eq, 2x, Gal:  -20
o
C (5 min) to 0
o





second and third trials indicated inefficient fucosylation, thereby prompting the need to 
further optimize the coupling efficiency of the Fuc BB, in order to remove the LacNAc 





In order to improve the coupling efficiency of the Fuc BB, the incubation time during 
glycosylation was increased to 30 min. However, the above trial (Table 3f) indicated 
that the increase in reaction time had no effect on the coupling efficiency of the BB, 
thereby leading to the formation of the LacNAc by-product. However, on the flip-side, 
the HPLC trace also confirmed that the coupling conditions for GlcNAc and Gal, i.e. 
6.5 eq of BB with two glycosylation cycles were the best conditions to obtain high 
coupling efficiencies for these particular building blocks as confirmed by the absence 
of deletion sequence lacking the GlcNac BB (capped linker) or the Gal BB (capped 
GlcNAc). The coupling conditions for the Fuc BB required further optimizations in order 











   25% 
Table 3f: Optimizing the coupling efficiency of Fuc BB by varying the incubation time during 
glycosylation  
Glycosylation Conditions: GlcNAc: -20
o
C (5 min) to 0
o
C (20 min), 6.5 eq, 2x, Fuc:  -40
o
C 
(5 min) to -20
o
C (30 min), 6.5 eq, 2x, Gal:  -20
o
C (5 min) to 0
o





Building block concentration –The Fuc BB was found to be glycosylating 
inefficiently using 6.5 equivalents and two glycosylation cycles. Therefore, the 
concentration of the Fuc BB was increased to 10 eq and just one glycosylation cycle 





From the HPLC trace of the above trial, it was evident that increasing the concentration 
of Fuc BB improved the coupling efficiency, and thus, no deletion sequence, i.e. 
LacNAc was observed in the HPLC anaylsis. Therefore, it was concluded that 6.5eq, 
2X, -20oC (5 min) to 0oC (20 min) for GlcNAc and Gal BB, and 10 eq, 1X, -40oC (5 min) 














   35% 
Table 3g: Optimizing coupling efficiency of Fuc BB by increasing the concentration of Fuc BB in the 
Glyconeer 
Glycosylation Conditions: GlcNAc: -20
o
C (5 min) to 0
o
C (20 min), 6.5 eq, 2x, Fuc:  -40
o
C 
(5 mins) to -20
o
C (20 min), 10 eq, 1x, Gal:  -20
o
C (5 min) to 0
o




3.5.1    Scale-up of the Lewisx   epitope synthesis 
 
With optimized glycosylation conditions for BBs 1-3 on the 0.0125 mmol scale in hand, 
the AGA of Lewisx was scaled up to 0.025 mmol to obtain multi-milligram quantities of 
the final oligosaccharide, and to test the scalability of the established protocols and 





The trials (Table 3h), indicated that the fucoslyation was inefficient, which was 
















     
     12% 
Table 3h: Applying the optimized protocols developed on the 0.0125 mmol scale for scale up synthesis 
of Lewis
x
 epitope  
Glycosylation Conditions: GlcNAc: -20
o
C (5 min) to 0
o





C (20 min), 10 eq, 1x, Gal:  -20
o
C (5 min) to 0
o







1 and 2. Further optimization of the reaction conditions for the assembly of the  Lewisx 
epitope on the 0.025 mmol scale. Since the glycosylation conditions for the building 
blocks of the scale-up trials were identical to that on smaller scale (0.0125 mmol), the 
focus was then shifted towards other parameters.   
Acid Wash – Since the first two scale-up trials indicated inefficient fucosylation, it was 
speculated that two acid washes per glycosylation cycle might have over-exposed the 
Fuc BB to the TMSOTf acid, thereby promoting its cleavage. Therefore, the number 





The HPLC trial (Table 3i), revealed that the reduced acid washes did not influence the 
outcome of the synthesis, as confirmed by the peak for LacNAc deletion sequence 













    22% 
Table 3i: Optimizing the coupling efficiency of Fuc BB on 0.025 mmol scale by reducing the number 
of acid washes to 1.  
Glycosylation Conditions: GlcNAc: -20
o
C (5 min) to 0
o





C (20 min), 10 eq, 1x, Gal:  -20
o
C (5 min) to 0
o





Argon mixing –   Mixing is known to play a fundamental role in synthesis scale up. It 
ensures homogeneous dispersion between multiple phases. Additionally, it also 
minimizes concentration/temperature gradient between two immiscible phases, thus 
improving mass transfer and increasing the rate of reaction. Therefore, it was 
speculated that increasing the argon mixing duration could be beneficial in improving 
the glycosylation efficiency of the Fuc BB on the 0.025 mmol scale. Thus, for the 
















    30% 
Table 3j: Optimizing the coupling efficiency of Fuc BB on the 0.025 mmol scale by increasing argon 
mixing  
Glycosylation Conditions: GlcNAc: -20
o
C (5 mins) to 0
o
C (20 mins), 6.5 eq, 2x, Fuc:  -40
o
C 
(5 mins) to -20
o
C (20 mins), 10 eq, 1x, Gal:  -20
o
C (5 mins) to 0
o
C (20 mins), 6.5 eq, 2x 
Glycosylation Conditions: GlcNAc: -20
o
C (5 min) to 0
o





C (20 min), 10 eq, 1x, Gal:  -20
o
C (5 min) to 0
o

















The HPLC trials above carried out with increased Argon mixing indicated no formation 
of LacNAc by-product, and thus, resulted in significantly improved yield and purity of 
the Lewisx epitope. Increased argon mixing showed that inefficient mixing was leading 
to the formation of LacNAc deletion sequence. Thereafter, with multi-milligram 
quantities of the protected Lewisx epitope structure in hand, efforts were then turned 





Glycosylation Conditions: GlcNAc: -20
o
C (5 min) to 0
o
C (20 min), 6.5 eq, 2x, Fuc:  -40
o
C 
(5 min) to -20
o
C (20 min), 10 eq, 1x, Gal:  -20
o
C (5 min) to 0
o


















In order to obtain the fully deprotected Lewisx epitope structure, the temporary 
protecting group, namely, -OBz protecting group was first removed via methanolysis. 
Thereafter, the permanent protecting group, i.e. –OBn functional group was cleaved 
by hydrogenation using Palladium catalyst under a H2 atmsophere.15 Additionally, the 
global deprotection also enabled the removal of the trichloroacetamide group (-
NHTCA), as well as the Cbz group thereby yielding an amine spacer at the reducing 
end of the fully deprotected Lewisx epitope structure. 
 
3.6.1   Establishing optimized conditions for global deprotection of 
Lewisx 
 
Different Palladium catalysts have been reported regarding the global deprotection of 
oligosaccharides. Some studies use only one type of Palladium catalyst, while others 
use a mixture of catalysts such as Pd(OH)2 on C and Pd on C.15,17 Optimization trials 
were conducted using different catalysts in order to select the best choice to procure 
a satisfactory yield of the final product.  
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Secondly, the work-up procedure, or the washing procedure of the Palladium catalyst 
after hydrogenation was also taken into consideration as an important parameter for 
obtaining high yields of the final deprotected glycan. Ineffective washing of the catalyst 
might lead to low yields of the final compound, owing to the compound getting trapped 
in the catalyst. With these factors in mind, optimization trials were carried out with 














      
Table 3k: Establishing Optimized conditions for Global deprotection of Lewisx   by varying the choice of 
catalyst    
Product 
-Fuc 
Catalyst Used: Pd(OH)2 on C 







From the HPLC trials above, it is evident that while near complete conversion into 
deprotected Lewisx could be seen with Pd(OH)2 on C, a combination of Pd(OH)2 on C 
and Pd on C did not yield any product. This proved beyond doubt that Pd(OH)2 on C 
is the most optimal catalyst for the global deprotection of Lewisx. It can be speculated 
that the rigorous washing procedures of the catalyst used in the 
first(TG_LeX_Deprotected_T1) and thrid (TG_LeX_Deprotected_T3) trials led to 
























Catalyst Used: Pd(OH)2 on C 
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The last step towards obtaining the Sialyl Lewisx target structure was the attachment 
of sialic acid moiety to the Lewisx trisaccharide via enzymatic sialylation.  
The biosynthetic pathway to synthesize Sialyl Lewisx comprises the attachment of 
Sialic acid to LacNAc, followed by fucosylation by an α-1,3 fucosyltransferase. This 
sequence is highly conserved since common human α-2,3 sialyltransferases cannot 
act on fucose containing Lewisx as a substrate (Patent no. US 9,255,257 B2). 
However, a mutant α-2,3 sialyltransferase from Pasteurella multicoda  was reported 
by Chen and co-workers33 which could transfer sialic acid to the fucosylated Lewisx 
epitope structure. They reported a significant advantage of adding sialic acid as the 
last synthetic step over normal sialyl Lewisx biosynthetic pathway, since it reduced the 
number of synthetic steps thereby simplifying the reaction scheme. The purification 
process was much easier as the negatively charged Sialyl Lewisx from the neutral 
Lewisx compared to separating both negatively charged Sialyl Lewisx and non-
fucosylated sialosides. Therefore, drawing inspiration from the findings of Chen,33 the 
Lewisx epitope synthesized via automated glycan assembly was subjected to 
enzymatic sialylation using bacterial α-2,3 sialyltransferases in collaboration with Prof. 
          
α-2,3-ST, MgCl2 , Tris/HCl pH 8, 
CIAP , dH2O 
68 
 
Sabine Flitsch’s group at the University of Manchester. Six bacterial α-2,3 
sialyltransferases along with five putative bacterial enzymes were screened, and the 













Procedure – The bacterial α-2,3 sialyltransferases were procured commercially from 
Prozyme as a suspension in NH4SO4, and stored at -80oC. The suspension was 
centrifuged and the supernatant was discarded. The pellet was then dissolved in 20 
μL distilled H2O. The concentration was then roughly estimated by Nanodrop. The 
stock solutions and reaction mixture were prepared as follows: 2 μL of Tris/HCl buffer, 
4 μL of CMP-Neu5Ac, 1 μL CIAP and 7 μL distilled H2O were added into an Eppendorf 
tip, and aliquoted into 6 vials, with 2 μL Lex (acceptor) and 2 μL of the silayltransferase. 
The reaction mixtures were then thawed, and incubated overnight at 37oC, and then 
analysed using MALDI.  
The initial screenings were performed using the bacterial α-2,3 sialyltransferases (as 
described in Table 3l, 3m), and the MALDI data is as follows:  
α-2,3-sialyltransferase Bacteria 
Tt_86 Pasteurella multicoda 
Tt_88 Photobacterium phosphoreum 
Tt_89 Pasteurella dagmatis 
Tt_190 Pasteurella dagmatis 
Tt_192 Photobacterium sp. JT-ISH-224 
Tt _193 Vibrio sp. JT-FAJ-1 
Enzyme Bacteria 
Tt_52 Campylobacter insulaenigrae 
Tt_123 Neissera meningitides MC58 
Tt_136 Haemophilus influenzae 
Tt_159 Streptococcus mitis 
Tt_127 Neisseria gonorrhoeae 
Table 3l: Bacterial α-2,3 sialyltransferases screened for enzymatic sialylation of 
Lewisx epitope structure 
Table 3m: Putative α-2,3 sialyltransferases screened for enzymatic sialylation of 





 The MALDI trace shown above indicates that the attachment of Sialic acid moiety to 
the Lewisx epitope structure could be accomplished using an α-2,3 sialyltransferase 











Figure 2: MALDI data of crude mixture after overnight incubation at 37oC with the α-2,3 sialyltransferase 
isolated from Photobacterium sp. JT-ISH-224 (Tt_192) 
α-2,3-ST, pH 8, incubated at 37
o




3.8   Conclusion and Outlook  
 
The synthesis of building blocks (BBs 1-4) required for automated glycan assembly of 
Lewisx epitope was optimized, and the monosaccharides were procured in multi-gram 
quantities. A noteworthy improvement made in the synthesis of building blocks was 
the minimal use of column chromatography, thereby reducing the time needed to 
access the final building block as well as solvents used for 40g batches. A workflow 
was established on the Glyconeer synthesizer to assemble these building blocks to 
obtain the Lewisx epitope.  
Next, inefficient fucosylation encountered during the AGA of the target structure, was 
overcome by increasing the concentration of the Fuc BB from 6.5 to 10 equivalents. 
Subsequently, a similar problem (inefficient fucosylation) was seen while scaling up 
the synthesis to 0.025 mmol scale, which could be overcome by increasing the time 
for argon mixing. Next, in order to obtain the fully deprotected Lewisx epitope structure, 
the global deprotection was optimized by identifying the most suitable Palladium 
catalyst (Pd(OH)2 on C) that resulted in minimal cleavage of Fuc in the final structure.  
Last but not the least, enzymatic sialylation was attempted on deprotected Lewisx 
using bacterial α-2,3 silayltransferases. However, these enzymes were unable to 
transfer sialic acid to the fucosylated Lewisx efficiently. Therefore, the mutated α-2,3 
silayltransferase from Pasteurella multicoda can be used to perform enzymatic 















Automated glycan assembly of Lewisa, Lewisy and Lewisb 
epitopes using the Glyconeer 
 
4.1   Introduction 
Lewisa and Lewisy are type I and type II blood group antigens that play an important 
role in tumor metastasis and signal transduction.1 The overexpression of these 
glycans is a sign of tumor progression and can be used to distinguish normal cells 
from tumor cells. Therefore, these tumor associated carbohydrate antigens are 
considered promising targets for designing anti-cancer vaccines.1 Lewisb on the other 
hand is a receptor for the gram negative bacterium Helicobacter pylori that causes 
chronic gastritis and gastric carcinoma.8 The biological relevance of these glycan 
structures have prompted several attempts to synthesize them by solution phase 
synthesis.32,34  
The optimization of automated glycan assembly of Lewisx epitope using the Glyconeer 
(see Chapter 3 for more details) paved the way for extending these protocols in order 
to access the Lewisa, Lewisy and Lewisb antigens by automation. The goal for 
synthesizing these molecules was not only to procure a repertoire of biologically 
relevant glycans, but also to prove the robustness of the synthetic protocols developed 
using the Glyconeer.  
This chapter is divided into four sections. The first section discusses the identification 
of building blocks upon retrosynthetic analysis of the target glycans, followed by 
highlighting the importance of the benzylidene intermediate to get faster access to 
the final building block. The second section describes the workflow used to assemble 
the target structures using the Glyconeer. Thereafter, the third section details the 
automated glycan assembly of the Lewisa epitope structure on the Glyconeer in order 
to consolidate the reproducibility of the established AGA protocols. Finally, the fourth 
section describes the special cases of Lewisy and Lewisb epitope structures, which 
proved to be challenging to assemble via automation on the Glyconeer synthesizer, 




4.2   Retrosynthetic analysis of target structure and identification of 
building blocks 
In continuation with the approach adopted for automated glycan assembly of Lewisx 
using the Glyconeer synthesizer (described in Chapter 3), the building blocks required 
to assemble the Lea, Ley and Leb epitope structures were identified upon 
retrosynthetic analysis as shown in Figure 3. The positions that required to be 
extended during automation were modified with temporary protecting groups, namely, 
levulinic ester (-Lev) and 9-fluorenylmethoxycarbonyl (Fmoc) carbonates. Secondly, 
in order to establish β-glycosidic linkage, participating protecting groups such as 
trichloroacetamide (TCA) for BB1 and benzoyl ester (OBz) for BB5 were installed in 
the C2 position. On the other hand, the Fuc BB was synthesized as a perbenzyl 
derivative to promote the formation of α-glycosidic linkage.  
        
 
 






























4.3   Utilizing the common intermediate to expedite the synthesis of 
building blocks 
In the process of optimizing the synthesis of BB1 and BB4 for AGA of the Lewisx 
epitope structure (see Chapter 3 for more details), the benzylidene derivatives 1e and 
2a were identified as common intermediates which were synthesized in multi-gram 
quantities. This intermediate had two major advantages, firstly,  it could be 
functionalized with a myriad of functional groups, thereby giving access to a plethora 
of differentially protected building blocks for automation. Secondly, it significantly 
reduced the number of synthetic steps to get quicker access to the final building block.  
 










As discussed in Chapter 2, the first four steps of the reaction scheme such as, 
peracetylation, thioglycosylation, deacetylation and formation of benzylidene 
intermediate were optimized, and scaled up to a 40g batch. For e.g. in the case of 
GlcNAc BB above (BB 1), the final building block 1h could be synthesized in 3 
synthetic steps, in contrast to 6 steps when started from the intermediate 1a (see 
Chapter 3).  
4.3.2    Galactose building block  
 
 
The synthesis of BB4 commenced from the “common intermediate” 4a (see Chapter 
2 for more details). The C2 and C3 hydroxyl groups were then modified as benzoyl 




performed to afford the C4 hydroxyl group free, which was finally derivatized as a 





4.4   Assembly of building blocks to obtain target structure 
  
With multi-gram quantities of building blocks in hand, the next step was to assemble 
them using the Glyconeer synthesizer to obtain the target oligosaccharides, which was 
accomplished by applying the optimized synthetic modules established during the 
synthesis of the Lewisx epitope structure. The application of these synthetic protocols 
to synthesize Lewisy, Lewisa and Lewisb epitopes was also beneficial in determining 
the robustness as well as reproducibility of these protocols. For all automated glycan 
assemblies, Merrifield resin loaded with a photolabile linker was used as solid 
support.9 A brief description of the synthetic modules used to assemble the Lea, Ley 






Module no.  Module name Conditions 
1. Resin swelling DCM, 25oC, 30 min 
2. Acid wash TMSOTf in DCM(anhydrous), -20oC 
3. Thioglycoside 
Glycosylation 
BB in DCM (anhydrous), T1(5 min) to T2 (20 
min) 
4.       Ac2O acidic capping  10% Ac2O, 2% Methanesulfonic acid in 
DCM(anhydrous)(v/v) 
5. Lev Deprotection Hydrazine acetate in py, AcOH, H2O, 25oC 
6. FMOC Deprotection 20% Piperidine in DMF(v/v), 25oC 
 
Table 4a: Synthetic modules required to synthesize the Lea, Ley and Leb epitope structures using 
the Glyconeer.  T1 = Initial temperature, T2 = Final Temperature 
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Lea: The synthesis was initiated by glycosylating BB1 (Figure 3) to the solid support, 
followed by capping7 the deletion sequences and cleaving the Levulinic ester 
protecting group. BB5 was then glycosylated to the C3 position, which was followed 
by removing the FMOC protecting group from C4 position of BB1. Finally, BB3 was 
glycosylated to this position and the deletion sequences were capped to afford the Lea 























Module 2, 3, 4 
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Ley: The first building block (BB1) was glycosylated to the solid support, and the 
deletion sequences were then capped. Then, the –Lev protecting group from C3 of 
BB1 was cleaved. Thereafter, BB3 was glycosylated to this position, the deletion 
sequences were capped, and the FMOC group was removed from the C4 position of 
BB1. In order to attach the second Fucose unit, a Gal BB bearing an FMOC protecting 
group at C2 position (BB5) was then glycosylated to the C4 position of BB1, followed 
by capping of the deletion sequences and removing the FMOC protecting group from 
C2 position of BB6. Finally, the second Fucose unit (BB3) was attached to this position 


























Leb: The workflow used to assemble the Leb epitope structure was similar to that of 
Ley with the exception of cleaving the FMOC protecting groups from the C2 position 
and C4 position of BB6 and BB1 respectively. BB3 was glycosylated simultaneously 






























Post automation steps 
After assembling the building blocks on the Glyconeer to obtain the final glycan 
structures, the resin loaded with the final oligosaccharide was subjected to 
photocleavage. The crude mixture was then subjected to HPLC analysis and 
purification (see Chapter 3 for more details).  
 
4.5   Determining the reproducibility of established glycosylation 
conditions 
Lewisa , Lewisb and Lewisy  antigens bear two monosaccharide units in common (BB1 
and BB3). Therefore, in order to get rapid access to these immunologically relevant 
glycans, it is of utmost importance to establish reproducible glycosylation conditions 
for these building blocks. Additionally, these monomers can also provide access to a 
plethora of other Lewis antigen derivatives, such as Lewisx dimeric, H antigen, KH-1 
antigen.27  
The streamlined glycosylation conditions established for these two building blocks 
while synthesizing the Lewisx epitope structure (see Chapter 3 for more details)   were 
applied to assemble the Lea, Ley and Leb epitope structures using the Glyconeer. For 
the remaining building blocks, i.e. BB5 and BB6 (Figure 3), the standard conditions 
reported by Delbianco12 (6.5 equivalents of BB) were implemented, and further 












4.5.1   Automated glycan assembly of Lewisa epitope structure 
After establishing a workflow for synthesizing the Lewisa epitope structure, the building 
























The HPLC traces (Table 4b) confirm that the glycosylation conditions established for 
BB1 and BB3 are reproducible as indicated by the formation of product and the 
absence of any deletion sequence. It also showed that 6.5 equivalents with two 




Table 4b: Automated glycan assembly of Lewisa epitope structure using the Glyconeer on the 
0.0125 mmol scale 
Glycosylation Conditions: GlcNAc: -20oC (5 min) to 0oC (20 min), 6.5 eq, 2x, Fuc:  -
40oC (5 min) to -20oC (20 min), 10 eq,1x, Gal:  -20oC (5 min) to 0oC (20 min), 6.5 eq, 2x 
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In a nutshell, the successful synthesis of the Lea epitope structure in the 0.0125 mmol 
scale indicated that the glycosylation conditions for BB1 and BB3 are highly 
reproducible, and afford the target structure in satisfactory yields (Table 4b). 
Therefore, with the optimized glycosylation conditions for BB1, BB3 and BB5 in hand, 
the synthesis of Lea epitope structure was then scaled up to 0.025 mmol in order to 
procure more material. Thus, drawing inspiration from the effect of increased argon 
mixing on efficiency of fucosylation for the scaled up synthesis of Lex epitope structure 
(see Chapter 3 for more details), the AGA of Lea epitope structure on the 0.025 mmol 




















Table 4c: Scale up trials (0.025 mmol) of Lewisa epitope structure using the Glyconeer 
Glycosylation Conditions: GlcNAc: -20oC (5 min) to 0oC (20 min), 6.5 eq, 2x, Fuc:  -40oC 






The HPLC trials (Table 4c) indicate that the scale up trials of the Lea epitope structure 
was successful, which was proved by the formation of product. Additionally, it again 
established the importance of increased argon mixing in achieving efficient 
fucosylation on the 0.025 mmol scale.  
 
4.6   Automated glycan assembly of Ley and Leb epitope structures: 
The curious case of difucosylation 
The Ley and Leb epitope structures bear two fucose units. While in Ley, one of the 
fucose moieties is attached to the C3 position of BB1, in Leb, it is attached to the C4 
position of BB1. Since the Ley epitope structure is identical to the Lex epitope, with the 
exception of an extra Fuc BB attached to the C2 position of Gal BB (Figure 3), a 
different Gal BB (BB6) having an FMOC carbonate in C2 position was chosen to 
extend the oligosaccharide chain during automation and thus obtain the target glycan. 
The optimized glycosylation conditions established for BB1 and BB3 (see Chapter 3 
for more details) were applied to synthesize Ley epitope via AGA.  
BB5 was utilized for the first time for AGA. Therefore, the activation temperature was 
chosen as 0oC to 20oC. This is because, from previous AGA trials for BBs bearing the 
–Stol leaving group at the anomeric centre, it was observed that these BBs could be 
activated only at higher temperatures. Therefore, the initial trials were conducted using 
















The failed synthetic trials (Table 4d)   indicated that the synthesis of the Lewisy epitope 
required further optimization. The coupling conditions established for BB1 and BB3 
were found to be optimal as well as reproducible, which was proved by the successful 
synthesis of Lewisa epitope structure and efforts turned towards streamlining the 


















Glycosylation Conditions: GlcNAc: -20oC (5 min) to 0oC (20 min), 6.5 eq, 2x, Fuc:  -40oC 
(5 min) to -20oC (20 min), 10 eq,1x, Gal:  -20oC (5 min) to 0oC (20 min), 6.5 eq, 2x 
Table 4d: Automated glycan assembly of Lewisy epitope structure using the Glyconeer on the 
0.0125 mmol scale 
84 
 
4.6.1   Establishing optimized glycosylation conditions for BB5 
 
BB5 bears an FMOC carbonate in C2 position (Figure 3) that may promote limited 
participation via anchimeric assistance, thereby resulting in poor stereoselectivity. 
Taking inspiration from the activation temperature reported by Guberman11 for BB5, -
30oC to -10oC was attempted in order to establish the optimized activation temperature 















The HPLC trace (Table 4d) showed that -30oC to -10oC yielded the most promising 
stereoselectivity. With these optimized glycosylation conditions in hand, the synthesis 





 Glycosylation Conditions: GlcNAc: -20oC (5 min) to 0oC (20 min), 6.5 eq, 2x, Gal:  
-30oC (5 min) to -10oC (20 min), 6.5 eq, 2x 
Table 4e: Automated glycan assembly of BB6 containing LacNAc dimer using the Glyconeer 
on the 0.0125 mmol scale 
β-anomer 
Structure of BB5 containing LacNAc dimer: 
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As indicated by the HPLC trace (Table 4f), the AGA of the trisaccharide was 
successful, as confirmed by the formation of product, and the absence of any deletion 
sequence. Therefore, with optimized glycosylation conditions for all the BBs required 
to assemble the Ley epitope structure in hand, the target tetrasaccharide was 







Glycosylation Conditions: GlcNAc: -20oC (5 min) to 0oC (20 min), 6.5 eq, 2x, Fuc:  -40oC 
(5 min) to -20oC (20 min), 10 eq, 1x, Gal:  -30oC (5 min) to -10oC (20 min), 6.5 eq, 2x 
Product 
Table 4f: Automated glycan assembly of the BB6 containing Lex trisaccharide on the Glyconeer on 
the 0.0125 mmol scale 
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4.6.2    Synthesis of Ley epitope structure using optimized 
conditions 
With optimized glycosylation conditions for all the BBs (BB1, BB3 and BB5) in hand, 





















Table 4g: Automated glycan assembly of the Ley tetrasaccharide using optimized glycosylation 











The HPLC traces (Table 4g), confirm that the automated glycan assembly of the 
Lewisy epitope using the Glyconeer failed. On the other hand, the successful synthesis 
of the Lewisx trisachharide using BB6 proved that the glycosylation conditions 
established for BB1, BB3 and BB6 were optimal and afforded the target trimer in 
satisfactory yield. These results led to the conclusion that the attachment of the second 
Fucose moiety was the most difficult synthetic step leading to repeated failed synthesis 
of the Lewisy epitope structure.  
In an effort to address this problem, the lactose spacer was included in the following 
synthetic trials, thus affording the complete Lewisy antigen, in a bid to establish the 
effect of the lactose spacer in the automated glycan assembly of Lewisy using the 




Glycosylation Conditions: GlcNAc: -20oC (5 min) to 0oC (20 min), 6.5 eq, 2x, Fuc:  -40oC 
(5 min) to -20oC (20 min), 10 eq,1x, Gal:  -30oC (5 min) to -10oC (20 min), 6.5 eq, 2x 





In order to assemble the Lewisy antigen structure, the standard conditions used for all 
the building blocks, i.e. 6.5 equivalents, two glycosylation cycles were implemented 
for BB7 and BB8. For the remaining BBs (BB1, BB3 and BB6), the optimized 























Table 4h: Automated glycan assembly of the Ley antigen using the Glyconeer on the 0.0125 mmol 
scale 
Glycosylation Conditions: Glc : -20oC (5 min) to 0oC (20 min), 6.5 eq, 2x, Gal: -20oC (5 
min) to 0oC (20 min), 6.5 eq, 2x, GlcNAc: -20oC (5 min) to 0oC (20 min), 6.5 eq, 2x, Fuc:  -





The successful synthetic trials of Ley antigen via AGA (Table 4h) led to the speculation 
that the introduction of the lactose spacer relieved the spatial restriction imposed on 
the introduction of the second Fuc BB, thereby leading to successful synthesis.  
In order to gain better insights into the complexity of difucosylation, the Lewisb epitope 
structure bearing two fucose moieties was assembled, in a bid to observe whether the 
problem of fucosylation was specific only to the Lewisy epitope, or persisted for all 







Glycosylation Conditions: GlcNAc: -20oC (5 min) to 0oC (20 min), 6.5 eq, 2x, Fuc:  -




Table 4h: Automated glycan assembly of the Leb epitope structure using the Glyconeer on the 
0.0125 mmol scale 
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Although the HPLC trials for the synthesis of Leb epitope indicate the formation of 
product, they also show the presence of by-products, namely the mono-fucosylated 
and un-fucosylated derivatives of Leb. These results led to the conclusion that the 
complexity of achieving successful synthesis of difucosylated moieties persisted in this 
case as well, albeit to a lesser extent compared to Lewisy epitope structure, which 
could further be attributed to the fact that in case of the Ley epitope, both the Fucose 
moieties appear in close spatial proximity to one another. On the other hand, in Leb, 
the two Fucose units are farther away from one another, thereby reducing the rigidity 
in the molecule, ultimately resulting in formation of product compared to Ley, wherein 
no product formation could be seen after several synthetic trials on the Glyconeer.  
 
4.7   Conclusion and Outlook 
 
The optimized synthetic protocols established for the synthesis of BB1 and BB3 led to 
the identification of a “common intermediate” 1e, 2a which was helpful in getting 
access to the final building block in fewer synthetic steps, thereby significantly 
reducing the time needed to synthesize the differentially protected building blocks for 
automation. The advantage provided by the intermediates 1e, 2a was evident in the 
synthesis of BB1 as well as BB4 wherein the final building block could be procured in 
merely four synthetic steps.  
Next, the reproducibility of the glycosylation conditions established for BB1 and BB3 
which are shared by Lewisx and Lewisa was proved by the successful synthesis of the 
later via automated glycan assembly using the Glyconeer. Additionally, the effect of 
increased argon mixing led to efficient fucoslyation in the scale up synthesis (0.025 
mmol) of Lewisa epitope as well.  
Finally, the automated glycan assembly of the Lewisy and Lewisb epitopes proved 
challenging, with no product formation seen in case of the Lewisy epitope. This 
problem could be solved by introducing the Lactose spacer to afford the complete 
antigen structure. This observation gave rise to the speculation that there is a spatial 
restriction in the introduction of the second fucose moiety thereby leading to repeated 
failed synthesis on the Glyconeer. However, it could be imagined that the lactose 
spacer reduces the rigidity in the structure, thereby leading to successful synthesis of 
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the Lewisy antigen. This observation paves the way for possible investigations into the 
spatial arrangement of the Lewisy epitope structure on the solid phase which could 
provide crucial details and also plausible solutions in order to overcome the challenge 























































Automated glycan assembly of poly-N-acetyl- 
glucosamines: Understanding their role in biofilm 
formation 
 
5.1   Introduction 
Poly-N-acetyl-β-(1,6)-glucosamine is an important constituent of the extracellular 
biofilm matrix of Staphylococci and Bacillus species.2 The intercellular adhesin 
involved in biofilm accumulation of Staphylococcus epidermidis is a linear β-1,6-linked 
glucosaminoglycan:8 Biofilm formation protects microorganisms from challenging 
environmental conditions, allow them to build communities, share resources and 
allows them to resist potential toxic compounds for example antibiotics.3 However 
biofilms formed by pathogenic bacteria and fungi can pose a serious threat due to the 
enhanced resistance against common antibiotics and pharmaceuticals in the biofilm.3 
Therefore, a treatment, which would target and destroy the biofilm matrix may render 
the bacteria again susceptible towards classic antibiotics. Several glycoside 
hydrolases have been identified to be able to degrade the extracellular matrix though 
often it isn’t entirely clear what the enzyme recognizes as substrate. Among these is 
family GH153, containing poly-N-acetyl-β-(1,6) hydrolases. Though, crystal structures 
are available, there are still no structural data available showing the interaction with 
the substrate, as well as the precise conformational itinerary of the catalytic cycle.  
In order to synthesize the PNAG oligomers to support the structural analysis for biofilm 
degrading hydrolases, I decided to employ automated glycan assembly using the 
Glyconeer synthesizer to generate a variety of GlcNAc oligomers. I started the 
synthesis using the optimized synthetic protocols developed for the assembly of the 
Lewis antigens (see Chapters 3 and 4). This should prove the general usability of the 
established protocols and help to validate the Glyconeer for the synthesis of complex 
long carbohydrates. The resulting oligomers were provided to the group of Dr. Roth, 




This chapter is divided into four sections. The first section describes the retrosynthetic 
analysis of the poly-N-acetyl-glucosamine oligomers, and identification of the 
necessary building block, required to assemble the desired oligosaccharides using the 
Glyconeer synthesizer. The second section discusses the advantage of having 
optimized protocols for the synthesis of a variety of structures via automation in a bid 
to extend the library of compounds assembled using the Glyconeer and prove the 
robustness of the established synthetic protocols. The third section highlights the 
global deprotection of the synthesized PNAG library. Finally, the fourth section 
describes use of the PNAG library to characterise the substrate specificity of the PelA 
glucosamine hydrolase domain from Pseudomonas aeruginosa. 
5.2   Retrosynthetic analysis of target structure and identification of 
building blocks 
Firstly, the building blocks were identified upon retrosynthetic analysis of the target 
structure (Figure 5). Since the oligosaccharide chain required to be extended along 
the C6 position, a temporary protecting group, namely, 9-fluorenylmethoxycarbonyl 
(FMOC) was installed in this position which could be cleaved during automation to 
elongate the oligosaccharide structure. Secondly, in order to ensure β-selectivity of 
the newly formed glycosidic linkage, the trichloroacetamide group (TCA) was installed 











Figure 5: Retrosynthetic analysis of Poly-N-Acetyl-Glucosamine oligomers and identification of building block 




5.3   Optimization and bulk synthesis of Building Blocks 
 
The first four steps of the synthetic scheme leading to the formation of the benzylidene 
intermediate 1e were optimized (Chapter 2) to obtain high yields. As a result, this 
intermediate was identified as a “common intermediate” which could be used to access 
a plethora of diverse, differentially protected building blocks for automated glycan 
assembly (Chapter 2). Therefore, the synthesis of this derivative was scaled up to a 
40g batch size and stocked up in multi-gram quantities.  
 
 





The synthetic scheme in blue represents the optimized route to BB8 (Chapter 2). 




procure bulk quantities of the building block. As discussed in Chapters 2 and 3, all the 
derivatives in the above reaction scheme could be either crystallized/precipitated, or 
used for further steps without purification, thereby diminishing the need for column 
chromatography, and ultimately saving resources, which proved advantageous for the 
multigram synthesis of BB8.  
 




The synthesis of BB14 commenced from the commercially available starting material 
1a. The optimized synthetic protocols developed for the synthesis of BB9 were then 




synthesis of intermediate 4e was performed in acetonitrile since there was no product 
formation using THF.  
5.4   Assembly of building block using the Glyconeer to obtain 
target oligomers 
 
With optimized synthetic protocols and multi-gram quantities of BB9 in hand, the next 
step was to establish a workflow in order to assemble the target structures (Figure 5) 
via automation. The synthetic modules and the workflow used to assemble the target 










Module no.  Module name Conditions 
1. Resin swelling DCM, 25oC, 30 min 
2. Acid wash TMSOTf in DCM(anhydrous), -20oC 
3. Thioglycoside 
Glycosylation 
BB in DCM (anhydrous), T1(5 min) to T2 (20 
min) 
4.       Ac2O acidic capping  10% Ac2O, 2% Methanesulfonic acid in 
DCM(anhydrous)(v/v) 
5. FMOC Deprotection 20% Piperidine in DMF(v/v), 25oC 
 
Table 5a: Synthetic modules required for automated glycan assembly of PNAG oligomers using 




















Since the target structures are β-1,6-GlcNAc homopolymers, the GlcNAc (BB6) was 
added sequentially to the growing chain to generate the target oligomers. The 
synthesis was commenced by swelling the resin with DCM, followed by the 
glycosylation of the BB6, capping the deletion sequences, and finally cleaving the 




n = 1,2 
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5.4.1   Post automation steps 
After assembling the oligomers via AGA using the Glyconeer synthesizer, the resin 
loaded with the target oligosaccharides was subjected to photocleavage (detailed 
procedure in SI), and analysed as well as purified by HPLC.  
The solvent gradient used for the analysis and purification of the crude samples by 
HPLC is governed by the solubility of the oligosaccharide in the solvent mixture used 
for analysis. While the glycans previously synthesized using the Glyconeer (Chapters 
3 and 4) could be analysed using the gradient mentioned in Chapter 3, the poly-N-
acetyl-glucosamine tetramer could not be dissolved in the usual solvent mixture, such 
as Hex/EA, 1:1. Therefore, the solvent gradient used for analysis and purification of 
the tetramer was modified based on the solubility of the crude sample (Hex/EA, 3:2) 



















%Ethyl Acetate % Hexane Flow Rate 
(mL/min) 
0.00 40 60 1.000 
5.00 40 60 1.000 
40.00 65 35 1.000 
45.00 100 0 1.000 
50.00 100 0 1.000 




5.5   Automated glycan assembly of poly-N-acetyl-glucosamine 
 
The automated glycan assembly of three different PNAG oligomers, a tetramer, 
pentamer and hexamer was performed (Figure 5).  
5.5.1   Automated glycan assembly of Poly-N-acetyl-Glucosamine tetramer 
 
To begin with, the standard conditions for glycosylation, such as 6.5 equivalents of BB 
and two glycosylation cycles were applied to glycosylate BB8, and further optimized 



















    30% 
Product 
PNAG tetramer (Protected): 






The HPLC trials in Table 5c show that the synthesis of the Poly-N-Acetyl glucosamine 
tetramer was successful in high purity. The HPLC traces also confirmed that the 
glycosylation conditions established for BB8 were optimal and reproducible, as shown 
by the consistent yields obtained for the consecutive trials depicted in Table 5c. 
5.5.2    Automated glycan assembly of Poly-N-Acetyl-Glucosamine pentamer 
and hexamer 
 
After the successful synthesis of the PNAG tetramer, efforts were then turned towards 
synthesis of the PNAG pentamer and hexamer structures by extending the number of 
glycosylation cycles accordingly. The established glycosylation conditions were 
applied once or two times more to obtain the desired structures. The crude material 
obtained upon photocleavage was found to be insoluble in Hex/EA used for HPLC 
analysis. Therefore, the coupling efficiencies were analyzed based on the obtained 













Glycosylation Conditions: GlcNAc(I): -20oC (5 min) to 0oC (20 min), 6.5 eq, 2x, 




































Table 5d: FMOC traces for automated glycan assembly of PNAG hexamer using the 
Glyconeer synthesizer 
Glycosylation Conditions: GlcNAc (I): -20oC (5 min) to 0oC (20 min), 6.5eq, 2x, GlcNAc 
(II-VI): -20oC (5 min) to 0oC (20 min), 6.5eq, 1x  
PNAG hexamer (protected):  
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The FMOC traces in Table 5d show that each glycosylation step proceeds with nearly 
quantitative yield. Therefore, owing to the positive results obtained from the FMOC 
traces, the PNAG pentamer and hexamer obtained upon photocleavage was directly 
subjected to global deprotection. 
 
5.6   Global Deprotection of poly-N-acetyl-glucosamine oligomers 
 
After purification and analysis of the protected PNAG oligomers, the permanent 
protecting group, namely, benzyl ether (OBn) was cleaved by hydrogenation using a 
Palladium catalyst, thereby affording the fully deprotected PNAG oligomers with a 
pentanyl amine spacer at the reducing end.  













The global deprotection of the PNAG tetramer was performed according to the 





















The HPLC trials in Table 5e indicate that the global deprotection of PNAG tetramer 
was successful, and proceeded with a satisfactory yield. The reproducibility of the 


































































PNAG pentamer (deprotected): 


































     42% 
PNAG hexamer (deprotected): 
Table 5g: Global deprotection of PNAG hexamer  
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With the fully deprotected PNAG oligomers in hand, the oligomers were used to 
evaluate the binding specificity of P. aeruginosa PaO1 PelA glycoside hydrolase 
domain.   
 
 
5.7   Characterisation of the binding affinity of PaO1 hydrolase 
towards different oligomers 
This ITC measurement was performed by Dr. Christian Roth and co-workers at Max 
Planck institute for Colloids and Interfaces. The affinity of the enzyme towards the 
synthesized PNAG oligomers was evaluated using Isothermal titration calorimetry 
(ITC). Initially only the tetramer was evaluated for binding (Fig.6). ITC confirmed 
binding of the tetramer to the enzyme albeit with only moderate affinity of 1.81±0.40 
µM. Furthermore, the evaluation of the thermodynamic profile showed that the reaction 
is nearly exclusively driven by entropy, whereas the enthalpic contribution is negligible. 
This points towards a binding mechanism, which involves the binding via hydrogen 
bonds, combined with the desolvation of the ligand. Unfortunately, the low enthalpic 
contributions made the measurements challenging, due to the low measurable heat. 
Subsequently, with optimized experimental conditions the hexamer was evaluated for 
binding. Surprisingly, the affinity with a KD of 2.85±0.97 µM is slightly worse compared 
to the tetramer. This indicates that the population of further subsites on the enzyme is 
not favourable. Recently, it was shown that glycoside hydrolase PgaB from Bortadella 
bronchiseptica favourably recognises partially deacetylated PNAG and is not active 
on homo-GlcNAc oligomers.  It might be possible that the population of further subsites 
and a gain of affinity might require deacetylated glucosamine moieties within the 
oligomer in a particular spacing.  Indeed, recently it was shown that most likely subsite 
+1 most likely needs to be populated by a deacetylated glucosamine residue for 
efficient catalysis.   
A comprehensive study on fungal hydrolases revealed that the PAO1 hydrolase, 
studied here, is rather active on Pel type polymers or Galactosaminogalactans with an 
α-1,4 linkage. Thus, the hydrolase had to be classified into family 166 of the 
carbohydrate active enzyme database (Lombard 2014). Nevertheless the moderate to 
low affinity of the ligand might indicate some plasticity in the substrate binding cleft or 














































Figure 6: Evaluation of binding affinity of PNAG tetramer for PAO1 enzyme from Pseudomonas 
aeruginosa using ITC  
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5.8   Conclusion and Outlook 
 
The optimized synthetic protocols developed for the synthesis of BB1 (see Chapters 
2 and 3 for more details) were successfully applied for the synthesis of BB8 and BB9 
in excellent yields and multi-gram quantities. The ready availability of optimized 
protocols enabled rapid access to the diverse, differentially protected building blocks 
(BB8 and BB9) in multi-gram quantities. With the building blocks in hand, the 
automated glycan assembly of the homo-GlcNAc oligomers were successfully 
attempted, affording the target structures in excellent yields. Unfortunately, the 
protected PNAG pentamer and hexamer could not be purified, therefore, the crude 
samples were subjected to global deprotection. The subsequent optimized global 
deprotection protocols led to fully deprotected ready to use oligomers, which were then 
used to characterise the substrate specificity of the glycosyl hydrolase PaO1 from 
Pseudomonas aeruginosa by Isothermal Titration Calorimetry (ITC). The experiments 
revealed that the PNAG tetramer and hexamer exhibited similar affinity towards the 
PaO1 enzyme. This observation indicated a saturation in the subsites of the enzyme 
towards homo-GlcNAc oligomers. Therefore, it could be speculated that deacetylated 
glucosamine moieties within the oligomer might lead to increased binding, which 
further opens up the possibility of synthesizing co-polymers containing different 
patterns of acetylated and deacetylated glucosamine (ABAB, AABB) oligomers in 
order to further expand the library of PNAG oligomers for evaluating binding affinities 












Automated Glycan Assembly of the N-glycan Core 
Structure: Exploring the Scope of Automated Glycan 
Assembly Using the Glyconeer 
 
6.1 Introduction 
Protein glycosylation is one of the most complex post-translational modifications.39 
Glycans are found on diverse protein classes and are often located on the extracellular 
side of the cell-surface.  Toxins, lectins, antibodies, hormones, viruses and bacteria 
interact with membrane bound glycoproteins and thereby participate in various 
biological processes. Glycoproteins are also involved in intracellular interactions, and 
play a major role in signal transduction.39 There are two major types of protein 
glycosylation, namely, N-glycosylation and O-glycosylation.39 
The biosynthesis of N-glycans involves the transfer of a pre-synthesized 
tetradecasaccharide (Glc3Man9GlcNAc2) from dolichol phosphate to an asparagine 
residue using the enzyme oligosaccharyl transferase (OTS). The terminal glucose 
residues are then removed by a complex pathway to form the common 
pentasaccharide core (Man3GlcNAc2). This core pentasaccharide is found to be highly 
conserved among eukaryotic N-glycans. It is further extended to obtain high mannose, 
hybrid- or complex type N-glycans. The recognition sites for N-glycans consist of a 
common peptide sequence of Asn-Xaa-Ser/Thr, where Xaa can be any of the 20 







Highly conserved core of N-glycans 
Figure 1: Structure of the N-linked glycans 
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This chapter is divided into three sections. The first section highlights the retrosynthetic 
analysis of the target structure and identification of building blocks, followed by the 
strategy adopted to establish the beta mannose linkage. The second section describes 
the solution phase synthesis of the beta mannose containing dimer, followed by 
establishing optimized reaction conditions in order to achieve the optimal 
stereoselectivity. Finally, the third section discusses the synthesis of the N-glycan core 
structure via automation using the Glyconeer synthesizer.  
 
6.2   Establishing the beta mannosidic linkage 
 
The stereoselective formation of beta mannosidic linkages is one of the most 
challenging glycosidic linkages to establish via synthetic carbohydrate chemistry. A 
number of methods have been described in the literature for forming beta mannosidic 
linkages such as the synthesis of a beta glucoside, followed by inversion of C-2 
configuration either by a nucleophilic displacement or an oxidation–reduction 
sequence.6 Intramolecular aglycon delivery has also been developed by several 
research groups as a method for the synthesis of 1,2-cis glycosides and has been 
applied to the synthesis of beta mannosides. Crich et.al.30 have reported the 
stereoselective formation of beta mannosides using 4,6-O-benzylidene intermediates 
in the presence of triflic anhydride and 2,6-di-tert-butyl-4-methylpyridine.30 In this 
method, the 4,6-O-benzylidene mannosyl sulfoxide is first activated with triflic 
anhydride to give α-mannosyl triflate. The acceptor then displaces the triflate 
intermediate to afford the β-mannoside.  
The method of choice adopted for establishing the beta mannosidic linkage is the Crich 
beta mannosylation using a mannose sulfoxide donor (BB11). As a start, a “proof of 
concept” study was performed to establish the beta mannosidic linkage via solution 
phase glycosylations. The beta mannose containing dimer was then used as a building 
block in order to assemble the N-glycan core structure using the Glyconeer 
synthesizer. Owing to the complexity of establishing the beta mannose linkage, this 
strategy provided the opportunity to procure the dimer in multi-gram quantities, and 
thereby minimize the time required to obtain the target structure. Finally, in order to 
extend the N-glycan chain using the Glyconeer, a differentially protected mannose 
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building block (BB12) was designed, with the possibility of selectively elongating the 














The mechanism proposed by Crich et.al.30 involves the displacement of the triflate 
from 6h by the carbohydrate acceptor (ROH) to give 6i that proceeds with the 
development of substantial oxacarbenium ion character. This observation may be 
interpreted either by a fully dissociative mechanism involving the formation of a 
transient contact ion pair (CIP) (Scheme1, path a), or by an equivalent mechanism 
involving an “exploded” transition state (Scheme1, path b). In the CIP mechanism, the 
triflate anion is closely associated with the face of the oxacarbenium ion from which it 
departs and shields that face from the incoming alcohol. In the alternative mechanism 
there is a loose association of the nucleophile with the anomeric center as the leaving 
group departs. The minor amount of α-anomer formed in these reactions most likely 
arises through the formation of a looser, perhaps solvent-separated, ion pair (SSIP) 
intermediate, which is in equilibrium with an initial CIP. The function of the torsionally 
disarming benzylidene group is to oppose rehybridization at the anomeric carbon, 
thereby shifting the complete set of equilibria toward the covalent triflate and away 
from the SSIP, thereby minimizing α-glycoside formation.  
 
Scheme 1: Proposed glycosylation mechanism for formation of beta mannose linkage30 
a CIP 






6.3   Retrosynthetic analysis of target structure and identification of 
building blocks 
The building blocks required for the synthesis of the target structures were identified 
upon retrosynthetic analysis as shown in Figure 2. In order to elongate the chain along 
the O4 position, BB10 was modified with the 9-fluorenylmethoxycarbonyl (FMOC) 
carbonate at this position. Secondly, to establish β-glycosidic linkage, participating 
protecting group such as trichloroacetamide (TCA) was installed in C2 position of 
BB10. The mannose building block (BB11) was modified as the benzylidene sulfoxide 
donor in order to establish the β-mannosidic linkage according to the Crich beta 







Figure 2: Retrosynthetic analysis of target structure and identification of building blocks (I) retrosynthetic 







6.4   Synthesis of building blocks  
 
The reaction conditions optimized for the synthesis of building blocks (see Chapter 2 
for more details) were applied to procure BB11. The first four steps of the synthetic 
scheme, namely, peracetylation, thioglycosylation, removal of acetyl groups, and 
introduction of the benzylidene acetal protecting group could be performed faster due 
to the ready availability of optimized synthetic protocols (Chapter 2). Similarly, the 
synthesis of BB10 could be expedited by starting the synthesis from the intermediate 
5a.  
6.4.1   Mannose building block           
 
 
 BB11 BB12 
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The synthesis of building blocks commenced from the free sugar 6a, followed by 
synthesis of the peracetylated intermediate 6b, that in turn was converted into the 
thioglycoside 6c. Then, the acetate groups were removed to afford intermediate 6d. 
The C4 and C6 positions were then modified as a benzylidene intermediate 6e. 
Subsequently, the C2 and C3 positions were benzylated to obtain intermediate 6f. 
Finally, the thioglycoside intermediate was then converted into a sulfoxide donor 
BB11. Secondly, the C3 position of intermediate 6e was modified as a silyl ether to 
afford intermediate 6g, which was the modified as a benzyl ether (OBn) at C2 position 
to obtain intermediate 6h. It was then converted into the sulfoxide building block BB12. 
Additionally, in this synthetic scheme, the intermediates could either be crystallized, or 
used for the next synthetic step without any purification, thereby significantly reducing 
the time required to procure the final building blocks (BB11, BB12).  
 




As depicted by the synthetic scheme, the BB10 was synthesized in two steps, thereby 
enabling faster access to the final building block. This synthetic scheme further 
highlights the importance of procuring intermediate 5a in multi-gram quantities, which 











6.5   Performing solution phase glycosylation reaction to establish 
beta mannosidic linkage 
Initially, the beta mannosylation was attempted via solution phase synthesis as a 
“proof of concept” to successfully achieve the formation of the beta mannosidic 
linkage. Since the method of choice was the Crich mannosylation, the mannosyl donor 
BB11 was glycosylated to the glucosamine acceptor 5b in the presence of Tf2O and 
TTBMP at -78oC. The various parameters associated with the reaction, namely, 
concentration of activators (Tf2O, TTBMP), donor and acceptor, as well as the order 
of adding reagents were varied and their effect on the formation of the beta mannosidic 





The data shown in Table 6a indicate that the variations in reaction conditions were 
unsuccessful in driving the reaction to afford exclusively beta mannose product. On 
the contrary, the stereoisomeric ratios obtained mostly yielded the alpha anomer, 
except in one case, where both the anomers were obtained in 1:1 ratio. Therefore, 
owing to the ambiguous results obtained upon solution phase glycosylation, the 
strategy to obtain the N-glycan core structure was modified.  Efforts were then 
Reaction Conditions α/β Ratio* 
Donor (1eq), Acceptor(1 eq), DTBMP(2.eq), 
Tf2O (0.65 eq) 
No product formed 
Donor (1eq), Acceptor(1.6 eq), DTBMP(1.5 
eq), Tf2O (0.65 eq) 
2:1 
Donor (1eq), Acceptor( 2.5eq), 
DTBMP(1eq), Tf2O (0.5 eq) 
3:1 
Donor (1eq), Acceptor(2eq), 
DTBMP(2.5eq),Tf2O (0.5 eq) 
1:1 
Table 6a: Effect of varying the reaction parameters on the stereoselectivity  
Note - * by NMR 
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turned towards establishing the beta mannose linkage via automation using the 
Glyconeer synthesizer in a bid to obtain streoselective formation of the beta mannose 
linkage.   
 
6.6   Automated glycan assembly of an N-glycan core structure 
In order to assemble the N-glycan core structure via automation using the Glyconeer 
synthesizer, the optimized synthetic modules developed for synthesizing the Lewis 

















Module no.  Module name Conditions 
1. Resin swelling DCM, 25oC, 30 min 
2. Acid wash TMSOTf in DCM(anhydrous), -20oC 
3. Thioglycoside Glycosylation BB in DCM (anhydrous), T1(5 min) to T2 (20 
min) 
4. Sulfoxide Glycosylation Tf2O/DTBMP,  1:3 in DCM(anhydrous) 
5.       Ac2O acidic capping  10% Ac2O, 2% Methanesulfonic acid in 
DCM(anhydrous)(v/v) 
6. FMOC Deprotection 20% Piperidine in DMF(v/v), 25oC 
 
Module 2,3,4, 
Table 6b: Synthetic modules used for automated glycan assembly of N-glycan core structure 





The synthesis was initiated by glycosylating BB10 to the solid support, followed by 
capping the deletion sequences. The temporary protecting group, namely, FMOC 
was cleaved, and BB10 was glycosylated to the C4 position. Thereafter, BB11 was 
glycosylated to the C4 position to afford the target structure.  
 
6.6.1   Establishing optimal glycosylation conditions for BB 10 and 
BB 11 
Initially, 6.5 equivalents and one glycosylation cycle was used, and the coupling 




















Table 6c: Automated glycan assembly of N-glycan core structure using the Glyconeer synthesizer 
Glycosylation Conditions: GlcNAc (I) : -20oC (5 min) to 0oC (20 min), 6.5 eq, 1x, GlcNAc 
(II) : -20oC (5 min) to 0oC (20 min), 6.5 eq, 1x, Man:  -20oC (5 min) to 0oC (20 min), 6.5 eq, 
2x 
Monomer Capped Dimer 
Uncapped Dimer 




The HPLC trace in Table 6c indicates that the glycosylation conditions used, such as 
6.5 equivalents of BB10 with one glycosylation cycle led to inefficient coupling, thereby 
leading to the formation of a monomer and uncapped dimer side products. It also 
confirmed that the coupling of BB11 was unsuccessful, thereby affording no product. 
My efforts were turned towards improving the coupling efficiency of BB10 by 
increasing the number of glycosylation cycles to two for both rounds of glycosylation 










The results obtained in Table 6d indicate that the increased number of glycosylation 
cycles improved the coupling efficiency of BB10 significantly, which was proved by the 
absence of any deletion sequence. With optimized glycosylation conditions for BB10 
in hand, efforts were then turned towards glycosylating the Mannose sulfoxide BB11.  
Similar to BB10, the BB11 was glycosylated using the standard conditions, such as 
6.5 equivalents and two glycosylation cycles. Another important parameter, namely 
temperature was expected to play a major role in establishing the beta mannosidic 










Table 6d: Automated glycan assembly of Chitin dimer  
Glycosylation Conditions: GlcNAc(I) : -20oC (5 min) to 0oC (20 min), 6.5 eq, 2x, GlcNAc(II) 














The HPLC traces in Table 6e indicate that the synthesis of the beta mannose 
containing dimer was successful.  The 1H NMR of the reaction mixture confirmed the 
formation of beta mannoside. This finding proved beyond doubt that the glycosylation 
conditions used for the coupling of the BB11 lead to the successful and stereoselective 
installation of the beta mannose linkage via automation using the Glyconeer 













     30% 
Man-β-1,4-GlcNAc: 
Table 6e: Automated glycan assembly of beta mannose containing dimer via automation using the 
Glyconeer synthesizer  
Glycosylation Conditions: GlcNAc(I):-20oC (5 min) to 0oC (20 min), 6.5 eq, 2x, GlcNAc(II) 




6.7   Conclusion 
 
The optimized synthetic protocols developed for procuring the building blocks (see 
Chapter 2 for more details) were successfully applied to obtain BB10 and BB11 in 
satisfactory yields. The ready availability of optimized protocols ensured faster access 
to diverse, differentially protected BBs 10-12. Thereafter, with the building blocks in 
hand, the beta mannosylation was attempted via solution phase glycosylation, which 
proved to be unsuccessful in affording a stereoisomeric excess, instead leading to the 
formation of anomeric mixtures. However, the automated glycan assembly of the beta 
mannose containing dimer showed promising results. A stereoselective beta mannose 
anomer could be obtained, without any anomeric mixtures. Thus, with these promising 
results in hand, the reproducibility of the glycosylation conditions can be established. 
Secondly, the diverse, differentially protected mannose BB12 can be utilized to extend 
the N-glycan chain via automation using the Glyconeer synthesizer. Lastly, the results 
obtained in this chapter open up the possibility of synthesizing the N-glycans, including 
























Conclusion and Outlook 
 
Automated glycan assembly has enabled rapid access to a plethora of complex 
oligosaccharides. The aim of this study was to streamline the entire process of 
automation in order to access a repertoire of biologically relevant glycans. The first 
step towards achieving this goal was to get faster access to diverse, differentially 
protected building blocks. The synthesis of these monomers was streamlined, and 
optimized protocols were developed, which enabled procuring many building blocks in 
multigram quantities (as explained in Chapter 2). Additionally, in order to further 
reduce the time required to obtain the final building blocks, the benzylidene derivatives 
1e, 2a (Chapter 2) were identified as common intermediates that were stocked up in 
multi-gram quantities, thereby significantly reducing the number of synthetic steps 
required to access the building blocks, and hence saving time.  
With the building blocks in hand, the target glycans were then assembled via 
automation using the Glyconeer synthesizer. Firstly, optimized synthetic protocols 
were developed for the automated glycan assembly of the Lewisx epitope (see Chapter 
3 for more details) to obtain the target glycan in excellent yields. Following the 
successful synthesis of the Lewisx epitope structure on a 0.0125 mmol scale, the 
synthesis was then scaled up to a 0.025 mmol scale, wherein it was observed that a 
successful synthesis could only be achieved by increasing the argon mixing, which 
further established the importance of effective mixing in scale-up synthesis. These 
optimized protocols were then employed to obtain the Lewisa, Lewisy and Lewisb 
antigens via automation (see Chapter 4 for more details). The automated glycan 
assembly of Lewisy and Lewisb epitopes proved to be challenging. However, this 
problem could be addressed by adding a lactose spacer to the Lewisy epitope 
structure, thereby affording the target structure in satisfactory yields.  
In order to further expand the repertoire of immunologically relevant glycans using the 
Glyconeer synthesizer, the N-acetyl-glucosamine oligomers, namely, tetramer, 
pentamer and hexamer were synthesized via automation with satisfactory yields (see 
Chapter 5 for more details). The successful synthesis of these oligomers not only 
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proved the reproducibility of the synthetic protocols developed for the AGA of complex 
glycans, but also validated the Glyconeer for synthesizing long structures.  
Since the PNAGs are known to be important constituents in the biofilm matrix of 
Staphylococci and Pseudomonas species, the PNAG oligomers accessed via AGA 
were then used to characterise the substrate specificity of the glycosyl hydrolase PaO1 
from Pseudomonas aeruginosa by Isothermal Titration Calorimetry (ITC). The 
experiments revealed that the PNAG tetramer and hexamer exhibited similar affinity 
towards the PaO1 enzyme. This observation indicated a saturation in the subsites of 
the enzyme towards homo-GlcNAc oligomers. Therefore, it could be speculated that 
deacetylated glucosamine moieties within the oligomer might lead to increased 
binding, which further opens up the possibility of synthesizing co-polymers containing 
different patterns of acetylated and deacetylated glucosamine (ABAB, AABB) 
oligomers in order to further expand the library of PNAG oligomers for evaluating 
binding affinities towards PaO1 enzyme.  
Finally, in a bid to push the boundaries of AGA, the beta mannosidic linkage, which is 
known to be one of the most difficult glycosidic linkages to establish via synthetic 
carbohydrate chemistry was attempted via automation using the Glyconeer 
synthesizer. The successful synthesis of the beta mannose via AGA leads to the 
possibility of synthesizing the highly branched N-linked glycans (see Chapter 6 for 















8.1   General Methods and Materials 
All reagents and solvents were acquired from commercial sources, unless stated otherwise. 
The resin equipped with a photocleavable linker (loading 0.40 mmol/g) was obtained from 
GlycoUniverse stock. Anhydrous solvents were obtained from a Solvent Dispensing System 
(J.C. Meyer). Amberlite IR-120 (Across Organics) protonic exchange resin was rinsed with 
THF, water, methanol and dichloromethane before use. NMR spectra were obtained using 
Ascend 400 (Bruker) and Agilent 400 MHz NMR Magnet (Agilent Technologies) spectrometers 
at 400 MHz (1H) and 100 MHz (13C) ,Varian 600 (Agilent) at 600 MHz (1H) and 150 MHz (13C), 
or an Ascend 700 (Bruker) at 700 MHz (1H) and 176 MHz (13C). CDCl3 was used as solvent 
and chemical shifts (δ) referenced to residual non-deuterated solvent peak unless stated 
otherwise. Splitting patterns are indicated as s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet; br, broad singlet for 1 H-NMR data. NMR chemical shifts (δ) are reported in ppm and 
coupling constants (J) are reported in Hz. Assignments were supported by COSY and HSQC 
experiments and compared with literature data when available. MALDI-TOF spectra were 
obtained with a Daltonics Autoflex Speed spectrometer (Bruker) using 2,5-dihydroxybenzoic 
acid (DHB) as matrix. ESI-HRMS were performed with a Xevo G2-XS Q-Tof (Waters). HPLCs 
were performed on Agilent 1200 Series systems, and analysed using YMC-Diol-300 column, 






















8.2    Experimental procedures for synthesis of building blocks 
 






Procedure: This procedure maintained an inert atmosphere throughout. To 45 mmol of 
compound 1b (22.1 g) 50 mL anhydrous dichloromethane (final concentration ~ 0.9 M) were 
added under argon atmosphere and placed on an ice bath to cool down to 0 °C. Then, 
50 mmol ethanethiol (3.7 mL, 1.1 eq.) were added via a syringe followed by dropwise addition 
of 33 mmol BF3 · Et2O (4.2 mL, 0.7 eq.) via a dropping funnel. The reaction was then allowed 
to stir at 0 °C for another 10 minutes, then removed from the ice bath and allowed to continue 
stirring for another 12 hours (overnight). The next day, the reaction mixture was poured into 
250 mL water and kept to stir for some time. The organic phase was then separated, washed 
with 250 mL saturated aqueous NaHCO3 (2x) and 250 mL brine (2x) and dried over MgSO4 
before it was concentrated and dried under high vacuum. 
Purification: The crude material (22.0 g) was dissolved in ethyl acetate (~ 100 mL) at 50 °C. 
When all of it dissolved, it was poured into a 1 L Erlenmeyer flask and, while stirring, hexane 
(~ 800 mL) was slowly added dropwise via a dropping funnel until precipitation started. The 
remainder volume of hexane was then quickly added under vigorous stirring. The precipitate 
so obtained was kept in the fridge overnight. The next day, the precipitate was filtered and 
washed with cold hexane to give 16.5 g of pure compound 1c after drying. 
% Yield = 88 
Analysis: TLC: Rf = 0.5 (Hex/EA 2:1) 
1H NMR (700 MHz, CDCl3) δ= 7.08 (d, J = 9.3 Hz, 1H, -NHCO), 5.39 – 5.32 (m, 1H, H-3), 5.10 
(t, J = 9.7 Hz, 1H, H-4), 4.68 (d, J = 10.3 Hz, 1H, H-1), 4.23 (dd, J = 12.3, 5.3 Hz, 1H, H-6a), 
4.17 – 4.09 (m, 1H, H-2, H-6b), 3.77 (ddd, J = 10.0, 5.2, 2.4 Hz, 1H, H-5), 2.77 – 2.65 (m, 2H, 
-SCH2), 2.06, 2.01 (d, J = 2.5 Hz, 6H, 3x-OAc), 1.25 (t, J = 7.4 Hz, 3H, -CH3). 
 13C NMR (176 MHz, CDCl3) δ=171.21, 170.78, 169.31, 162.02 (4x C=O), 83.87 (C-1), 76.14 
(C-5), 73.27 (C-3), 68.60 (C-4), 62.46 (C-6), 54.73 (C-2), 24.36 (COCH3), 20.84 (COCH3), 











Procedure: This procedure maintained an inert atmosphere throughout. In a 250 mL round 
bottom flask, 21 mmol of 1a (10g) were flushed with argon for several minutes before adding 
23 mL anhydrous DCM (final concentration: ~ 0.9M). The reaction flask was then placed in an 
ice bath to cool down to 0oC. Then, p-toluylthiol (22 mmol, 3g) was added, followed by 
dropwise addition of BF3.Et2O (16mmol, 2mL) via a dropping funnel. After the addition, the 
reaction was left to stir at room temperature for ~ 12 hours. Then, the reaction mixture was 
diluted with DCM (~ 100mL) and poured into a separating funnel. It was extracted with H2O (~ 
90 mL, 1x), Sat. aq. NaHCO3 (~ 90 mL, 2x) and Brine (~90 mL, 1x). The combined organic 
phase was dried with MgSO4, concentrated and dried under high vacuum.  
Purification: The crude material was dissolved in ethyl acetate (~ 25 mL) at 50oC on a heating 
mantle. Then, Hexane (~350 mL) was first added dropwise until precipitation starts, and then 
quickly under rigorous stirring. The precipitate so obtained was kept in the fridge overnight to 
induce more precipitation. Then, the precipitate was washed with cold Hexane to give 10g 
pure GlcN2. 
% Yield = 80 
Analysis: TLC:  Rf = 0.5 (Hex/EA 2:1) 
1H NMR (400 MHz, CDCl3) δ 7.42 – 7.38 (m, 2H,-Ar), 7.11 (d, J = 3.1 Hz, 1H,-Ar), 7.10 – 7.08 
(m, 1H), 5.35 (t, J = 9.9 Hz, 1H,H-3), 5.04 (t, J = 9.8 Hz, 1H,H-4), 4.76 (d, J = 10.4 Hz, 1H,H-
1), 4.22 (dd, J = 12.3, 5.2 Hz, 1H,H-6a), 4.17 (dd, J = 12.3, 2.6 Hz, 1H,H-6b), 4.01 (q, J = 10.2 
Hz, 1H,H-2), 3.74 (ddd, J = 10.1, 5.2, 2.6 Hz, 1H,H-5), 2.34 (s, 3H,-SCH3), 2.08 (s, 3H,-
COCH3), 2.00 (s, 3H,-COCH3), 1.88 (s, 3H,-COCH3). 
13C NMR (101 MHz, CDCl3) δ 171.25 (OC=O), 170.68(OC=O), 169.27(OC=O), 
161.74(OC=O), 139.19(-Ar), 134.18(-Ar), 129.87(-Ar), 127.66(-Ar), 92.38(CCl3), 86.72(C-1), 












Procedure:  This procedure maintained an inert atmosphere throughout. In a 100 mL 3-
necked round bottom flask, 22 mmol of 1a (11g) were flushed with argon for several minutes 
before adding 26 mL anhydrous DCM (final concentration: ~ 0.9M). The reaction flask was 
then placed in an ice bath to cool down to 0oC. 5-tert-butyl-2-methyl-phenyl thiol (24 mmol, 4.4 
mL) was added, followed by dropwise addition of BF3.Et2O (16.4 mmol, 2 mL) via a dropping 
funnel. After the addition, the reaction was removed from the ice bath and left to stir at room 
temperature for ~ 12 hours. Then, the reaction mixture was diluted with EA (~100mL) and 
poured into a separating funnel. It was then extracted with H2O (~ 75 mL, 1x) Sat. aq. NaHCO3 
(~ 75 mL, 2x) and Brine (~ 75 mL, 2x). The combined organic layer was dried with MgSO4, 
concentrated and dried under high vacuum.  
Purification: The crude material was dissolved in Ethyl acetate (~ 30 mL) at 50oC on a heating 
mantle. When all of it dissolved, Hexane (~ 150 mL) was first added dropwise until precipitation 
started, and then quickly under rigorous stirring. The precipitate so obtained was then kept in 
the fridge overnight, and then washed and flitered with cold Hexane to give 10g of pure GlcN 
3.  
% Yield = 58 
Analysis: TLC: Rf = 0.6 (Hex/EA 2:1) 
1H NMR (700 MHz, CDCl3) δ 7.59 (d, J = 2.2 Hz, 1H), 7.25 (d, J = 9.5 Hz, 1H, -NHCO), 7.24 
(d, J = 2.1 Hz, 1H), 7.13 (dd, J = 7.9, 0.9 Hz, 1H), 5.37 (dd, J = 10.4, 9.4 Hz, 1H,H-3), 5.10 (t, 
J = 10.5, 8.7 Hz, 1H,H-4), 4.73 (d, J = 10.5 Hz, 1H,H-1), 4.24 (dd, J = 12.3, 5.2 Hz, 1HH-6a), 
4.18 (td, J = 10.4, 9.3 Hz, 2H,H-2), 4.11 (dd, J = 12.3, 2.2 Hz, 1H,H-6b), 3.71 (ddd, J = 10.1, 
5.2, 2.2 Hz, 1H,H-5), 2.38 (s, 3H,-SCH3), 2.03 (d, J = 20.2 Hz, 6H,-COCH3), 1.75 (s, 3H,-
COCH3), 1.28 (s, 9H,-C(CH3)3). 
 
13C NMR (176 MHz, CDCl3) δ 171.40(OC=O), 170.63(OC=O), 169.08(OC=O), 
161.83(OC=O), 149.76(-Ar), 137.94(-Ar), 131.60(-Ar), 131.21(-Ar), 130.16(-Ar), 126.11(-Ar), 
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87.76, 77.24, 77.06, 76.88, 75.95, 73.43, 68.33, 62.43, 54.53(C-2), 31.33(-C(CH3)3, 20.73(-
SCH3), 20.49(-CH3), 20.12(-CH3). 
 





Procedure:  This procedure maintained an inert atmosphere throughout. To 17mmol of 
peracetylated mannose (6.6g) were added 39 mL anhydrous DCM (final concentration: ~ 
0.4M) under argon atmosphere and placed in an ice bath to cool down to 0oC. Then, EtSH 
(3mmol, 2.5 mL) was added followed by dropwise addition of BF3.Et2O (42mmol, 5.2mL). 
Then, the reaction was left to stir at room temperature for ~ 12 hours (overnight). Then, the 
reaction mixture was diluted with DCM (~ 85mL) and poured into a separating funnel. It was 
then extracted with Sat. aq. NaHCO3 (~ 100 mL, 2x) and Brine (~ 100 mL, 2x). The combined 
organic phase was dried with MgSO4, concentrated and dried under high vacuum.  
Purification: The crude material was dissolved in Ethyl Acetate (~ 20 mL) at 50oC on a heating 
mantle. When all of it dissolved, Hexane (~100mL) was first added dropwise at room 
temperature until precipitation starts, and then quickly under rigorous stirring. The precipitate 
so formed was kept in the fridge overnight to induce more precipitation. Then, it was washed 
and filtered with cold Hexane to give 4.2 g of pure Man1.  
% Yield = 63 
Analysis: TLC: Rf = 0.5 (Hex/EA 2:1) 
1H NMR (700 MHz, CDCl3) δ 5.33 – 5.28 (m, 2H, H-3, H-4), 5.27 (d, J = 1.8 Hz, 1H,H-1), 5.24 
(dd, J = 10.0, 3.3 Hz, 1H,H-5), 4.38 (dddd, J = 9.8, 5.4, 2.4, 0.7 Hz, 1H,H-2), 4.30 (dd, J = 
12.3, 5.4 Hz, 1H,H-6a), 4.08 (dd, J = 12.2, 2.4 Hz, 1H,H-6b), 2.68 – 2.57 (m, 2H,-SCH2), 2.15 
(s, 3H,-COCH3), 2.07 (s, 3H,-COCH3), 2.03 (s, 3H,-COCH3), 1.97 (s, 3H,-COCH3), 1.29 (t, J = 
7.4 Hz, 3H,-SCH3). 
 
13C NMR (176 MHz, CDCl3) δ 170.69(OC=O), 170.08(OC=O), 169.87(OC=O), 
169.83(OC=O), 82.38(C-1), 71.28(C-3), 69.59(C-2), 69.02(C-4), 66.49(C-5), 62.54(C-6), 











Procedure: This procedure maintained an inert atmosphere throughout. To 25 mmol of 
pentaacetate mannose (9.6g), were added 61 mL anhydrous DCM (final concentration: ~ 0.4 
M) under argon atmosphere and placed in an ice bath to cool down to 0oC. Then, p-toluylthiol 
(49 mmol, 6.1 g) were added followed by dropwise addition of BF3.Et2O (61mmol, 7.6mL). 
Then, the reaction was allowed to stir at room temperature for ~ 12 hours. Then, the reaction 
was diluted with DCM (~ 100 mL) and poured into a separating funnel. It was then extracted 
with Sat. aq. NaHCO3 (~ 100 mL, 2x) and Brine (~ 100mL, 2x). The combined organic layer 
was dried with MgSO4, concentrated and dried under high vacuum.  
 % Yield = 60 
Analysis: TLC: Rf = 0.6 (Hex/EA 2:1) 
1H NMR (700 MHz, CDCl3) δ 7.38 – 7.36 (m, 2H,-Ar), 7.13 – 7.11 (m, 2H,-Ar), 5.49 (dd, J = 
2.8, 1.6 Hz, 1H,H-2), 5.41 (d, J = 1.6 Hz, 1H,H-1), 5.32 (dd, J = 3.8, 1.1 Hz, 2H,H-4,H-3), 4.60 
– 4.52 (m, 1H,H-5), 4.29 (dd, J = 12.2, 5.9 Hz, 1H,H-6a), 4.10 (dd, J = 12.3, 2.4 Hz, 1H,H-6b), 
2.32 (s, 3H,-COCH3), 2.14 (s, 3H,-SCH3), 2.07 (s, 3H,-COCH3), 2.05 (s, 3H,-COCH3), 2.01 (s, 
3H,-COCH3). 
 
13C NMR (176 MHz, CDCl3) δ 170.59 (OC=O)), 169.97(OC=O), 169.86(OC=O), 
169.80(OC=O), 132.71(-Ar), 130.04(-Ar), 129.93(-Ar), 129.88(-Ar), 86.10(C-1), 70.96, 69.52, 














Procedure: This procedure maintained an inert atmosphere throughout. To 11.5mmol of 
peracetylated fucose (3.8g), 58mL anhydrous DCM (final concentration: ~ 0.2M) were added 
under argon atmosphere and placed in an ice bath to cool down to 0oC. Then, EtSH (13mmol, 
1mL) were added followed by dropwise addition of BF3.Et2O (15mmol, 2mL). Then, the 
reaction was left to stir at room temperature for ~ 12 hours. Then, the reaction was quenched 
with Sat. aq. NaHCO3 (~ 80mL) and stirred for a while. It was then poured into a separating 
funnel and the organic phase was extracted. The aqueous phase was then extracted with 
DCM (~80mL, 3x). The combined organic phase was then washed with Brine (~80mL, 3x). It 
was then dried with MgSO4, concentrated and dried under high vacuum.  
% Yield = 60 
Analysis: TLC: Rf = 0.6 (Hex/EA 2:1) 
1H NMR (500 MHz, CDCl3) δ 5.25 (dd, J = 3.4, 1.1 Hz, 1H,H-4), 5.20 (t, J = 9.9 Hz, 3H), 5.03 
(dd, J = 10.0, 3.5 Hz, 1H), 4.44 (d, J = 9.9 Hz, 1H), 3.80 (qd, J = 6.4, 1.1 Hz, 1H), 2.81 – 2.63 
(m, 3H), 2.15 (s, 3H,-OCOCH3), 2.04 (s, 3H,-OCOCH3), 1.96 (s, 3H), 1.27 (t, 3H), 1.20 (d, J = 
6.5 Hz, 3H,-CH3). 
 
13C NMR (126 MHz, CDCl3) δ 170.76(OC=O), 170.25(OC=O), 169.78(OC=O), 83.63(C-1), 
















Procedure: This procedure maintained an inert atmosphere throughout. To 11.5 mmol of 
peracetylated fucose (3.8g), 58 mL anhydrous DCM (final concentration: ~ 0.2 M) were added 
under argon atmosphere, and placed in an ice bath to cool down to 0oC. Then, p-toluylthiol 
(13mmol, 1.5g) were added followed by dropwise addition of BF3.Et2O (15mmol, 1.85mL). 
Then, the reaction was allowed to stir at room temperature for ~ 12 hours. The reaction mixture 
was then quenched with Sat. aq. NaHCO3 (~80 mL) and stirred for a while. Then, it was poured 
into a separating funnel, and the organic phase was extracted. The aqueous phase was 
extracted with DCM (~ 80mL, 2x). The combined organic phase was extracted with Brine (~80 
mL, 2x). It was then dried with MgSO4, concentrated and dried under high vacuum.  
Purification: The crude material was dissolved in Ethyl acetate (~ 10 mL) at 50oC on a heating 
mantle. When all of it dissolved, Hexane (~ 80 mL) was added at room temperature under 
constant stirring. The precipitate so obtained was kept in the fridge. It was then washed and 
filtered with cold hexane to give 1.1 g of pure Fuc2.  
% Yield = 50 
Analysis: TLC: Rf = 0.78 (Hex/EA 2:1) 
1H NMR (700 MHz, CDCl3) δ= 7.42 – 7.39 (m, 2H, -Ar), 7.13 – 7.11 (m, 2H, -Ar), 5.24 (ddd, J 
= 3.3, 1.1, 0.4 Hz, 1H, H-4), 5.22 – 5.16 (m, 1H, H-2), 5.03 (dd, J = 10.0, 3.4 Hz, 1H, H-3), 
4.63 (d, J = 10.0 Hz, 1H, H-1), 3.80 (qd, J = 6.4, 1.1 Hz, 1H, H-5), 2.34 (s, 3H, -SCH3), 2.13 , 
2.08 , 1.96 (s, 3H, 3xOAc), 1.22 (d, J = 6.5 Hz, 3H, -CH3). 
13C NMR (176 MHz, CDCl3) δ = 170.90, 170.41, 169.77 (3x C=O), 138.50, 133.22, 129.91, 
129.37 (4x -Ar), 87.14 (C-1), 73.42 (C-3), 72.77 (C-5), 70.67 (C-4), 67.73 (C-2), 21.46, 21.19, 















Procedure: This procedure maintained an inert atmosphere throughout. To 11.5 mmol of 
peracetylated fucose (3.8g), 58 mL anhydrous DCM (final concentration: ~0.2 M) were added 
under argon atmosphere, and placed in an ice bath to cool down to 0oC. Then, 5-tert-butyl-2-
methyl-phenyl thiol (13mmol, 2.3 mL) were added followed by dropwise addition of BF3.Et2O 
(15mmol, 1.85mL). Then, the reaction was allowed to stir at room temperature for ~ 12 hours. 
The reaction mixture was then quenched with Sat. aq. NaHCO3 (~80 mL) and stirred for a 
while. Then, it was poured into a separating funnel, and the organic phase was extracted. The 
aqueous phase was extracted with DCM (~ 80mL, 2x). The combined organic phase was 
extracted with Brine (~80 mL, 2x). It was then dried with MgSO4, concentrated and dried under 
high vacuum.  
% Yield = 65 
Analysis: TLC: Rf = 0.6 (Hex/EA 2:1) 
1H NMR (700 MHz, CDCl3) δ 7.59 (d, J = 2.2 Hz, 2H,-Ar), 7.24 (d, J = 2.1 Hz, 2H,-), 7.13 (dd, 
J = 7.9, 0.9 Hz, 1H), 5.37 (dd, J = 10.4, 9.4 Hz, 1H,H-3), 5.10 (t, J = 10.5, 8.7 Hz, 1H,H-4), 
4.73 (d, J = 10.5 Hz, 1H,H-1), 4.24 (dd, J = 12.3, 5.2 Hz, 1HH-6a), 4.18 (td, J = 10.4, 9.3 Hz, 
2H,H-2), 2.38 (s, 3H,-SCH3), 2.03 (d, J = 20.2 Hz, 6H,-COCH3), 1.75 (s, 3H,-COCH3), 1.28 (s, 
9H,-C(CH3)3). 
 
13C NMR (176 MHz, CDCl3) δ 171.40(OC=O), 170.63(OC=O), 169.08(OC=O), 
161.83(OC=O), 149.76(-Ar), 137.94(-Ar), 131.60(-Ar), 131.21(-Ar), 130.16(-Ar), 126.11(-Ar), 












Procedure: This procedure maintained an inert atmosphere throughout. In a 100 mL 3-necked 
round bottom flask, NaOAc () and Ac2O () were added and refluxed at 1550C for ~ 5 minutes. 
Then, the temperature was reduced to 1200C, and peracetylated mannose was added portion 
wise (23mmol, 5g). The reaction was allowed to stir at 1200C for ~ 10 mins, and then allowed 
to cool down to room temperature and stir for ~ 30 minutes. Then, ice was added into the 
reaction mixture, and stirred at r.t. for a while. The yellow solid so obtained was diluted with 
DCM (~ 50 mL) poured into a separating funnel, and the organic phase was extracted with 
Sat. aq. NaHCO3 (~ 50 mL,2x). The combined organic phase was then extracted with Brine 
(~80 mL,2x). It was then dried with MgSO4, concentrated and dried under high vacuum.  
Purification: The crude material was dissolved in EA (~ 50 mL) at   50oC. When all of it 
dissolved, Hex (~ 100 mL) was added first dropwise until precipitation starts, and then 
quickly under rigorous stirring. The precipitate so obtained was then washed and filtered with 
cold Hexane.  
% Yield = 72 
Analysis: TLC: Rf = 0.5 (Hex/EA 2:1) 
1H NMR (700 MHz, CDCl3) δ 5.38 (dd, J = 3.4, 1.2 Hz, 1H,H-4), 5.19 (t, J = 10.0 Hz, 1H,H-2), 
5.01 (dd, J = 10.0, 3.4 Hz, 1H,H-3), 4.46 (d, J = 10.0 Hz, 1H,H-1), 4.12 (dd, J = 11.3, 6.7 Hz, 
1H,H-6a), 4.07 (dd, J = 12.1, 7.0 Hz, 1H,H-6b), 3.90 (td, J = 6.7, 1.2 Hz, 1H,H-5), 2.75 – 2.62 
(m, 2H,-SCH2), 2.11 (s, 3H,-OCOCH3), 2.02 (s, 3H,-OCOCH3), 2.00 (s, 3H,-OCOCH3), 1.94 
(s, 3H,-OCOCH3), 1.24 (t, J = 7.5 Hz, 3H,-SCH3). 
 
  13C NMR (176 MHz, CDCl3) δ 170.38(OC=O), 170.24(OC=O), 170.07(OC=O), 
169.58(OC=O), 84.08(C-1), 74.43(C-5), 72.07, 71.96(C-3), 67.35(C-4), 67.27(C-2), 61.53(C-













Procedure: This procedure maintained an inert atmosphere throughout. In a 100 mL 3-necked 
round bottom flask, _ mmol _  (10.6g) was purged with argon for several minutes before adding 
23 mL anhydrous DCM (final concentration: ~ 0.9M). Then, the reaction was placed in an ice 
bath to cool down to 0oC. Then, p-toluylthiol () was added into it, followed by dropwise addition 
of BF3.Et2O (). After the addition, the flask was removed from the ice bath and allowed to stir 
at room temperature for ~ 12 hours. The reaction mixture was then diluted with DCM (~ 100 
mL) and poured into a separating funnel. The organic phase was then extracted with Sat. aq. 
NaHCO3 (~ 100 mL, 2x) and Brine (~ 100 mL, 2x). The combined organic phase was dried 
with MgSO4, concentrated and dried under high vacuum.  
Purification: The crude material was dissolved in EA (~ 25 mL) at 400C on a heating mantle. 
When all of it dissolved, the flask was removed from the heating mantle, and hexane (~ 100 
mL) was added dropwise until precipitation started and then quickly under rigorous stirring at 
room temperature. The precipitate so obtained was then kept in the fridge overnight. Then, it 
was washed and filtered with cold Hexane to give _g of pure Gal2.  
% Yield = 85 
Analysis: TLC: Rf = 0.6 (Hex/EA 2:1) 
1H NMR (700 MHz, CDCl3) δ 7.41 – 7.36 (m, 2H,-Ar), 7.13 – 7.08 (m, 2H,-Ar), 5.38 (dq, J = 
2.7, 1.3 Hz, 1H,H-4), 5.19 (t, J = 10.0, 9.1 Hz, 1H,H-2), 5.02 (dd, J = 10.0, 4.9 Hz, 1H,H-3), 
4.63 (d, J = 10.0 Hz, 1H,H-1), 4.16 (ddt, J = 11.4, 6.9, 1.4 Hz, 1H,H-6a), 4.12 – 4.03 (m, 3H), 
3.89 (ddt, J = 6.6, 5.1, 1.2 Hz, 1H,H-5), 2.32 (d, J = 2.8 Hz, 3H,-SCH3), 2.15 – 2.12 (m, 3H), 
2.09 (d, J = 1.1 Hz, 3H), 2.09 – 2.06 (m, 5H), 2.02 (d, J = 1.1 Hz, 5H), 1.96 – 1.93 (m, 3H). 
 
13C NMR (176 MHz, CDCl3) δ 138.51(-Ar), 133.21(-Ar), 129.70(-Ar), 128.69(-Ar), 89.78(C-1), 











Procedure: This procedure maintained an inert atmosphere throughout. To 10 mmol of 
peracetylated galactose (4g), 51 mL anhydrous DCM (final concentration: ~ 0.2 M) were 
added under argon atmosphere, and placed in an ice bath to cool down to 0oC. Then, 5-tert-
butyl-2-methyl-phenyl thiol (14mmol, 2.6mL) were added followed by dropwise addition of 
BF3.Et2O (17mmol, 2.1mL). Then, the reaction was allowed to stir at room temperature for ~ 
12 hours. The reaction mixture was then quenched with Sat. aq. NaHCO3 (~80 mL) and stirred 
for a while. Then, it was poured into a separating funnel, and the organic phase was extracted. 
The aqueous phase was extracted with DCM (~ 80mL, 2x). The combined organic phase was 
extracted with Brine (~80 mL, 2x). It was then dried with MgSO4, concentrated and dried under 
high vacuum.  
% Yield = 69 
Analysis: TLC: Rf = 0.6 (Hex/EA 2:1) 
1H NMR (700 MHz, CDCl3) δ 7.29 (d, J = 2.0 Hz, 2H,-Ar), 7.15 (dd, J = 7.8, 0.9 Hz, 1H,-Ar), 
7.11 (d, J = 1.9 Hz, 1H,-Ar), 5.43 (dd, J = 3.4, 1.1 Hz, 1H), 5.06 (dd, J = 10.0, 3.4 Hz, 1H), 
4.66 (d, J = 10.1 Hz, 1H,H-1), 4.15 (dd, J = 11.4, 7.0 Hz, 2H), 3.92 (td, J = 6.6, 1.2 Hz, 1H), 
2.38 (d, J = 0.6 Hz, 3H), 2.29 (d, J = 0.6 Hz, 5H), 2.16 – 2.15 (m, 8H), 2.11 (d, J = 2.7 Hz, 4H), 
2.04 (s, 2H), 2.02 (d, J = 2.5 Hz, 5H), 2.01 (s, 2H), 1.99 (s, 3H), 1.32 (s, 8H), 1.29 (s, 15H). 
 
13C NMR (176 MHz, CDCl3) δ 170.40(OC=O), 170.32(OC=O), 170.18(OC=O), 
170.11(OC=O), 169.92(OC=O), 169.50(OC=O), 168.96(OC=O), 149.78, 149.72, 149.65, 
137.28, 133.36, 133.20, 131.86, 130.52, 130.38, 130.33, 130.16, 130.11, 127.14, 125.68, 
123.17, 89.80(C-1), 87.71(C-1’), 77.34, 77.16, 76.98, 74.44, 72.08, 68.85, 67.56, 67.51, 67.45, 
67.38, 66.54, 61.73, 61.32, 34.53, 34.42, 31.41, 31.36, 31.26, 31.07, 20.95, 20.91, 20.76, 











Step 1 Procedure: Installation of the trichloroacetyl group 
This procedure maintained an inert atmosphere throughout. In a 500 mL 3-neck round bottom 
flask 105 mmol of per-O-acetylated glucosamine hydrochloride 1a were flushed with argon for 
several minutes before adding 350 mL of anhydrous dichloromethane (final concentration: 
~ 0.3 M). Gently stirring, the system was cooled to 0 °C on an ice bath followed by the addition 
of 210 mmol trimethylamine. Maintaining the temperature at 0 °C, 134 mmol trichloroacetyl 
chloride were added over a period of 10 minutes using a dropping funnel. The reaction was 
allowed to stir at 0 °C for another 2.5 hours. Then, the flask was removed from the ice bath 
and 350 mL water were added under vigorous stirring. After stirring for several more minutes, 
the reaction mixture was poured into a separating funnel, the organic phase was separated 
and subsequently washed with 350 mL saturated aqueous NaHCO3 (1x), neutralised with 
350 mL 1 N HCl (1x) and washed with 350 mL brine (2x). Finally, the organic phase was dried 
over MgSO4, the solvent removed by evaporation and the resulting solid was dried under high 
vacuum to give 46.6 g of pure compound 1b as a colourless foam. 
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Step 1 Analysis 
TLC: Rf = 0.56 (Hex/EA 2:1) 
1H NMR (400 MHz, CDCl3) δ= 7.23 (s, 1H, -NHCO), 5.80 (d, J = 8.8 Hz, 1H, H-1), 5.40 (dd, J 
= 10.8, 9.4 Hz, 1H, H-3), 5.16 (dd, J = 10.0, 9.5 Hz, 1H, H-4), 4.36 – 4.30 (m, 1H, H-2), 4.29 
– 4.25 (m, 1H, H-6b), 4.15 (dd, J = 12.5, 2.2 Hz, 1H, H-6a), 3.90 (ddd, J = 10.0, 4.9, 2.2 Hz, 
1H, H-5), 2.11, 2.10, 2.07, 2.05 (s, 3H, -3x OAc).  
13C NMR (101 MHz, CDCl3) δ=171.66, 170.78, 169.47, 169.43, 162.43, (5x C=O), 92.32 
(CCl3), 92.10 (C-1), 73.27 (C-5), 72.01 (C-3), 68.02 (C-4), 61.83 (C-6), 54.56 (C-2), 20.87, 
20.85, 20.69, 20.66 (4x CH3C=O). 
Step 2 Procedure: Thioglycosylation 
This procedure maintained an inert atmosphere throughout. To 45 mmol of compound 1b 
(22.1 g) 50 mL anhydrous dichloromethane (final concentration ~ 0.9 M) were added under 
argon atmosphere and placed on an ice bath to cool down to 0 °C. Then, 50 mmol ethanethiol 
(3.7 mL, 1.1 eq.) were added via a syringe followed by dropwise addition of 33 mmol 
BF3 · Et2O (4.2 mL, 0.7 eq.) via a dropping funnel. The reaction was then allowed to stir at 
0 °C for another 10 minutes, then removed from the ice bath and allowed to continue stirring 
for another 12 hours (overnight). The next day, the reaction mixture was poured into 250 mL 
water and kept to stir for some time. The organic phase was then separated, washed with 
250 mL saturated aqueous NaHCO3 (2x) and 250 mL brine (2x) and dried over MgSO4 before 
it was concentrated and dried under high vacuum. 
Step 2 Purification  
The crude material (22.0 g) was dissolved in ethyl acetate (~ 100 mL) at 50 °C. When all of it 
dissolved, it was poured into a 1 L Erlenmeyer flask and, while stirring, hexane (~ 800 mL) 
was slowly added dropwise via a dropping funnel until precipitation started. The remainder 
volume of hexane was then quickly added under vigorous stirring. The precipitate so obtained 
was kept in the fridge overnight. The next day, the precipitate was filtered and washed with 
cold hexane to give 16.5 g of pure compound 1c after drying. 
Step 2 - Analysis 
TLC: Rf = 0.5 (Hex/EA 2:1) 
1H NMR (700 MHz, CDCl3) δ= 7.08 (d, J = 9.3 Hz, 1H, -NHCO), 5.39 – 5.32 (m, 1H, H-3), 
5.10 (t, J = 9.7 Hz, 1H, H-4), 4.68 (d, J = 10.3 Hz, 1H, H-1), 4.23 (dd, J = 12.3, 5.3 Hz, 1H, 
H-6a), 4.17 – 4.09 (m, 2H, H-2, H-6b), 3.77 (ddd, J = 10.0, 5.2, 2.4 Hz, 1H, H-5), 2.77 – 2.65 
(m, 2H, -SCH2), 2.06, 2.01 (d, J = 2.5 Hz, 6H, 3X-OAc), 1.25 (t, J = 7.4 Hz, 3H, -CH3). 
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 13C NMR (176 MHz, CDCl3) δ=171.21, 170.78, 169.31, 162.02 (4x C=O), 83.87 (C-1), 76.14 
(C-5), 73.27 (C-3), 68.60 (C-4), 62.46 (C-6), 54.73 (C-2), 24.36 (COCH3), 20.84 (COCH3), 
20.72 (COCH3), 20.67(SCH2), 14.98(-CH3). 
Step 3 Procedure: Removal of the acetyl groups 
This procedure maintained an inert atmosphere throughout. In a 250 mL 3-necked round 
bottom flask 33 mmol of compound 1c (16.5 g) were flushed with argon for several minutes 
before adding 77 mL of anhydrous methanol (final concentration: ~ 0.4 M). Gently stirring at 
room temperature, 13.33 mmol of 5.4 M sodium methanolate in MeOH (2.5 mL, 0.4 eq.) were 
added via a syringe. The reaction was allowed to stir at room temperature for another 2 hours. 
Then, the reaction mixture was passed through a column of 25 mL Amberlite-H+ resin several 
times until pH of the filtrate stabilised at 6. The resin was the washed with MeOH (~ 3 bed 
volumes) and the combined filtrate and wash solution were then removed by evaporation. The 
resulting residue was dried under high vacuum to give 11.8 g of pure compound 1d as white 
solid. 
Step-3-Analysis 
TLC: Rf = 0.6 (Hex/EA 1:1) 
1H NMR (700 MHz, D2O) δ = 4.81 (d, J = 10.4 Hz, 1H, H-1), 3.96 – 3.93 (m, 1H), 3.84 (t, J = 
10.2 Hz,1H, H-3), 3.77 (dd, J = 11.3, 4.0 Hz, 2H, H-6), 3.77 – 3.72 (m, 2H), 3.56 – 3.49 (m, 
2H), 2.85 – 2.69 (m, 2H, -SCH2), 1.28 (t, J = 7.4 Hz, 3H, -CH3). 
13C NMR (176 MHz, D2O) δ= 164.55 (NHC=O), 91.60 (CCl3), 83.40 (C-1), 79.97 (C-4), 74.48 
(C-3), 69.93 (C-6), 60.88 (C-5), 56.69 (C-2), 24.62 (-SCH2), 14.48 (-CH3). 
Step 4 Procedure: Benzylidene formation 
This procedure maintained an inert atmosphere throughout. To 74 mmol of compound 1d 
(27.1 g) 150 mL anhydrous THF (final concentration: ~ 0.5 M) were added under argon 
atmosphere. Gently stirring at room temperature, 146 mmol of benzaldehyde dimethyl acetal 
(22 mL, 2.0 eq.) were added via a syringe followed by addition of 13 mmol camphor sulfonic 
acid (3.0 g, 0.2 eq.) via a powder funnel. The reaction was allowed to stir at room temperature 
for ~ 12 hours (overnight). The next day, the reaction mixture was diluted with 100 mL ethyl 
acetate and under vigorous stirring 200 mL of saturated aqueous NaHCO3 was added. After 
stirring for several minutes, the reaction mixture was poured into a separating funnel, the 
organic phase was separated and subsequently washed with 150 mL brine (2x). Finally, the 




Step 4 Purification  
The crude material was dissolved in DCM (~220 mL) at on a heating mantle set to 55oC. When 
all of it dissolved, it was poured into a 1 L Erlenmeyer flask and then hexane (~ 800 mL) was 
added into it dropwise via a dropping funnel until precipitation started. The remainder volume 
of hexane was then quickly added under vigorous stirring. The precipitate so obtained was 
then kept in the fridge overnight. The next day, the precipitate was filtered and washed with 
cold hexane to give 24.6 g of pure compound 1e after drying. 
Step-4- Analysis 
TLC: Rf = 0.47 (Hex.EA: 3:1) 
1H NMR (700 MHz,DMSO-d6) δ = 8.88 (d, J = 9.3 Hz, 1H, -NHCO), 7.46 (dd, J = 7.4, 2.2 Hz, 
2H, -Ar), 7.41 – 7.35(m, 3H, -Ar), 5.62 (s, 1H, -PhCH), 5.53 (d, J = 6.3 Hz, 1H, -OH), 4.78 (d, 
J = 10.4 Hz, 1H, H-1), 4.22 (dd, J = 10.1, 5.0 Hz, 1H,H-6a), 3.84 (td, J = 9.3, 6.3 Hz, 1H, H-
3), 3.73 (q, J = 9.7 Hz, 2H, H-2, H-5), 3.51 (t, J = 9.3 Hz, 1H, H-4), 3.39 (td, J = 9.8, 5.1 Hz, 
1H, H-6b), 2.70 – 2.57 (m, 2H, -SCH2), 1.18 (t, J = 7.4 Hz, 3H, -CH3).  
13C NMR (176 MHz, DMSO) δ = 161.26 (NHC=O), 137.66 (aryl-C), 128.87 (aryl-C), 
128.03(aryl-C), 126.33 (aryl-C), 100.63(-PhCH), 93.08 (CCl3), 83.78 (C-1), 81.12 (C-4), 70.93 
(C-6), 70.22 (C-3), 67.68 (C-5), 56.98 (C-2), 23.51(-SCH2), 15.09(-CH3). 
Step 5 Procedure: Installation of the levulinoyl group 
This procedure maintained an inert atmosphere throughout. In a 1 L 3-neck round bottom flask 
53 mmol of compound 1e (24.3 g) were flushed with argon for several minutes before adding 
380 mL anhydrous dichloromethane (final concentration: ~ 0.1 M). The mixture was stirred at 
room temperature. Meanwhile, in a separate 100 mL round bottom flask, 80 mmol N,N’-
dicyclohexylcarbodiimide (16.5 g, 1.5 eq.) and 64 mmol levulinic acid (7.4 g, 1.2 eq.) were 
dissolved in 20 mL anhydrous dichloromethane and stirred at room temperature for 10 
minutes. This mixture was then transferred to the reaction flask. The reaction was allowed to 
stir at room temperature for 3 hours. The precipitate that formed during the reaction was 
filtered off washed and with DCM. The filtrate so obtained was poured into a separating funnel 
and washed with 250 mL 1 N HCl (1x), 250 mL saturated aqueous NaHCO3 (1x) and 250 mL 
H2O (1x). The organic phase was dried over MgSO4 before it was concentrated and dried 






Step 5 Purification  
The crude material was dissolved in 150 mL ethanol (abs.) at 70 °C on a heating mantle. When 
all of it dissolved, it was kept in the freezer overnight. The next day, the crystals so obtained 
were washed and filtered with cold ethanol to give 17.8 g of pure compound 1f after drying. 
Step 5-Analysis 
TLC: Rf = 0.6 (Hex/EA 4:1) 
1H NMR (700 MHz,CDCl3) δ =7.61 (d, J = 9.8 Hz, 1H, -NHCO), 7.50 – 7.48 (m, 2H, -Ar), 7.37 
– 7.32 (m, 3H, -Ar), 5.56 (t, J = 9.8 Hz, 1H, H-3), 5.49 (s, 1H, -PhCH), 4.52 (d, J = 10.4 Hz, 
1H, H-1), 4.17 (q, J = 10.1 Hz, 1H,H-2), 3.93 (dd, J = 10.1, 4.8 Hz, 1H, H-6a), 3.67 (t, J = 9.5 
Hz, 1H, H-4), 3.59 (t, J = 10.0 Hz, 1H, H-6b), 3.54 (td, J = 9.6, 4.8 Hz, 1H, H-5), 2.79 – 2.63 
(m, 4H,-CH2CH2), 2.59 – 2.52 (m, 2H, -SCH2), 2.13 (s, 3H, -COCH3), 1.18 (t, J = 7.4 Hz, 3H, -
CH3).  
13C NMR (176 MHz, CDCl3) δ =205.57 (ketone-C=O), 173.70 (O-C=O), 162.19 (NHC=O), 
137.14 (aryl-C), 128.92 (aryl-C), 128.23 (aryl-C), 125.91 (aryl-C), 100.78 (-PhCH), 92.62 
(CCl3), 84.59 (C-1), 78.83 (C-4), 73.13 (C-3), 70.20 (C-5), 68.23 (C-6), 54.67 (C-2), 37.97 (-
CH2), 29.72 (CH3-C=O), 28.25 (-CH2), 24.59(-SCH2), 14.95(-SCH3). 
Step 6 Procedure: Opening of the benzylidene at C4 
This procedure maintained an inert atmosphere throughout. In a 500 mL 3-neck round bottom 
flask 30 mmol of compound 1f (16.6 g) were flushed with argon for several minutes before 
adding 150 mL of anhydrous dichloromethane (final concentration: ~ 0.2 M). Gently stirring at 
room temperature, 120 mmol Et3SiH (19 mL, 4.0 eq.) were added via a syringe followed by 
addition of molecular sieves (4 Å, 5.0 g). The reaction was allowed to stir at room temperature 
for 30 minutes. Thereafter, the system was cooled to 0oC on an ice bath followed by addition 
of 120 mmol trifluoroacetic acid (9 mL, 4.0 eq.) over a period of 10 minutes via a dropping 
funnel. After the addition, the flask was removed from the ice bath and stirred at room 
temperature for 2.5 hours. Then, the reaction was quenched with ~ 20 mL triethylamine until 
no more gas evolved. It was then diluted with 100 mL DCM, poured into a separating funnel, 
and washed with 350 mL H2O (2x), 350 mL saturated aqueous NaHCO3 (2x) and 350 mL brine 
(2x). The organic phase was then dried over MgSO4 before it was concentrated and dried 






Step 6 Purification  
The crude material was dissolved in 50 mL absolute ethanol at 50 °C on a heating mantle and 
kept in the freezer overnight. The crystals so obtained were filtered and washed with cold 
ethanol. The filtrate obtained was concentrated and dried under high vacuum to 15.7 g of pure 
compound 1g. 
Step 6- Analysis 
TLC: Rf = 0.78 (Hex/EA 1:1) 
1H NMR (700 MHz, DMSO-d6) δ = 8.94 (d, J = 9.3 Hz, 1H, -NHCO), 7.39 – 7.27 (m, 5H, -Ar), 
5.53 (dt, J = 5.9, 1.7 Hz, 1H, 4-OH), 5.11 (t, J = 10.4, 8.8 Hz, 1H, H-3), 4.83 (d, J = 10.4 Hz, 
1H, H-1), 4.54 (d, J = 1.9 Hz, 2H, -CHBn), 3.79 – 3.71 (m, 2H, H-2, H-6b), 3.59 (dd, J = 11.3, 
1.7 Hz, 1H, H-6a), 3.45 (ddd, J = 9.2, 5.6, 1.7 Hz, 1H, H-5), 3.41 (dddd, J = 10.0, 8.9, 5.9, 1.7 
Hz, 1H, H-4), 2.69 – 2.55 (m, 4H, -CH2CH2), 2.48 (dd, J = 7.0, 1.7 Hz, 2H, -SCH2), 2.39 (dtd, J 
= 17.2, 6.9, 1.7 Hz, 1H), 2.09 (t, J = 1.5 Hz, 3H, -COCH3), 1.19 (d, J = 7.4 Hz, 3H, -SCH3).  
13C NMR (176 MHz, DMSO) δ = 206.32 (ketone-C=O), 171.59 (O-C=O), 161.23 (NHC=O), 
138.52 (aryl-C), 128.27 (aryl-C), 127.50 (aryl-C), 92.68 (CCl3), 82.28 (C-1), 79.47 (C-5), 76.09 
(C-3), 72.37 (PhCH2-), 69.34 (C-6), 68.03 (C-4), 54.49 (C-2), 37.38 (-CH2), 29.61 (CH3-C=O), 
27.73 (-CH2), 23.44 (-SCH2), 15.11 (-SCH3). 
Step 7 Procedure: Installation of the Fmoc-group 
This procedure maintained an inert atmosphere throughout. To 28 mmol of compound 1g 
(15.7 g) 220 mL anhydrous dichloromethane (final concentration: ~0.1 M) were added under 
argon atmosphere and placed in an ice bath to cool down to 0oC. Then, 85 mmol pyridine 
(7.0 mL, 3.0 eq.) were added via a syringe. After ~ 5 mins, 58 mmol Fmoc-chloride (15.0 g, 
2.0 eq.) were dissolved in 15 mL DCM and added into the reaction flask via a syringe. The 
reaction was then allowed to stir on ice for another 30 minutes and for another ~ 12 hours 
(overnight) after removing the ice bath. The next day, 60 mL MeOH was added into the 
reaction mixture and kept to stir for some time. Then, it was poured into a separating funnel, 
and washed with 100 mL H2O (2x). The aqueous layer was then extracted with 85 mL ethyl 
acetate (1x). The combined organic layers were then dried over MgSO4 before it was 







Step 7 Purification  
The crude material was dissolved in 20 mL ethyl acetate at 45°C on a heating mantle. When 
all of it dissolved, it was poured into a 500 mL Erlenmeyer flask, and then 200 mL hexane 
were added into it dropwise via a dropping funnel until precipitation started. The remainder 
volume of hexane (~ 600 mL) was then quickly added under vigorous stirring. The precipitate 
so obtained was then kept in the fridge overnight. The next day, it was filtered and washed 
with cold hexane to give 12.5 g of pure compound 1h after drying as an off-white powder. 
Step 7 – Analysis 
TLC: Rf = 0.6 (Hex/EA 4:1) 
1H NMR (700 MHz, CDCl3) δ = 7.80 – 7.76 (m, 2H), 7.55 (tq, J = 8.4, 0.9 Hz, 2H), 7.40 (ddt, J 
= 7.4, 6.6, 0.9 Hz, 2H), 7.34 (d, J = 9.4 Hz, 1H, -NHCO), 7.32 – 7.26 (m, 3H), 7.23 – 7.20 (m, 
2H), 7.18 – 7.14 (m, 1H), 5.60 (dd, J = 10.4, 9.4 Hz, 1H, H-3), 5.11 (t, J = 9.7 Hz, 1H, H-4), 
4.74 (d, J = 10.3 Hz, 1H, H-1), 4.52 – 4.45 (m, 3H), 4.30 (dd, J = 10.5, 7.9 Hz, 1H, H-6a), 4.23 
(dd, J = 12.0, 7.4 Hz, 1H, H-6b), 4.19 (td, J = 10.4, 9.4 Hz, 1H, H-2), 3.95 (dt, J = 10.0, 3.9 Hz, 
1H, H-5), 3.65 (dd, J = 11.2, 7.7 Hz, 2H, CH2-Fmoc), 2.79 – 2.69 (m, 2H, -SCH2), 2.69 – 2.43 
(m, 4H, -CH2CH2), 2.07 (s, 3H, -COCH3), 1.25 (t, J = 7.4 Hz, 3H, -CH3).  
13C NMR (176 MHz, CDCl3) δ = 205.88 (ketone-C=O), 173.20 (O-C=O), 162.09 (NHC=O), 
154.13 (aryl-C), 143.67(aryl-C), 143.25 (aryl-C), 141.31 (aryl-C), 137.83 (aryl-C), 128.37(aryl-
C), 128.02 (aryl-C), 128.00 (aryl-C), 127.31 (aryl-C), 127.29 (aryl-C), 125.26 (aryl-C), 125.18 
(aryl-C), 120.16 (aryl-C), 92.47 (CCl3), 83.63 (C-1), 77.02 (C-5), 73.76 (C-3), 73.68 (C-4), 
73.30 (PhCH2), 70.66 (C-6), 69.08 (Fmoc-CH2), 54.78 (C-2), 46.70 (Fmoc-CH), 37.85 (-CH2), 
29.62 (CH3-C=O), 28.20 (-CH2), 24.09 (SCH2), 15.00 (SCH3).  


















Procedure: This procedure maintained an inert atmosphere throughout. In a 1L 3-necked 
round bottom flask, 178mmol of Carbosynth intermediate_ (40g) was  purged with argon for 
several minutes before adding 360mL anhydrous THF (final concentration: ~ 0.5M). This was 
followed by addition of CSA (31mmol, 7.2g) and PhCH(OMe)2 (357mmol, 54mL). The reaction 
was then allowed to stir at room temperature. After ~ 2 hours, the reaction was diluted with 
EA (~100mL) and poured into a separating funnel. It was then extracted with Sat. aq. NaHCO3 
(~ 150mL, 2x) and Brine (~150 mL,2x). The combined organic phase was then dried with 
MgSO4, concentrated and dried under high vacuum.  
Purification: The crude material was dissolved in DCM (~220mL) at 50oC on a heating mantle. 
When all of it dissolved, the flask was removed from the heating mantle, and filtered hot into 
a 1L Erlenmeyer flask. Then Hexane (~800 mL) was first added dropwise until precipitation 
started, and then quickly under rigorous stirring. The precipitate so obtained was kept in the 
fridge overnight. It was then washed with cold DCM/Hexane 4:1 to get 4og of pure 2a as a 
white solid.  
% Yield = 72  
Analysis: TLC: Rf = 0.6 (Hex/EA 4:1) 
1H NMR (700 MHz, CDCl3) δ 7.50 – 7.44 (m, 2H,-Ar), 7.34 (d, J = 6.5 Hz, 2H,-Ar), 5.48 (s, 
1H,-PhCH), 4.31 (d, J = 9.5 Hz, 1H,H-1), 4.27 (d, J = 12.3 Hz, 1H,H-6a), 4.16 (d, J = 3.3 Hz, 
1H,H-4), 3.96 (d, J = 12.3 Hz, 1H,H-6b), 3.78 (t, J = 9.4 Hz, 1H,H-2), 3.63 (dd, J = 9.2, 3.6 Hz, 
2H,H-3,H-4), 3.41 (s, 4H), 2.84 – 2.66 (m, 3H,-SCH2), 1.24 (t, J = 7.4 Hz, 1H,-SCH3). 
 
13C NMR (176 MHz, CDCl3) δ 137.78(-Ar), 136.40(-Ar), 134.53(-Ar), 129.80(-Ar), 129.27(-Ar), 
129.04(-Ar), 128.31(-Ar), 126.53(-Ar), 101.42(-PhCH), 85.28(C-1), 75.76(C-4), 73.84(C-3), 









Step 1 Procedure: Installation of silyl group at C3 
This procedure maintains an inert atmosphere throughout. In a 500 mL 3-necked round bottom 
flask, 64 mmol of 2a (20g) were flushed with argon for several minutes before adding 160 mL 
anhydrous dichloromethane (final concentration: ~ 0.4M). The reaction flask was then placed 
on an ice bath, followed by addition of TBDMSCl (77 mmol, 12g) and Imidazole (90mmol, 6g). 
After the addition, the reaction was allowed to stir at room temperature for ~ 18 hours. After 
overnight stirring, the reaction was quenched with Sat. aq. NaHCO3 (~200 mL). The reaction 
mixture was then poured into a separating funnel, and the organic ühase was extracted with 
DCM (~100 mL, 3x). The combined organic phase was then washed with Brine (~100mL, 2x), 
dried with MgSO4, concentrated and dried under high vacuum to give 28g of 2b.  
Step 1- Analysis 
1H NMR (700 MHz, Chloroform-d) δ 7.50 (ddd, J = 8.0, 1.6, 0.6 Hz, 2H,-Ar), 7.38 – 7.31 (m, 
3H,-Ar), 5.50 (s, 1H, PhCH), 4.35 (d, J = 9.5 Hz, 1H, H-1), 4.34 (dd, J = 12.4, 1.5 Hz, 1H, H-
6a), 4.07 (dd, J = 3.6, 0.9 Hz, 2H, H-4), 4.01 (dd, J = 12.4, 1.9 Hz, 1H, H-6a), 3.88 (t, J = 9.3 
Hz, 1H, H-2), 3.72 (dd, J = 9.0, 3.6 Hz, 1H, H-3), 3.47 (q, J = 1.7 Hz, 1H, H-5), 2.82 (dq, J = 
12.6, 7.4 Hz, 1H, SCHH), 2.73 (dq, J = 12.6, 7.5 Hz, 1H, , SCHH), 1.31 (t, J = 7.5 Hz, 3H, 
CH3), 0.92 (s, 9H, t-BuSi), 0.13 (s, 3H, SiCH3), 0.13 (s, 3H, SiCH3). 
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13C NMR (176 MHz, Chloroform-d) δ 138.10, 128.86, 128.18, 126.26, 126.19, 101.06 
(PhCH), 85.39 (C1), 76.94 (C4), 75.59 (C3), 70.34 (C5), 69.55 (C6), 68.95 (C2), 25.85 
(SiC(CH3)3), 23.24 (SCH2), 18.34 (SiC(CH3)3), 15.35 (SCH2CH3), -4.24 (SiCH3), -4.53  (SiCH3). 
Step 2 Procedure: Installation of benzoyl group at C2 
This procedure maintained an inert atmosphere throughout. To 65 mmol of 2b (28g), 405 mL 
anhydrous DCM (final concentration: ~ 0.2M) were added under argon atmosphere and placed 
in an ice bath to cool down to 0oC. Then, benzoic anhydride (195 mmol, 44g) and DMAP 
(33mol, 4g) were added successively, followed by dropwise addition of Et3N (390mmol, 
54mL). The reaction was allowed to stir on ice bath for ~ 15 mins, and then stirred at room 
temperature for ~ 12 hours. After overnight stirring, the reaction mixture was poured into a 
separating funnel, and the organic phase was extracted with Sat. aq. NaHCO3 (~ 300mL, 3x) 
and Brine (~300 mL, 2x). The combined organic phase was then dried with MgSO4, 
concentrated and dried under high vacuum.  
Step 2 - Purification  
The crude material was dissolved in EtOH (abs) (~ 60 mL) at 65oC on a heating mantle. When 
all of it dissolved, the crude material was kept in the freezer overnight to induce crystallization. 
The crystals so obtained were washed and filtered with cold EtOH to give 19g pure 2c. 
Step 2 – Analysis 
1H NMR (700 MHz, Chloroform-d) δ 8.04 (dd, J = 8.2, 1.1 Hz, 2H), 7.57 – 7.52 (m, 3H), 7.44 
(td, J = 7.6, 1.7 Hz, 2H), 7.41 – 7.34 (m, 3H), 5.60 (t, J = 9.6 Hz, 1H, H-2), 5.53 (s, 1H, PhCH), 
4.56 (d, J = 9.9 Hz, 1H, H-1), 4.39 (dd, J = 12.2, 1.6 Hz, 1H, H-6a), 4.14 (dd, J = 3.7, 1.1 Hz, 
1H, H-4), 4.05 (dd, J = 12.2, 1.8 Hz, 1H, H-6b), 4.02 (d, J = 9.0, 2.6 Hz, 1H, H-3), 3.55 (q, J = 
1.5 Hz, 1H, H-5), 2.91 (dq, J = 12.3, 7.5 Hz, 1H, SCHH), 2.75 (dq, J = 12.3, 7.5 Hz, 1H, SCHH), 
1.26 (t, J = 7.5 Hz, 3H, SCH2CH3), 0.75 (s, 9H), 0.05 (s, 3H), -0.12 (s, 3H). 
13C NMR (176 MHz, Chloroform-d) δ 165.39 (C=O), 138.02, 133.01, 130.45, 129.87, 128.97, 
128.40, 128.27, 126.38, 101.21 (PhCH), 82.90 (C1), 76.98 (C4), 73.64 (C3), 70.36 (C5), 70.20 
(C2), 69.52 (C6), 25.56 (SiC(CH3)3), 22.86 (SCH2), 18.04 (SiC(CH3)3), 15.00 (SCH2CH3), -4.44 







Step – 3 Procedure: Regioselective opening of benzylidene ring 
This procedure maintained an inert atmosphere throughout. In a 500 mL, 3-necked round 
bottom flask, 89 mL anhydrous DCM (final concentration: ~ 0.4M) were added under argon 
atmosphere and placed in an ice bath to cool down to 0oC. Then, 1M BH3 in THF (4eq) was 
added dropwise via a dropping funnel followed by addition of TMSOTf (18mmol, 3mL) via a 
syringe. The reaction was stirred on the ice bath for ~ 1.5 hours. Then, the reaction was 
quenched with Et3N/MeOH 1:10 till no more gas evolved. The reaction mixture was then 
concentrated, and the syrup so obtained was re-dissolved in DCM, and poured into a 
separating funnel, and the organic phase was extracted with Sat. aq. NaHCO3 (~ 150 mL, 2x) 
and Brine (~ 150mL,2x). The combined organic phase was dried with MgSO4, concentrated 
and dried under high vacuum to give 14g of 2d.  
Step 3 – Analysis 
1H NMR (700 MHz, Chloroform-d) δ 8.05 (dd, J = 8.4, 1.3 Hz, 1H), 7.59 – 7.53 (m, 1H), 7.47 
– 7.42 (m, 3H), 7.41 – 7.34 (m, 4H), 7.33 – 7.28 (m, 1H), 5.66 (br s, 1H, H-2), 5.10 (d, J = 11.7 
Hz, 1H, 4-CH), 4.60 (d, J = 11.7 Hz, 1H, 4-OCHHPh), 4.51 (d, J = 9.4 Hz, 1H, H-1), 3.98 (brd, 
J = 9.4 Hz, 1H, H-3), 3.85 (dd, J = 11.2, 6.7 Hz, 1H, H-6a), 3.78 (dd, J = 2.8, 1.1 Hz, 1H, H-
4), 3.61 (ddd, J = 6.6, 5.2, 1.2 Hz, 1H, H-5), 3.57 (dd, J = 11.2, 5.3 Hz, 1H, H-6b), 2.76 (dq, J 
= 12.4, 7.4 Hz, 1H, SCHH), 2.69 (dq, J = 12.4, 7.5 Hz, 1H, SCHH), 1.21 (t, J = 7.5 Hz, 3H, 
SCH2CH3), 0.79 (s, 9H), 0.12 (s, 3H), -0.07 (s, 3H). 
13C NMR (176 MHz, Chloroform-d) δ 165.31 (C=O), 138.45, 132.90, 130.23, 129.74, 128.36, 
128.24, 127.93, 127.71, 83.70 (C1), 78.96 (C5), 76.80 (C4), 75.70 (C3), 74.78 (4-OCH2Ph), 
70.85 (C2), 62.16 (C6), 25.47 (SiC(CH3)3), 23.55 (SCH2), 17.74(SiC(CH3)3), 14.77(SCH2CH3), 
-4.05 (SiCH3), -5.10 (SiCH3). 
Step 4 Procedure: Installation of benzyl group at C6 
This procedure maintained an inert atmosphere throughout. To 26 mmol of 2d (14g), 123 mL 
of anhydrous THF (final concentration: ~ 0.2M) were added under argon atmosphere and 
placed in an ice bath to cool down to 0oC. Then, NaH (69mmol, 3g) was added, followed by 
dropwise addition of BnBr (39mmol, 5mL) via a dropping funnel. The reaction was left to stir 
on the ice bath for ~ 15 mins, and then left to stir at room temperature for ~ 18 hours. The 
reaction was then quenched with Sat. aq. NH4Cl (~80 mL) till no more bubbling occurred. The 
reaction mixture was then transferred into a separating funnel, and the organic phase was 
extracted. The aqueous phase was then extracted with DCM (~60mL,1x) and the combined 




Step 4 – Purification 
The crude material was dissolved in Ethyl Acetate (~ 20mL) at 50oC on a heating mantle. 
When all of it dissolved, Hexane (~50 mL) was then added dropwise via a dropping funnel. 
The crude material was then kept in the freezer overnight to induce crystallization. Then, the 
crystals so obtained were washed and filtered with cold Hexane to give pure 16g of pure 2e.  
Step 4 – Analysis 
TLC: Rf = 0.78 (Hex/EA 4:1) 
1H NMR (700 MHz, CDCl3) δ =7.52 – 7.50 (m, 2H, -Ar), 7.43 – 7.28 (m, 15H,-Ar), 7.05 – 7.02 
(m, 2H, -Ar), 5.02 (d, J = 11.6 Hz, 1H, -CH2Bn), 4.82 (d, J = 10.2 Hz, 1H, -CH2Bn), 4.78 – 4.73 
(m, 3H, -CH2Bn), 4.68 (d, J = 11.6 Hz, 1H, -CH2Bn), 4.56 (d, J = 9.6 Hz, 1H, H-1), 3.91 (t, J = 
9.4 Hz, 1H, H-2), 3.64 (dd, J = 2.9, 1.0 Hz, 1H, H-4), 3.60 (dd, J = 9.2, 2.8 Hz, 1H, H-3), 3.52 
(qd, J = 6.4, 1.0 Hz, 1H, H-5), 2.31 (s, 3H, -SCH3), 1.28 (d, J = 6.4 Hz, 3H, -CH3). 
13C NMR (176 MHz, CDCl3) δ= 138.80(-Ar), 138.51(-Ar),, 138.41(-Ar), 137.10(-Ar), 132.20(-
Ar), 130.48(-Ar), 129.52(-Ar), 128.44(-Ar), 128.36(-Ar), 128.33(-Ar), 128.15(-Ar), 127.97(-Ar), 
127.69(-Ar), 127.59(-Ar), 127.45(-Ar), 87.90(C-1), 84.61(C-4), 76.66(C-2), 75.55(-CH2Bn ), 
74.58(-CH2Bn, C-5), 72.87(-CH2Bn, C-3), 21.13(-SCH3), 17.34(-CH3). 
 
Step 5 Procedure: Removal of Silyl group from C3 
This procedure maintained an inert atmosphere throughout. To 26 mmol of 2e (16g), 172 mL 
anhydrous ACN (final concentration: ~ 0.15M) under argon atmosphere and placed in an ice 
bath to cool down to 0oC. Then, BF3.Et2O (28mmol, 3.5mL) was added dropwise via a syringe. 
The reaction was allowed to stir on ice bath for 5 mins, followed by quenching by dropwise 
addition of Sat. aq. NaHCO3 (~ 80 mL). The reaction mixture was then poured into a separating 
funnel, and the organic phase was extracted. The combined organic phase was then washed 
with Brine (~ 100 mL, 1x). It was then dried with MgSO4, concentrated and dried under high 
vacuum to give 7g of 2f.  
Step 5 – Analysis 
1H NMR (500 MHz, DMSO-d6) δ 7.98 (dd, J = 8.2, 1.0 Hz, 2H), 7.67 (tt, J = 7.7, 7.3, 1.3 Hz, 
1H), 7.58 – 7.50 (m, 2H), 7.41 – 7.17 (m, 10H), 5.55 (d, J = 5.4 Hz, 1H, 3-OH), 5.19 (t, J = 9.7 
Hz, 1H, H-2), 4.93 (d, J = 11.4 Hz, 1H, PhCHH), 4.70 (d, J = 10.0 Hz, 1H, H-1), 4.52 (d, J = 
11.5 Hz, 1H, PhCHH), 4.50 (d, J = 12.1 Hz, 1H, PhCHH), 4.44 (d, J = 12.0 Hz, 1H, PhCHH), 
3.97 (ddd, J = 9.7, 5.5, 3.1 Hz, 1H, H-3), 3.89 (td, J = 6.1, 1.1 Hz, 1H, H-5), 3.83 (dd, J = 3.2, 




13C NMR (126 MHz, DMSO-d6) δ 165.14(OC=O), 138.98(-Ar), 138.20(-Ar), 133.23(-Ar), 
130.05(-Ar), 129.35(-Ar), 128.61(-Ar), 128.24, 128.13, 127.63, 127.62, 127.49, 127.35, 
82.77(C-1), 77.34, 76.70, 74.42, 72.61, 72.29, 71.67, 68.82, 40.02, 39.85, 39.69, 39.52, 39.35, 
39.19, 39.02, 23.51(-SCH2), 15.10(-CH3). 
 
Step 6  Procedure: Installation of FMOC group at C3 
This procedure maintained an inert atmosphere throughout. To 13mmol of 2f (7g) was added 
100 mL (final concentration: ~ 0.13M) under argon atmosphere and placed in an ice bath to 
cool down to 0oC. Then, pyridine (39mmol, 3.14mL) was added via a syringe, followed by 
addition of FMOC (pre-dissolved in DCM) (26mmol, 7g). The reaction was then allowed to stir 
on ice bath for ~ 10 mins, and then left to stir at room temperature overnight. The reaction was 
then quenched with 1N HCl (~ 20 mL), and added into a separating funnel. The organic phase 
was then extracted and the aqueous phase was extracted with DCM (~80 mL, 3x). The 
combined organic phase was dried with MgSO4, concentrated and dried under high vacuum.  
Step 6 – Purification 
The crude material was dissolved in EtOH(abs.)(300 mL) at 70oC on a heating mantle. Hen 
all of it dissolved, it was kept in the freezer to induce crystallization. The crystals so obtained 
were washed and filtered with cold EtOH to give 11g of pure 2g.  
Step 6 – Analysis 
TLC: Rf = 0.5 (Hex/EA 5:1) 
1H NMR (400 MHz, Chloroform-d) δ 8.09 – 7.98 (m, 2H), 7.73 – 7.63 (m, 2H), 7.58 – 7.48 
(m, 1H), 7.49 – 7.26 (m, 16H), 7.10 – 7.15 (m, 2H), 5.75 (t, J = 9.9 Hz, 1H, H-2), 5.07 (dd, J = 
10.0, 3.0 Hz, 1H, H-3), 4.79 (d, J = 11.5 Hz, 1H, PhCHH), 4.60 (d, J = 9.9 Hz, 1H, H-1), 4.56 
– 4.44 (m, 3H, PhCH2, PhCHH), 4.30 (dd, J = 10.4, 7.1 Hz, 1H, H-6a), 4.22 (dd, J = 10.4, 7.8 
Hz, 1H, H-6b), 4.14 (d, J = 2.9 Hz, 1H, H-4), 4.06 (t, J = 7.4 Hz, 1H, H-5), 3.82 (t, J = 6.6 Hz, 
1H, Fmoc-CH), 3.67 (d, J = 6.6 Hz, 2H, Fmoc-CH2), 2.74 (dtt, J = 19.8, 12.5, 7.5 Hz, 2H, 
SCH2), 1.23 (t, J = 7.4 Hz, 3H, CH3). 
13C NMR (101 MHz, Chloroform-d) δ 165.34, 154.63, 143.36, 142.92, 141.30, 141.19, 
138.01, 137.81, 133.31, 130.04, 129.66, 128.56, 128.48, 128.40, 128.25, 127.99, 127.97, 
127.90, 127.82, 127.20, 127.17, 125.27, 125.05, 120.05, 83.81, 79.11, 77.45, 77.33, 77.13, 
76.81, 75.17, 74.07, 73.65, 70.19, 68.65, 68.14, 46.55, 23.97, 14.89. 
HRMS (ESI) m/z calcd. for [M+Na]+ 753.2498. Found 753.2498. 
150 
 




Step1 Procedure: Peracetylation of L-Fucose 
This procedure does not need an inert atmosphere. In a 250 mL 3-neck round bottom flask 
61 mmol sodium acetate (5.0 g, 0.5 eq.) were mixed with 973 mmol acetic anhydride (92 mL, 
8.0 eq.). A reflux condenser was fitted to one of the necks, and the flask was placed on a 
heating mantle. The reaction was then refluxed at 170 °C for 5 minutes. 122 mmol of L-fucose 
3a (20.0 g) were then added in portions over a period of 10 minutes and the temperature was 
decreased to 120°C. After the addition, the reaction was allowed to cool down to room 
temperature for 30 minutes. The reaction was then poured into ice in a 500 mL beaker and 
stirred for 1 hour. It was then poured into a separating funnel and extracted with 250 mL ethyl 
acetate (1X). Subsequently, the organic phase was washed with 150 mL saturated aqueous 
NaHCO3 (2x) and 150 mL brine (2x). Finally, the organic phase was dried with MgSO4, the 
solvent removed by evaporation and the resulting oil was dried under high vacuum to give 
42.9 g of pure compound 3b. 
Step-1 Analysis 
TLC: Rf = 0.57 (Hex/EA 2:1) 
1H NMR (700 MHz,CDCl3) δ = 5.66 (d, J = 8.3 Hz, 1H, H-1), 5.29 – 5.26 (m, 1H, H-2), 5.24 
(dd, J = 3.5, 1.1 Hz, 1H, H-4), 5.06 – 5.04 (m, 1H, H-3), 3.93 (qd, J = 6.4, 5.9, 1.4 Hz, 1H, H-
5), 2.16, 2.08, 2.06, 2.00 (s, 3H, 4x-OAc), 1.19 (dd, J = 6.5, 0.7 Hz, 3H, -CH3) .  
13C NMR (176 MHz, CDCl3) δ= 170.55, 170.04, 169.49, 169.18 (4x C=O), 92.15 (C-1), 76.38 





Step 2 Procedure: Thioglycosylation 
This procedure maintained an inert atmosphere throughout. To 130 mmol of compound 3b 
(42.9 g) 250 mL anhydrous dichloromethane (final concentration: ~ 0.5 M) were added under 
argon atmosphere and placed on an ice bath to cool down to 0 °C. Then, 142 mmol p-
toluenethiol (18.0 g, 1.0 eq.) were added via a powder funnel followed by dropwise addition of 
168 mmol BF3·Et2O (21 mL, 1.3 eq.) over 10 minutes via a dropping funnel. The reaction was 
allowed to stir on ice bath for another 5 minutes, then removed from the ice bath and allowed 
to stir at room temperature for 1.5 hours. Then, 250 mL Sat. aq. NaHCO3 was added into the 
reaction flask and kept to stir for some time. It was then poured into a separating funnel, and 
the organic phase was separated. The aqueous phase was then extracted with 150 mL 
dichloromethane (2x). The combined organic phase was subsequently washed with 150 mL 
brine (2x). Finally, the organic phase was dried over MgSO4 before it was concentrated and 
dried under high vacuum. 
Step 2 Purification  
The crude material was dissolved in ethyl acetate (~ 20 mL) at 50 °C on a heating mantle. 
When all of it dissolved, it was removed from the mantle, and hexane (~ 80 mL) was added 
into it dropwise via a dropping funnel until precipitation started. The remainder volume of 
hexane was then added quickly under vigorous stirring. The precipitate so obtained was then 
kept in the fridge overnight. The next day, the precipitate was filtered and washed with cold 
hexane to give 21.3 g of pure compound 3c after drying. 
Step 2 - Analysis 
TLC: Rf = 0.78 (Hex/EA 2:1) 
1H NMR (700 MHz, CDCl3) δ= 7.42 – 7.39 (m, 2H, -Ar), 7.13 – 7.11 (m, 2H, -Ar), 5.24 (ddd, J 
= 3.3, 1.1, 0.4 Hz, 1H, H-4), 5.22 – 5.16 (m, 1H, H-2), 5.03 (dd, J = 10.0, 3.4 Hz, 1H, H-3), 
4.63 (d, J = 10.0 Hz, 1H, H-1), 3.80 (qd, J = 6.4, 1.1 Hz, 1H, H-5), 2.34 (s, 3H, -SCH3), 2.13 , 
2.08 , 1.96 (s, 3H, 3xOAc), 1.22 (d, J = 6.5 Hz, 3H, -CH3). 
13C NMR (176 MHz, CDCl3) δ = 170.90, 170.41, 169.77 (3x C=O), 138.50, 133.22, 129.91, 
129.37 (4x -Ar), 87.14 (C-1), 73.42 (C-3), 72.77 (C-5), 70.67 (C-4), 67.73 (C-2), 21.46, 21.19, 








Step 3 Procedure: Removal of the acetyl groups 
This procedure maintained an inert atmosphere throughout. In a 500 mL 3-neck round bottom 
flask 54 mmol of compound 3c (21.3 g) were flushed with argon for several minutes before 
adding 125 mL methanol (final concentration: ~ 0.5 M). Gently stirring at room temperature, 
22 mmol NaOMe in MeOH (5.4 M) (4.0 mL, 0.4 eq) were added into it via a syringe. The 
reaction was then allowed to stir at room temperature for ~ 12 hours (overnight). The next day, 
the reaction was passed through a column of Amberlite resin (~ 25 mL) in a sintered funnel till 
pH of the filtrate reaches 6. The solvent was then removed by evaporation and the resulting 
solid was dried under high vacuum to give 20.6 g of pure compound 3d after drying. 
Step 3-Analysis 
TLC: Rf = 0.3 (Hex/EA 1:2) 
1H NMR (700 MHz, DMSO-d6) δ = 7.35 – 7.30 (m, 2H, -Ar), 7.14 – 7.09 (m, 2H, -Ar), 4.49 (d, 
J = 9.2 Hz, 1H, H-1), 4.10 (s, 3H, -OH), 3.58 (qd, J = 6.5, 1.1 Hz, 1H, H-5), 3.48 – 3.46 (m, 
1H,H-3), 3.34 (t, J = 10.5, 9.1 Hz, 2H, H-2, H-4), 2.27 (s, 3H, -SCH3), 1.11 (d, J = 6.4 Hz, 3H, 
-CH3)  
13C NMR (176 MHz, DMSO-d6) δ =135.74, 130.21, 129.31 (-Ar), 87.67 (C-1), 74.74 (C-4), 
73.87 (C-5), 71.05 (C-3), 68.82 (C-2), 20.47 (-SCH3), 16.75 (-CH3). 
 
Step 4 Procedure: Installation of benzyl groups 
This procedure maintained an inert atmosphere throughout. In a 500 mL 3-neck round bottom 
flask 19 mmol of compound 3d (5.1 g) were flushed with argon for several minutes before 
adding 86 mL of anhydrous N,N-dimethylformamide (final concentration: ~ 0.22 M). Gently 
stirring, the system was cooled to 0 °C on an ice bath followed by the addition of 113 mmol 
sodium hydride (4.5 g, 6.0 eq.) via a powder funnel. Maintaining the temperature at 0 °C, 
68 mmol benzyl bromide (8.06 mL) were added dropwise over 10 minutes via a dropping 
funnel. Then, the flask was removed from the ice bath, and allowed to stir at room temperature 
for 2 hours. The reaction was then quenched with 10 mL Sat.aq. NH4Cl (until no more gas 
evolved). Then, it was diluted with 80 mL dichloromethane and poured into a separating 
funnel. The organic phase was separated, and the aqueous phase was extracted with 100 mL 
DCM (2x). The combined organic phase was washed with 150 mL brine (2x). Finally, it was 







Step 4-Purification  
The crude material was dissolved in H2O (~ 10 mL) at 60 °C on a heating mantle. When all of 
it dissolved, absolute ethanol (~ 60 mL) was added into it dropwise until precipitation started. 
The remainder volume of ethanol was the added quickly under vigorous stirring. The 
precipitate so obtained was kept in the fridge overnight. The next day, the precipitate was 
washed and filtered with cold ethanol to give 8.6 g of pure compound 3e after drying. 
Step 4- Analysis 
TLC: Rf = 0.76 (Hex/EA 4:1) 
1H NMR (700 MHz, CDCl3) δ =7.52 – 7.50 (m, 2H, -Ar), 7.43 – 7.28 (m, 15H,-Ar), 7.05 – 7.02 
(m, 2H, -Ar), 5.02 (d, J = 11.6 Hz, 1H, -CH2Bn), 4.82 (d, J = 10.2 Hz, 1H, -CH2Bn), 4.78 – 4.73 
(m, 3H, -CH2Bn), 4.68 (d, J = 11.6 Hz, 1H, -CH2Bn), 4.56 (d, J = 9.6 Hz, 1H, H-1), 3.91 (t, J = 
9.4 Hz, 1H, H-2), 3.64 (dd, J = 2.9, 1.0 Hz, 1H, H-4), 3.60 (dd, J = 9.2, 2.8 Hz, 1H, H-3), 3.52 
(qd, J = 6.4, 1.0 Hz, 1H, H-5), 2.31 (s, 3H, -SCH3), 1.28 (d, J = 6.4 Hz, 3H, -CH3). 
13C NMR (176 MHz, CDCl3) δ= 138.80(-Ar), 138.51(-Ar),, 138.41(-Ar), 137.10(-Ar), 132.20(-
Ar), 130.48(-Ar), 129.52(-Ar), 128.44(-Ar), 128.36(-Ar), 128.33(-Ar), 128.15(-Ar), 127.97(-Ar), 
127.69(-Ar), 127.59(-Ar), 127.45(-Ar), 87.90(C-1), 84.61(C-4), 76.66(C-2), 75.55(-CH2Bn ), 
74.58(-CH2Bn, C-5), 72.87(-CH2Bn, C-3), 21.13(-SCH3), 17.34(-CH3). 
HRMS (ESI, positive mode): Calculated m/z [M+Na]+ = 563.2227, Found: 563.2267 
 









Step 1 Procedure: Installation of benzoyl groups at C2 and C3 
This procedure maintained an inert atmosphere throughout. In a 500 mL 3-necked round 
bottom flask, 109 mmol of 2a (34g) were flushed with argon for several minutes before adding 
340 mL anhydrous DCM (final concentration: ~ 0.32M). The reaction was then allowed to stir 
at room temperature, followed by addition of Bz2O (327 mmol, 74g), Et3N (436 mmol, 60 mL) 
and DMAP (3 mol% per OH group, 0. 740 g) successively. After 4 hours, the reaction mixture 
was washed with 1N HCl (300 mL, 2x), Sat. aq. NaHCO3 (300 mL, 2x) and Brine (300 mL, 
2x). The combined organic phase was dried with MgSO4, concentrated and dried under high 
vacuum.  
Step 1 – Purification 
The crude material was dissolved in Ethyl acetate (~ 100 mL) at 50oC on a heating mantle. 
When all of it dissolved, Hexane (~ 200 mL) was added at room temperature to induce 
precipitation. The precipitate so obtained was washed and filtered with cold Hexane to give 
50 g of pure 4b.  
Step 1 – Analysis 
1H NMR (700 MHz, Chloroform-d) δ 7.99 – 7.96 (m, 4H), 7.52 – 7.47 (m, 4H), 7.40 – 7.33 
(m, 7H), 5.96 (t, J = 9.9 Hz, 1H, H-2), 5.54 (s, 1H), 5.40 (dd, J = 10.0, 3.5 Hz, 1H, H-3), 4.73 
(d, J = 9.9 Hz, 1H, H-1), 4.63 (dd, J = 3.5, 1.1 Hz, 1H, H-4), 4.42 (dd, J = 12.4, 1.6 Hz, 1H, H-
6a), 4.10 (dd, J = 12.4, 1.8 Hz, 1H, H-6b), 3.73 (q, J = 1.6 Hz, 1H, H-5), 2.95 (dq, J = 12.3, 7.5 
Hz, 1H, SCHH), 2.81 (dq, J = 12.3, 7.5 Hz, 1H, SCHH), 1.31 (t, J = 7.5 Hz, 3H, SCH2CH3). 
13C NMR  (176 MHz, Chloroform-d) δ 166.29 (C=O), 165.47 (C=O), 137.73, 133.49, 133.28, 
130.05, 129.92, 129.70, 129.29, 129.17, 128.53, 128.47, 128.33, 126.43, 101.17 (-PhCH), 
83.07 (C1), 74.01, 73.99 (C4, C2), 70.08 (C5), 69.35 (C6), 67.33 (C3), 23.08 (CH2), 15.02 
(CH3). 
Step 2  Procedure: Regioselective opening of benzylidene ring at C6 
This procedure maintained an inert atmosphere throughout. In a 500 mL, 3-necked round 
bottom flask, 36 mmol 4a (19g) were flushed with argon for several minutes before adding 89 
mL anhydrous DCM (final concentration: ~ 0.4M) and placed in an ice bath to cool down to 
0oC. Then, 1M BH3 in THF (4eq) was added dropwise via a dropping funnel followed by 
addition of TMSOTf (18mmol, 3mL) via a syringe. The reaction was stirred on the ice bath for 
~ 1.5 hours. Then, the reaction was quenched with Et3N/MeOH 1:10 till no more gas evolved. 
The reaction mixture was then concentrated, and the syrup so obtained was re-dissolved in 
DCM, and poured into a separating funnel, and the organic phase was extracted with Sat. aq. 
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NaHCO3 (~ 150 mL, 2x) and Brine (~ 150mL,2x). The combined organic phase was dried with 
MgSO4, concentrated and dried under high vacuum to give 14g of 4c.  
Step 2 – Analysis 
TLC: Rf = 0.3 (Hex/EA 3:1) 
1H NMR (700 MHz, DMSO-d6) δ 7.92 – 7.86 (m, 3H,-Ar), 7.83 – 7.80 (m, 2H,-Ar), 7.62 – 7.57 
(m, 2H,-Ar), 7.56 – 7.52 (m, 1H,-Ar), 7.48 – 7.43 (m, 4H,-Ar), 7.33 – 7.23 (m, 4H,-Ar), 5.54 
(dd, J = 9.8 Hz, 1H), 5.02 (d, J = 9.3 Hz, 1H), 4.99 (dd, J = 6.1, 4.9 Hz, 1H), 4.97 – 4.89 (m, 
1H), 4.64 – 4.59 (m, 2H), 2.72 – 2.60 (m, 2H,-SCH2), 1.17 (t, J = 7.4 Hz, 3H,-CH3). 
 
13C NMR (176 MHz, DMSO) δ 164.95(OC=O), 138.97(-Ar), 138.23(-Ar), 133.69(-Ar), 133.55(-
Ar), 129.84, 129.39, 129.25, 129.17, 129.13, 129.08, 129.04, 128.81, 128.67, 128.56, 128.52, 
128.25, 128.12, 82.61(C-1),78.70, 75.87, 74.41, 68.63, 65.60, 56.02, 25.29(-SCH2), 14.95(-
SCH3). 
 
Step 3 Procedure: Installation of benzyl group at C6 
This procedure maintained an inert atmosphere throughout. To 26 mmol of 4c (14g), 123 mL 
of anhydrous THF (final concentration: ~ 0.2M) were added under argon atmosphere and 
placed in an ice bath to cool down to 0oC. Then, NaH (69mmol, 3g) was added, followed by 
dropwise addition of BnBr (39mmol, 5mL) via a dropping funnel. The reaction was left to stir 
on the ice bath for ~ 15 mins, and then left to stir at room temperature for ~ 18 hours. The 
reaction was then quenched with Sat. aq. NH4Cl (~80 mL) till no more bubbling occurred. The 
reaction mixture was then transferred into a separating funnel, and the organic phase was 
extracted. The aqueous phase was then extracted with DCM (~60mL,1x) and the combined 
organic phase was dried with MgSO4, concentrated and dried under high vacuum.  
Step 3– Purification 
The crude material was dissolved in Ethyl Acetate (~ 20mL) at 50oC on a heating mantle. 
When all of it dissolved, Hexane (~50 mL) was then added dropwise via a dropping funnel. 
The crude material was then kept in the freezer overnight to induce crystallization. Then, the 
crystals so obtained were washed and filtered with cold Hexane to give pure 16g of pure 4d.  
Step 3– Analysis 
TLC: Rf = 0.5 (Hex/EA 4:1) 
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1H NMR (400 MHz, CDCl3) δ 8.07 – 7.92 (m, 7H,-Ar), 7.65 – 7.54 (m, 3H,-Ar), 7.50 – 7.40 (m, 
8H), 7.27 – 7.23 (m, 3H,-Ar), 5.32 (dd, J = 9.7, 3.1 Hz, 1H,H-3), 4.93 – 4.87 (m, 2H), 4.80 (dd, 
J = 8.9, 2.8 Hz, 1H), 4.63 (d, J = 9.7 Hz, 1H,H-1), 4.60 – 4.56 (m, 2H), 4.53 – 4.44 (m, 3H), 
4.01 – 3.95 (m, 1H), 2.87 – 2.70 (m, 2H,-SCH2), 1.36 – 1.32 (m, 4H,-SCH3). 
 
13C NMR (101 MHz, CDCl3) δ 166.21(OC=O), 166.09(OC=O), 138.32(-Ar), 138.30(-Ar), 
138.24(-Ar), 138.12, 137.86, 137.76, 137.66, 137.58, 137.49, 129.87, 129.84, 129.81, 129.80, 
129.75, 85.64 (C-1), 76.02, 75.96, 75.78, 74.69, 73.57, 25.37 (-SCH2), 15.24(-SCH3)  
 
 





Step1: Installation of benzyl group at C3 
This procedure maintained an inert atmosphere throughout. 1e (23.7 g , 51.887 mmol) was 
weighed into a 500 mL 3-necked R.B. flask fitted with a septum and Ar balloon and flushed 
with Ar for a while. THF (236 mL, 0.22 M) was added into it, and the reaction flask was then 
placed in an ice bath. NaH (60% dispersion in mineral oil) (5.39 g, 134.906 mmol) was added 
via a powder funnel, followed by dropwise addition of BnBr (9.24 mL, 77.83 mmol) via a 
dropping funnel. After adding all the reagents, the flask was removed from the ice bath and 
left to stir at room temperature overnight. After overnight stirring, the reaction was quenched 
with Sat. aq. NH4Cl (~ 50 mL) till no more gas evolved and no more bubbling occurred. The 
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reaction mixture was diluted with DCM (~ 100 mL) and poured into a separating funnel. The 
organic phase was then extracted. The aqueous phase was then extracted with DCM (~ 100 
mL, 2X). The organic phase was then subsequently washed with Brine (~ 150 mL, 2X). It was 
then dried with MgSO4, concentrated and dried under high vacuum for ~ 1 hr.  
Step 1-Puriifcation 
Ethyl acetate (distilled) (~ 150 mL) was added to the crude material at 55oC on a heating 
mantle. The precipitate so obtained was kept in the fridge overnight to induce more 
precipitation. It was then washed with cold ethyl acetate.  
Step1-Analysis 
TLC: Rf = 0.47 (Hex/EA 5:1) 
1H NMR (400 MHz, DMSO-d6) δ 9.16 (d, J = 9.0 Hz, 1H, -NHCO), 7.48 – 7.20 (m, 11H, -Ar), 
5.73 (s, 1H, -PhCH), 4.82 (d, J = 10.1 Hz, 1H, H-1), 4.74 (d, J = 11.5 Hz, 1H, -CH2Bn), 4.65 
(d, J = 11.5 Hz, 1H, -CH2Bn), 4.27 (dd, J = 10.1, 5.0 Hz, 1H, H-6a), 3.93 – 3.83 (m, 1H), 3.47 
(td, J = 9.8, 5.0 Hz, 1H, H-5), 2.65 (qq, J = 12.8, 7.4 Hz, 2H, -SCH2), 1.19 (t, J = 7.4 Hz, 3H , 
-SCH3). 
13C NMR (176 MHz, DMSO) δ 161.22 (NHC=O), 138.26(-Ar), 128.10(-Ar), 127.40(-Ar), 
125.88(-Ar), 100.02(-PhCH), 92.93(-CCl3), 83.74(C-1), 80.77, 78.91, 73.59, 69.97, 67.62, 
55.61(C-2), 15.08(-SCH3). 
Step 2: Regioselective ring opening of benzylidene ring at C6 
5a (8.6 g , 15.72 mmol) was weighed into a 3-necked 250 mL R.B. flask fitted with a septum 
and Ar balloon and flushed with Ar for a while. DCM (105 mL, 0.15 M) was added into it, and 
the reaction flask was placed in an ice bath. 1M BH3 in THF (62.90 mmol) was added dropwise 
via a dropping funnel, followed by addition of TMSOTf (1.42 mL, 7.863 mmol) via a syringe. 
The reaction was allowed to stir on ice bath. After ~ 1.5 hrs, the reaction was quenched with 
Et3N/MeOH 1:10 (~ 44mL) till no more gas evolved. It was then diluted with DCM (~ 75 mL) 
and poured into a separating funnel. It was subsequently washed with Sat. aq. NaHCO3 (~ 
150 mL, 2X) and Brine (~ 150 mL, 2X). The organic phase was collected, dried with MgSO4, 
concentrated and dried under high vacuum.  
Step 2 – Analysis 
TLC: Rf = 0.47 (Hex/EA 2:1) 
1H NMR (700 MHz, DMSO-d6) δ 9.13 (d, J = 9.2 Hz, 1H, -NHCO), 7.36 – 7.22 (m, 10H, -Ar), 
4.82 (t, J = 5.7 Hz, 1H, -OH), 4.72 (d, J = 11.1 Hz, 1H, -CH2Bn), 4.64 (d, J = 11.1 Hz, 1H,-
CH2Bn), 4.31 (t, J = 5.2 Hz, 1H), 3.88 (t, J = 9.4 Hz, 1H), 3.81 (q, J = 9.7 Hz, 1H), 3.72 (ddd, 
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J = 12.1, 5.1, 1.9 Hz, 1H), 3.58 (dd, J = 11.4, 8.1 Hz, 1H), 3.52 (t, J = 9.4 Hz, 1H), 3.39 (td, J 
= 6.5, 5.0 Hz, 1H), 3.31 (ddd, J = 9.9, 4.9, 1.8 Hz, 1H), 2.66 (ddq, J = 45.3, 12.5, 7.4 Hz, 2H,-
SCH2), 1.20 (t, J = 7.4 Hz, 3H,-SCH3). 
13C NMR (176 MHz, DMSO) δ 161.12(NHC=O), 138.34(-Ar), 138.21(-Ar), 128.22(-Ar), 
128.11(-Ar), 127.70(-Ar), 127.5(-Ar), 127.44(-Ar), 93.04(-CCl3), 82.91(C-1), 82.66, 80.06, 
77.87, 74.25, 73.98, 66.99, 60.35, 56.02, 39.88, 39.76, 39.64, 25.11(-SCH2), 14.88(-SCH3). 
 
Step 3 – Procedure: Installation of the FMOC group at C6 
This procedure maintained an inert atmosphere throughout. 5b (10.6 g, 19.311 mmol) was 
purged with Ar for a while. DCM (54 mL , 0.36 M) was added into it , and quickly transferred 
into a 3-necked 250 mL R.B: flask (already flushed with Ar). The reaction flask was then placed 
in an ice bath. Pyridine (4.67 mL , 57.93 mmol) was added into it via a syringe. FMOC-Cl (5.99 
g , 23.17 mmol) was dissolved in DCM (~ 10 mL) and then added into the reaction flask. The 
reaction was allowed to stir on ice bath for ~ 10 mins and then left to stir at room temperature 
overnight. After overnight stirring, MeOH (~ 50 mL) was added into the reaction flask, and then 
poured into a separating funnel, and the organic phase was extracted. The aqueous phase 
was then extracted with EtOAc (~ 100 mL, 3X). The combined organic phase was then 
extracted with Brine (~ 100 mL, 2X). It was then dried with MgSO4, concentrated and dried 
under high vacuum.  
Step 3- Purification 
The crude material was dissolved in Ethyl acetate (~ 250 mL) at 55oC on a heating mantle. 
When all of it dissolved, it was filtered hot into an Erlenmeyer flask, and EtOH (abs) (~ 250 
mL) was added into it. It was then kept in the fridge overnight to induce crystallization. The 
crystals so obtained were washed and filtered with cold EtOH. 
Step 3 – Analysis 
TLC: Rf = 0.4 (Hex/EA 5:1) 
1H NMR (700 MHz, CDCl3) δ 7.77 (ddt, J = 7.6, 2.0, 0.9 Hz, 2H), 7.62 (ddq, J = 9.2, 7.5, 0.9 
Hz, 2H), 7.41 (tdt, J = 7.5, 1.9, 0.8 Hz, 2H), 7.36 – 7.27 (m, 13H), 6.91 (d, J = 8.3 Hz, 1H), 
4.93 (d, J = 10.1 Hz, 1H), 4.85 (dd, J = 18.0, 10.9 Hz, 2H), 4.77 (d, J = 10.8 Hz, 1H), 4.63 (d, 
J = 11.0 Hz, 1H), 4.47 (dd, J = 11.7, 2.3 Hz, 1H), 4.40 (qd, J = 10.5, 7.5 Hz, 2H), 4.32 (dd, J 
= 11.6, 5.4 Hz, 1H), 4.26 (t, J = 7.5 Hz, 1H), 4.08 (dd, J = 9.7, 8.4 Hz, 1H), 3.77 (td, J = 9.9, 
8.2 Hz, 1H), 3.70 (ddd, J = 9.6, 5.4, 2.3 Hz, 1H), 3.64 (dd, J = 9.5, 8.3 Hz, 1H), 2.78 – 2.66 




13C NMR (176 MHz, CDCl3) δ 161.76(NHC=O), 155.05(OC=O), 143.50(-Ar), 143.38(-Ar), 
141.41(-Ar), 137.64(-Ar), 137.50(-Ar), 128.71(-Ar), 128.23(-Ar), 128.15(-Ar), 128.11(-Ar), 
128.04(-Ar), 128.01(-Ar), 127.31(-Ar), 125.32(-Ar), 125.27(-Ar), 120.20(-Ar), 92.53(-CCl3), 














Step 1: Procedure - Installation of the troc group 
This procedure maintained an inert atmosphere throughout. In a 100 mL 3-necked round 
bottom flask, 8.3 mmol of 1a (3.2 g) was purged with argon for several minutes before adding 
21 mL of anhydrous DCM (final concentration: ~ 0.4M). The flask was the placed in an ice 
bath to cool down to 0oC. Then, Et3N (16.6mmol, 2.3 mL) was added via a syringe, followed 
by dropwise addition of Cl3CCH2OCOCl (11mmol, 1.5 mL) via a dropping funnel. The reaction 
was then allowed to stir on ice bath. After ~ 2.5 hours, the reaction was quenched with H2O (~ 
40 mL) and allowed to stir for ~ 20 minutes. Then, the reaction mixture was poured into a 
separating funnel, and the organic phase was extracted. The organic phase was then 
extracted with 1N HCl (~ 50 mL, 1x), Sat. aq. NaHCO3 (~ 50 mL, 1x) and Brine (~ 50 mL, 1x). 
The combined organic phase was then dried with MgSO4, concentrated and dried under high 
vacuum to give 3.8 g of pure 4a.  
Analysis: TLC: Rf = 0.5 (Hex/EA 4:1) 
1H NMR (700 MHz, CDCl3) δ 5.73 (d, J = 8.7 Hz, 1H,H-1), 5.40 (d, J = 9.5 Hz, 1H,H-3), 5.25 
(d, J = 9.6 Hz, 1H,-NHCO), 5.10 (t, J = 9.7 Hz, 1H,H-4), 4.72 (d, J = 3.9 Hz, 2H,-Cl3CCH2), 
4.28 (dd, J = 12.3, 4.6 Hz, 1H,H-6a), 4.11 (dd, J = 12.5, 4.6 Hz, 1H,H-6b), 3.96 (q, J = 9.6 Hz, 
1H,H-2), 3.85 (ddd, J = 10.1, 4.6, 2.3 Hz, 1H,H-5), 2.10 (d, J = 3.2 Hz, 3H), 2.08 (s, 3H,-
OCOCH3), 2.04 (d, J = 2.3 Hz, 6H,-OCOCH3). 
 
13C NMR (176 MHz, CDCl3) δ 170.99(OC=O), 170.77(OC=O), 169.53(OC=O), 
169.36(NHC=O), 95.53(-CCl3), 92.42 (C-1), 72.91, 72.22, 68.16, 61.76, 55.20(C-2), 
20.98(OCOCH3), 20.85(-OCOCH3), 20.75(OCOCH3), 20.72(-OCOCH3). 
 
 
Step 2: Procedure – Thioglycosylation 
This procedure maintained an inert atmosphere throughout. To 7.3 mmol of 4a (3.8g), 10 mL 
anhydrous DCM (final concentration: ~ 0.7M) was added under argon atmosphere and placed 
in an ice bath to cool down to 0oC. Then, p-toluylthiol (8 mmol, 1g) was added, followed by 
dropwise addition of BF3.Et2O (5.4 mmol, 0.7 mL). Then, the flask was removed from the ice 
bath for ~ 5 minutes, and then left to stir at room temperature for ~ 12 hours. After 2.5 hours, 
the reaction mixture was diluted with DCM (~ 100 mL) and poured into a separating funnel. 
Then, it was extracted with Sat.aq. NaHCO3 (~ 75 mL, 2x) and Brine (~ 75 mL, 2x). The 





Step 2 – Purification 
The crude material was dissolved in EA (~ 50 mL) at 55oC on a heating mantle. When all of it 
dissolved, the flask was removed from the heating mantle, and Hexane (~ 80 mL) was first 
added dropwise at room temperature, and then quickly under rigorous stirring. The precipitate 
so obtained was kept in the fridge overnight. Then, it was washed and filtered with cold Hexane 
to give 3.1 g pure 4b.  
Step 2 – Analysis 
TLC: Rf = 0.6 (Hex/EA 2:1) 
1H NMR (700 MHz, CDCl3) δ 7.42 – 7.39 (m, 2H,-Ar), 7.13 – 7.10 (m, 2H,-Ar), 5.29 – 5.25 (m, 
2H,-NHCO,H-4), 5.01 (t, J = 9.7 Hz, 1H,H-3), 4.79 (d, J = 10.0 Hz, 1H,H-1), 4.72 (d, J = 12.1 
Hz, 1H,-Cl3CCH2), 4.22 (dd, J = 12.2, 5.3 Hz, 1H,H-6a), 4.16 (dd, J = 12.2, 2.4 Hz, 1H), 3.70 
(ddd, J = 10.0, 5.0, 2.3 Hz, 1H,H-5), 3.65 (q, J = 9.9 Hz, 1H,H-2), 2.34 (s, 3H,-SCH3), 2.08 (s, 
3H,-OCOCH3), 2.00 (s, 3H,-OCOCH3), 1.99 (s, 3H,-OCOCH3). 
 
13C NMR (176 MHz, CDCl3) δ 170.72(OC=O), 169.57(NHC=O), 133.79(-Ar), 129.87(-Ar), 
95.53(-CCl3), 86.81(C-1), 75.90, 74.67, 73.34, 68.66, 62.44, 55.15(C-2), 21.31(-SCH3), 
20.88(OCOCH3), 20.76(OCOCH3), 20.72(OCOCH3). 
 
Step 3 – Procedure – Removal of the acetyl groups  
This procedure maintained an inert atmosphere throughout. In a 100 mL 3-necked round 
bottom flask, 5.3 mmol of compound 4b (3.1 g) was purged with argon for several minutes 
before adding 38 mL of anhydrous MeOH (final concentration: ~ 0.14M). Then, NaOMe in 
MeOH (2.11 mmol, 0.4 mL) was added via a syringe and the reaction was left to stir a room 
temperature for ~ 12 hours. Then, the reaction mixture was neutralized by passing the reaction 
mixture through a bed of amberlite resin till pH reaches 6. The filtrate so obtained was then 
concentrated and dried under high vacuum to give 2.1 g of pure 4c.   
Step – 3- Analysis 
TLC: Rf = 0.6 (Hex/EA 1:1) 
1H NMR (700 MHz, DMSO-d6) δ 7.36 – 7.30 (m, 2H), 7.13 (d, J = 9.0 Hz, 1H), 7.11 (d, J = 8.0 
Hz, 2H), 6.81 (t, J = 6.9 Hz, 1H), 5.10 (d, J = 5.3 Hz, 1H,-OH), 5.07 – 5.03 (m, 1H,-OH), 4.66 
(d, J = 9.9 Hz, 1H,H-1), 4.56 (t, J = 6.3, 5.4 Hz, 1H), 4.04 (d, J = 6.8 Hz, 1H), 3.69 (ddd, J = 
11.8, 5.3, 1.3 Hz, 1H), 3.45 (dd, J = 11.9, 5.9 Hz, 1H), 3.26 (d, J = 9.5 Hz, 1H), 3.12 (dt, J = 




13C NMR (176 MHz, DMSO) δ 135.89(-Ar), 131.53(-Ar), 129.80(-Ar), 129.47(-Ar), 86.83(-
CCl3), 81.14(C-1), 75.47, 75.30, 70.31, 61.00, 56.45, 51.28(C-2), 20.57(-SCH3). 
 
Step 4 – Procedure: Benzylidene formation 
This procedure maintained an inert atmosphere throughout. To 7.8 mmol of compound 4c (3.6 
g) 31 mL anhydrous ACN (final concentration: ~ 0.25M) were added under argon atmosphere. 
Gently stirring at room temperature, benzaldehyde dimethyl acetal (16mmol, 2.3 mL) were 
added via a syringe followed by addition of p-toluenesulfonic acid acid (1.4 mmol, 0.3 g.) via 
a powder funnel. The reaction was allowed to stir at room temperature for ~ 12 hours 
(overnight). The next day, the reaction mixture was diluted with 75 mL ethyl acetate and under 
vigorous stirring 100 mL of saturated aqueous NaHCO3 was added. After stirring for several 
minutes, the reaction mixture was poured into a separating funnel, the organic phase was 
separated and subsequently washed with 100 mL brine (2x). Finally, the organic phase was 
dried with MgSO4 before it was concentrated and dried under high vacuum. 
Step 4 Purification  
The crude material was dissolved in DCM (~60 mL) at on a heating mantle set to 55oC. When 
all of it dissolved, it was poured into a 500 mL Erlenmeyer flask and then hexane (~ 200 mL) 
was added into it dropwise via a dropping funnel until precipitation started. The remainder 
volume of hexane was then quickly added under vigorous stirring. The precipitate so obtained 
was then kept in the fridge overnight. The next day, the precipitate was filtered and washed 
with cold hexane to give 3 g of pure compound 4d after drying. 
Step-4- Analysis 
TLC: Rf = 0.47 (Hex.EA: 3:1) 
1H NMR (700 MHz, DMSO-d6) δ 7.47 – 7.30 (m, 6H), 7.29 (d, J = 9.5 Hz, 1H,-NHCO), 7.15 
(d, J = 8.1 Hz, 2H), 5.60 (s, 1H,-PhCH), 5.46 (d, J = 5.9 Hz, 1H), 4.85 (d, J = 10.5 Hz, 1H,H-
1), 4.19 (dt, J = 10.2, 4.7 Hz, 1H,H-6b), 3.69 (t, J = 10.1 Hz, 1H,H-6a,H-3), 3.60 (td, J = 9.2, 
5.8 Hz, 1H,H-5), 3.45 (t, J = 9.3 Hz, 1H,H-4), 3.40 (t, J = 9.7 Hz, 1H,H-2), 2.50 (p, J = 1.8 Hz, 
3H), 2.29 (s, 3H). 
 
13C NMR (176 MHz, DMSO) δ 130.64(-Ar), 129.61(-Ar), 128.00(-Ar), 126.32(-Ar), 100.63(-






Step 5 – Procedure: Installation of benzyl group at C3 
This procedure maintained an inert atmosphere throughout. 4e (2.2g , 4mmol) was weighed 
into a 100 mL 3-necked R.B. flask fitted with a septum and Ar balloon and flushed with Ar for 
a while. THF (17mL, 0.2 M) was added into it, and the reaction flask was then placed in an ice 
bath. NaH (60% dispersion in mineral oil) (0.4g, 10.4mmol) was added via a powder funnel, 
followed by dropwise addition of BnBr (mL, mmol) via a dropping funnel. After adding all the 
reagents, the flask was removed from the ice bath and left to stir at room temperature 
overnight. After overnight stirring, the reaction was quenched with Sat. aq. NH4Cl (~ 50 mL) 
till no more gas evolved and no more bubbling occurred. The reaction mixture was diluted with 
DCM (~ 100 mL) and poured into a separating funnel. The organic phase was then extracted. 
The aqueous phase was then extracted with DCM (~ 100 mL, 2X). The organic phase was 
then subsequently washed with Brine (~ 150 mL, 2X). It was then dried with MgSO4, 
concentrated and dried under high vacuum for ~ 1 hr.  
Step 5-Puriifcation 
Ethyl acetate (distilled) (~ 150 mL) was added to the crude material at 55oC on a heating 
mantle. The precipitate so obtained was kept in the fridge overnight to induce more 
precipitation. It was then washed with cold ethyl acetate.  
Step 5-Analysis 
TLC: Rf = 0.47 (Hex/EA 5:1) 
 
Step 6 Procedure: Installation of FMOC group at C6 
This procedure maintained an inert atmosphere throughout. 4f (g, mmol) was purged with Ar 
for a while. DCM (mL , M) was added into it , and quickly transferred into a 3-necked 250 mL 
R.B: flask (already flushed with Ar). The reaction flask was then placed in an ice bath. Pyridine 
(mL , mmol) was added into it via a syringe. FMOC-Cl (g , mmol) was dissolved in DCM (~ 10 
mL) and then added into the reaction flask. The reaction was allowed to stir on ice bath for ~ 
10 mins and then left to stir at room temperature overnight. After overnight stirring, MeOH (~ 
50 mL) was added into the reaction flask, and then poured into a separating funnel, and the 
organic phase was extracted. The aqueous phase was then extracted with EtOAc (~ 100 mL, 
3X). The combined organic phase was then extracted with Brine (~ 100 mL, 2X). It was then 





Step 3- Purification 
The crude material was dissolved in Ethyl acetate (~ 250 mL) at 55oC on a heating mantle. 
When all of it dissolved, it was filtered hot into an Erlenmeyer flask, and EtOH (abs) (~ 250 
mL) was added into it. It was then kept in the fridge overnight to induce crystallization. The 
crystals so obtained were washed and filtered with cold EtOH. 
Step 3 – Analysis 
TLC: Rf = 0.4 (Hex/EA 5:1) 
1H NMR (700 MHz, Chloroform-d) δ 7.77 (ddt, J = 7.6, 2.0, 0.9 Hz, 2H,-Ar), 7.62 (ddq, J = 
9.2, 7.5, 0.9 Hz, 2H,-Ar), 7.41 (tdt, J = 7.5, 1.9, 0.8 Hz, 2H,-Ar), 7.36 – 7.27 (m, 13H,-Ar), 6.91 
(d, J = 8.3 Hz, 1H), 4.93 (d, J = 10.1 Hz, 1H,H-1), 4.85 (dd, J = 18.0, 10.9 Hz, 2H), 4.77 (d, J 
= 10.8 Hz, 1H), 4.63 (d, J = 11.0 Hz, 1H,-CH2Bn), 4.47 (dd, J = 11.7, 2.3 Hz, 1H,-CH2Bn), 4.40 
(qd, J = 10.5, 7.5 Hz, 2H,-FMOC(CH2)), 4.32 (dd, J = 11.6, 5.4 Hz, 1H), 4.26 (t, J = 7.5 Hz, 
1H,-FMOC(CH)), 4.08 (dd, J = 9.7, 8.4 Hz, 1H), 3.77 (td, J = 9.9, 8.2 Hz, 1H), 3.70 (ddd, J = 
9.6, 5.4, 2.3 Hz, 1H,H-5), 3.64 (dd, J = 9.5, 8.3 Hz, 1H,H-2), 2.78 – 2.66 (m, 2H,-SCH2), 1.27 
(t, J = 7.4 Hz, 3H,-SCH3). 
 
 





Step1 Procedure: Regioselective opening of Benzylidene ring at C4 
This procedure maintained an inert atmosphere throughout. In a 500 mL 3-necked round 
bottom flask, 22 mmol of 5a (22 g) were purged with argon for several minutes before adding 
170 mL of anhydrous DCM (final concentration: ~ M) and molecular sieves (4 Å). The 
suspension was stirred at room temperature for 10 minutes and then, Et3SiH (88 mmol, 14 
mL) was added, and placed in an ice bath to cool down to 0oC. After ~ 30 minutes, TFA (91 
mmol, 7 mL) was added dropwise via a dropping funnel over 5 minutes. The reaction was 
allowed to stir at 0oC for ~ 15 minutes, and then left to stir at room temperature. After 3 hours, 
5a 5b 5c 
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the reaction mixture was quenched by dropwise addition of Et3N (~ 40 mL) till no more gas 
evolved. The reaction mixture was then diluted with DCM (130 mL) and poured into a 
separating funnel. It was then extracted with Sat. aq. NaHCO3 (300 mL, 3x) and Brine (300 
mL, 2x). The combined organic phase was dried with MgSO4, concentrated and subjected to 
purification.  
Step 1 Purification 
The crude material was subjected to column chromatography (Hex/EA 6:1 to 2:1) to give 9 g 
of pure 5b.  
Step 1 Analysis 
1H NMR (700 MHz, DMSO-d6) δ 9.06 (d, J = 9.0 Hz, 1H, -NHCO), 7.35 (d, J = 5.3 Hz, 3H, -
Ar), 7.29 – 7.28 (m, 4H, -Ar), 7.25 – 7.22 (m, 1H, -Ar), 5.56 (d, J = 6.3 Hz, 1H, -OH), 4.80 (dd, 
J = 11.1, 1.9 Hz, 1H, -CH2Bn), 4.68 (d, J = 9.9 Hz, 1H, H-1), 4.61 (dd, J = 11.1, 6.2 Hz, 1H), 
4.54 (d, J = 1.3 Hz, 2H), 3.77 (dd, J = 11.1, 1.5 Hz, 1H), 3.58 (dd, J = 11.0, 5.7 Hz, 1H), 3.43 
– 3.36 (m, 2H), 2.63 (ddq, J = 42.3, 12.8, 7.4 Hz, 2H,-SCH2), 1.22 – 1.18 (m, 3H,-SCH3). 
 
Step 2 Procedure: Installation of FMOC group at C4 
This procedure maintained an inert atmosphere throughout. 10 mmol of 5b (5.8 g) were 
purged with argon for several minutes before adding 75 mL of anhydrous DCM (final 
concentration: ~ 0.13M). The reaction was allowed to stir at room temperature and Pyridine 
(32 mmol, 2.6 mL) were added , followed by FMOC-Cl (11.6 mmol, 3.01 g). The colour of the 
reaction ixture turned from faint yellow to ornage to finally red. After 3 hours, the reaction was 
diluted with DCM (~ 75 mL) and extrcated with H2O (150 mL, 2x) and Brine (150 mL, 2x). The 
combined organic phase was dried with MgSO4, concentrated and dried under high vacuum.  
Step 2 Purification 
The crude material was dissolved in EA (~ 15 mL) and Hexane (~15 mL) at 70oC on a heating 
mantle. When all of it dissolved, it was kept in the freezer to induce crystallization. After ~ 4 
days, crytsals could be incued by scratching. Then, the crystals so obatined were washed and 
filtered with cold Hex/EA 1:1, and dried in the desiccator to give 6 g of pure BB 10.  
Step 2 Analysis 
TLC: Rf = 0.5 (Hex/EA 4:1) 
1H NMR (500 MHz, Chloroform-d) δ 7.75 (ddt, J = 7.7, 3.0, 0.9 Hz, 2H,-Ar), 7.57 (dd, J = 7.5, 
1.0 Hz, 1H,-Ar), 7.52 (dd, J = 7.5, 1.0 Hz, 1H,-Ar), 7.39 (td, J = 7.5, 1.0 Hz, 2H,-Ar), 7.36 – 
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7.17 (m, 12H,-Ar), 6.93 (d, J = 7.9 Hz, 1H, NHC=O), 5.04 (d, J = 10.3 Hz, 1H, H-1), 4.94 (dd, 
J = 9.9, 9.0 Hz, 1H, H-4), 4.64 (s, 2H, 3-OCH2Ph), 4.53 (s, 2H, 6-OCH2Ph), 4.33 (dd, J = 9.6, 
6.4 Hz, 1H, Fmoc CHH), 4.29 (dd, J = 9.6, 6.4 Hz, 1H, Fmoc CHH), 4.24 (dd, J = 10.0, 9.0 Hz, 
1H, H-3), 4.11 (t, J = 7.2 Hz, 1H, Fmoc CH), 3.77 (ddd, J = 9.9, 5.2, 3.8 Hz, 1H, H-5), 3.70 – 
3.61 (m, 3H, H-2, H-6a, H-6b), 2.73 (qq, J = 12.7, 7.4 Hz, 2H, SCH2), 1.29 (t, J = 7.4 Hz, 3H, 
CH3). 
13C NMR (126 MHz, Chloroform-d) δ 161.80 (NHC=O), 154.39 (OC=O), 143.38(-Ar), 
143.19(-Ar), 141.42(-Ar), 141.38(-Ar), 137.96(-Ar), 137.41(-Ar), 128.55, 128.45, 128.05, 
127.97, 127.77, 127.76, 127.32, 127.30, 125.23, 125.12, 120.22, 120.20, 92.41 (Cl3C), 82.56 
(C-1), 78.88 (C-3), 77.41 (C-2), 76.26 (C-4), 74.84 (3-OCH2), 73.70 (6-OCH2), 70.24 (Fmoc 

























Step 1- Procedure: Installation of acetyl groups 
This procedure does not need an inert atmosphere. In a 250 mL 3-neck round bottom 
flask mmol sodium acetate (10 g, 0.5 eq.) were mixed with  mmol acetic anhydride ( 101 mL, 
10.0 eq.). A reflux condenser was fitted to one of the necks, and the flask was placed on a 
heating mantle. The reaction was then refluxed at 120 °C for 5 minutes. 122 mmol of D 
MANNOSE (20.0 g) were then added in portions over a period of 10 minutes and the 
temperature was maintained at 120oC. After the addition, the reaction was allowed to cool 
down to room temperature for 30 minutes. The reaction was then poured into ice in a 500 mL 
beaker and stirred for 1 hour. It was then poured into a separating funnel and extracted with 
250 mL ethyl acetate (1X). Subsequently, the organic phase was washed with 150 mL 
saturated aqueous NaHCO3 (2x) and 150 mL brine (2x). Finally, the organic phase was dried 
with MgSO4, the solvent removed by evaporation and the resulting oil was dried under high 
vacuum to give  44 g of pure compound 6b as a yellow oil. 
Step 1 Analysis 
TLC: Rf = 0.5 (Hex/EA 2:1)    
1H NMR (400 MHz, CDCl3) δ 6.08 (d, J = 1.5 Hz, 1H,H-1), 5.37 – 5.32 (m, 1H), 5.30 – 5.22 
(m, 1H), 4.28 (ddd, J = 12.4, 10.0, 5.1 Hz, 1H), 4.09 (dd, J = 12.4, 2.4 Hz, 1H), 2.17 (d, J = 
3.4 Hz, 2H), 2.10 – 2.08 (m, 6H,-OAc), 2.00 (d, J = 1.0 Hz, 3H,-OAc). 
 
13C NMR (101 MHz, CDCl3) δ 177.25(OC=O), 170.86(OC=O), 170.39(OC=O), 
169.93(OC=O), 169.72(OC=O), 90.70(C-1), 73.38, 70.77, 68.85, 65.63, 62.22(C-6), 20.98, 
20.89, 20.88, 20.84, 20.78 
  
Step 2 – Procedure: Thioglycosylation 
This procedure maintained an inert atmosphere throughout. To 129 mmol of compound 6b 
(50.2 g) 430 mL anhydrous dichloromethane (final concentration: ~ 0.3  M) were added under 
argon atmosphere and placed on an ice bath to cool down to 0 °C. Then, 257 mmol ethanethiol 
(19 mL, 2.0 eq.) were added via a powder funnel followed by dropwise addition of 321 mmol 
BF3·Et2O (40 mL, 2.5 eq.) over 10 minutes via a dropping funnel. The reaction was allowed to 
stir on ice bath for another 5 minutes, then removed from the ice bath and allowed to stir at 
room temperature for ~ 12 hours. Then, the reaction mixture was poured into an Erlenmeyer 
flask, and 500 mL Sat. aq. NaHCO3 was added into it and kept to stir for some time. It was 
then poured into a separating funnel, and the organic phase was separated. The combined 
organic phase was subsequently washed with 400 mL brine (2x). Finally, the organic phase 
was dried over MgSO4 before it was concentrated and dried under high vacuum. 
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Step 2 Purification  
The crude material was dissolved in ethyl acetate (~ 125 mL) at 55 °C on a heating mantle. 
When all of it dissolved, it was removed from the mantle, and hexane (~ 750 mL) was added 
into it dropwise via a dropping funnel until precipitation started. The remainder volume of 
hexane was then added quickly under vigorous stirring. The precipitate so obtained was then 
kept in the fridge overnight. The next day, the precipitate was filtered and washed with cold 
hexane to give g of pure compound 6c after drying. 
Step 2 - Analysis 
TLC: Rf = 0.5 (Hex/EA   3:1) 
1H NMR (700 MHz, CDCl3) δ 5.33 – 5.28 (m, 2H, H-3, H-4), 5.27 (d, J = 1.8 Hz, 1H,H-1), 5.24 
(dd, J = 10.0, 3.3 Hz, 1H,H-5), 4.38 (dddd, J = 9.8, 5.4, 2.4, 0.7 Hz, 1H,H-2), 4.30 (dd, J = 
12.3, 5.4 Hz, 1H,H-6a), 4.08 (dd, J = 12.2, 2.4 Hz, 1H,H-6b), 2.68 – 2.57 (m, 2H,-SCH2), 2.15 
(s, 3H,-COCH3), 2.07 (s, 3H,-COCH3), 2.03 (s, 3H,-COCH3), 1.97 (s, 3H,-COCH3), 1.29 (t, J = 
7.4 Hz, 3H,-SCH3). 
 
13C NMR (176 MHz, CDCl3) δ 170.69(OC=O), 170.08(OC=O), 169.87(OC=O), 
169.83(OC=O), 82.38(C-1), 71.28(C-3), 69.59(C-2), 69.02(C-4), 66.49(C-5), 62.54(C-6), 
25.56(-SCH2), 21.02(-COCH3), 20.79(-COCH3), 20.72(-COCH3), 14.85(-SCH3). 
 
Step 3 – Procedure: Removal of the acetyl groups 
This procedure maintained an inert atmosphere throughout. In a 500 mL 3-neck round bottom 
flask mmol of compound 6c (21.3 g) were flushed with argon for several minutes before 
adding mL DCM/MeOH 1:1 (final concentration: ~ 0.5 M). Gently stirring at room temperature, 
22 mmol NaOMe in MeOH (5.4 M) (mL, 0.4 eq) were added into it via a syringe. The reaction 
was then allowed to stir at room temperature for ~ 12 hours (overnight). The next day, the 
reaction was passed through a column of Amberlite resin (~ 25 mL) in a sintered funnel till pH 
of the filtrate reaches 6. The solvent was then removed by evaporation and the resulting solid 
was dried under high vacuum to give g of pure compound 6d after drying. 
Step 3-Analysis 
TLC: Rf = 0.5 (Hex/EA  1:1) 
1H NMR (400 MHz, MeOH-d4) δ 5.25 (d, J = 1.4 Hz, 1H,H-1), 3.90 (dt, J = 3.0, 1.9 Hz, 2H), 
3.82 (dd, J = 11.9, 2.4 Hz, 1H), 3.73 (dd, J = 11.8, 5.8 Hz, 1H), 3.66 – 3.63 (m, 2H), 2.77 – 




13C NMR (101 MHz, MeOH-D4) δ 84.64(C-1), 84.54, 73.51, 72.42, 71.89, 67.54, 61.45, 
24.40(-SCH2), 13.95(-SCH3). 
 
Step 4 –Procedure: Benzylidene formation 
This procedure maintained an inert atmosphere throughout. To 31mmol of compound 6d 
(7g), 62mL anhydrous THF (final concentration: ~ 0.5 M) were added under argon 
atmosphere. Gently stirring at room temperature, mmol of benzaldehyde dimethyl acetal 
( 9.4mL, 2.0 eq.) were added via a syringe followed by addition of 5.5 mmol camphor sulfonic 
acid (1.3g, 0.2 eq.) via a powder funnel. The reaction was allowed to stir at room temperature 
for ~ 12 hours (overnight). The next day, the reaction mixture was diluted with 100 mL ethyl 
acetate and under vigorous stirring 200 mL of saturated aqueous NaHCO3 was added. After 
stirring for several minutes, the reaction mixture was poured into a separating funnel, the 
organic phase was separated and subsequently washed with 150 mL brine (2x). Finally, the 
organic phase was dried with MgSO4 before it was concentrated and dried under high vacuum. 
Step 4 Purification  
The crude material was dissolved in DCM (~ 80mL) at on a heating mantle set to 55oC. When 
all of it dissolved, it was poured into a 1 L Erlenmeyer flask and then hexane (~ 600 mL) was 
added into it dropwise via a dropping funnel until precipitation started. The remainder volume 
of hexane was then quickly added under vigorous stirring. The precipitate so obtained was 
then kept in the fridge overnight. The next day, the precipitate was filtered and washed with 
cold hexane to give g of pure compound 6e after drying. 
Step-4- Analysis 
TLC: Rf = 0.5 (Hex/EA  3:1) 
1H NMR (700 MHz, DMSO-d6) δ 7.46 – 7.44 (m, 2H), 7.38 – 7.36 (m, 2H), 5.61 (s, 1H,-PhCH), 
5.36 (d, J = 4.1 Hz, 1H,-OH), 5.23 (d, J = 1.2 Hz, 1H,H-1), 5.08 (d, J = 6.2 Hz, 1H,-OH), 4.10 
(dd, J = 10.0, 4.8 Hz, 1H,H-6a), 3.95 (td, J = 9.8, 4.7 Hz, 1H,H-4), 3.89 (t, J = 9.5 Hz, 1H,H-
3), 3.82 – 3.80 (m, 1H), 3.77 (t, J = 10.1 Hz, 1H), 3.67 (ddd, J = 9.6, 6.1, 3.4 Hz, 1H,H-5), 2.65 
– 2.54 (m, 2H,-SCH2), 1.22 (t, J = 7.4 Hz, 3H,-CH3). 
 
13C NMR (176 MHz, DMSO) δ 137.89 (-Ar), 128.79(-Ar), 127.97(-Ar), 126.35(-Ar), 101.16(-






Step 5 – Procedure: Installation of benzyl groups 
This procedure maintained an inert atmosphere throughout. To 6 mmol of 6e (2g), 28mL of 
anhydrous DMF (final concentration: ~ 0.2 M) were added under argon atmosphere and 
placed in an ice bath to cool down to 0oC. Then, NaH (26mmol, 1g) was added, followed by 
dropwise addition of BnBr (15mmol, 2mL) via a dropping funnel. The reaction was left to stir 
on the ice bath for ~ 15 mins, and then left to stir at room temperature for ~ 18 hours. The 
reaction was then quenched with Sat. aq. NH4Cl (~5mL) till no more bubbling occurred. The 
reaction mixture was then transferred into a separating funnel, and the organic phase was 
extracted. The aqueous phase was then extracted with DCM (~60mL,1x) and the combined 
organic phase was dried with MgSO4, concentrated and dried under high vacuum.  
Step 5 – Purification 
The crude material was dissolved in Ethyl Acetate (~ 20mL) at 50oC on a heating mantle. 
When all of it dissolved, Hexane (~50 mL) was then added dropwise via a dropping funnel. 
The crude material was then kept in the freezer overnight to induce crystallization. Then, the 
crystals so obtained were washed and filtered with cold Hexane to give 4g of pure 6f.  
Step 5 – Analysis 
TLC:  Rf = 0.6 (Hex/EA 5:1) 
 
Step 6 – Procedure: Formation of sulfoxide  
This procedure maintained an inert atmosphere throughout. In a 250 mL 3-necked round 
bottom flask, 7.5 mmol of 6f (3.7g) were purged with argon for several minutes before adding 
50 mL of anhydrous DCM (final concentration: ~ 0.15M). The reaction flask was then placed 
in an ice bath to cool down to 0oC. Then, m-CPBA (7.5 mmol, 1.3g) was weighed into a 100 
mL round bottom flask, and purged with argon for several minutes before adding ~ 20 mL 
DCM. This solution was then added dropwise to the reaction flask via a dropping funnel. The 
reaction was llowed to stir on ice bath. After ~ 1 hour, the reaction was quenched with Sat. aq. 
NaHCO3 (~ 10 mL) till no more gas evolved. It was then poured into a separating funnel and 
the organic phase was extracted, and washed with Brine (~ 100 mL, 2x). The combined 






Step 6 – Purification 
The crude material was dissolved in EtOH (abs) (~50 mL) at 50oC on a heating mantle. When 
all of it dissolved, it was kept in the freezer overnight to induce crystallization. The crystals so 
obtained were washed and filtered with cold EtOH to give 1.4g of pure 6g. 
Step 6 - Analysis  
TLC: Rf = 0.5 (Hex/EA 4:1) 
1H NMR (500 MHz, CDCl3) δ 7.50 – 7.45 (m, 2H), 7.43 – 7.26 (m, 13H), 5.64 (s, 1H,-PhCH), 
4.83 (dd, J = 17.8, 11.9 Hz, 2H,-CH2Bn), 4.70 (dd, J = 16.7, 11.9 Hz, 2H,-CH2Bn), 4.62 (d, J 
= 1.5 Hz, 1H,H-1), 4.52 (dd, J = 3.4, 1.5 Hz, 1H,H-2), 4.35 (dd, J = 10.1, 9.2 Hz, 1H,H-4), 4.21 
(dd, J = 10.2, 4.6 Hz, 1H,H-6a), 4.13 (dd, J = 10.1, 3.4 Hz, 1H,H-6b), 3.72 (td, J = 9.5, 4.6 Hz, 
1H,H-3), 2.78 (ddq, J = 134.0, 13.3, 7.4 Hz, 2H,-SCH2), 1.35 (t, J = 7.5 Hz, 3H,-SCH3). 
 
13C NMR (126 MHz, CDCl3) δ 138.22(-Ar), 137.70(-Ar), 137.29(-Ar), 129.15(-Ar), 128.59(-Ar), 
128.55(-Ar), 128.48(-Ar), 128.44(-Ar), 128.36(-Ar), 128.12(-Ar), 127.79(-Ar), 127.77(-Ar), 
127.75(-Ar), 126.16(-Ar), 101.73(-PhCH), 92.87(C-1), 78.02, 76.27, 74.19, 73.29, 73.17, 
70.19, 68.31, 44.16(-S(O)CH2), 6.00(-S(O)CH3). 
 



















Step 1 – Procedure: Installation of silyl group at C3 
This procedure maintained an inert atmosphere throughout. In a 100 mL3-necked round 
bottom flask, 3.2 mmol of 6e (1g) were purged with argon for several minutes before adding 
25 mL of anhydrous DCM (final concentration: ~ 0.13M). The reaction flask was then placed 
in an ice bath to cool down to 0oC. Then, TBDMS-Cl (3.8 mmol, 0.58g) were added, followed 
by Imidazole (4.48 mmol, 0.305g). The reaction was then allowed to stir at room temperature 
for ~ 12 hours. Then, the reaction was quenched with Sat. aq. NaHCO3 (~ 50 mL) under 
constant stirring, and stirred for a while. Then, it was poured into a separating funnel, and the 
organic phase was extracted and washed with Brine (~ 100 mL, 2x). The combined organic 
phase was then dried with MgSO4, concentrated and dried under high vacuum to give 1g of 
6g. 
Step 1 – Analysis 
TLC: Rf = 0.6 (Tol/EA 3:1) 
1H NMR (700 MHz, DMSO-d6) δ 7.46 – 7.42 (m, 3H,-Ar), 7.38 – 7.34 (m, 4H,-Ar), 5.64 (s, 
1H,-PhCH), 5.30 (d, J = 4.2 Hz, 1H), 5.24 (d, J = 1.4 Hz, 1H,H-1), 4.10 (dd, J = 10.1, 4.3 Hz, 
1H), 3.91 – 3.88 (m, 1H), 2.62 – 2.58 (m, 2H), 1.22 (t, J = 7.4 Hz, 4H), 0.84 (d, J = 3.1 Hz, 




13C NMR (176 MHz, DMSO) δ 127.91(-Ar), 126.00(-Ar), 100.86(-PhCH), 85.79(C-1), 78.17, 
72.78, 70.39, 67.65, 64.71, 25.70(-SCH2), 14.94(-SCH3), -3.21(-C(CH3)3), -4.53(-Si(CH3)), -
4.91(-Si(CH3)) 
 
Step 2 – Procedure: Installation of benzyl group at C2 
This procedure maintained an inert atmosphere throughout. To 2.3 mmol of 6g (1g), 11 mL of 
anhydrous DCM (final concentration: ~ 0.2M) were added and purged with argon for several 
minutes and placed in an ice bath to cool down to 0oC. Then, NaH (4.7 mmol, 0.18g) were 
added, followed by dropwise addition of BnBr (2.8 mmol, 0.3 mL) via a dropping funnel. The 
reaction was then removed from the ice bath and allowed to stir at room temperature. After ~ 
4.5 hours, the reaction was quenched with Sat. aq. NH4Cl (~ 5mL) till no more bubbling 
occurred. The reaction mixture was then diluted with DCM (~ 75 mL) and poured into a 
separating funnel. The organic phase was extracted and washed with Brine (~ 100 mL, 2x). 
The combined organic phase was then dried with MgSO4, concentrated and subjected to 
purification.  
Step 2 - Purification   
The crude material was purified with dry flash chromatography. (Tol/EA 6:1 to 2:1) to give 
0.8 g of pure 6h. 
Step 2 – Analysis 
TLC: Rf = 0.7 (Tol/EA 3:1) 
1H NMR (700 MHz, CDCl3) δ 7.53 – 7.49 (m, 3H,-Ar), 7.41 (t, J = 7.4 Hz, 3H,-Ar), 7.38 – 7.33 
(m, 7H,-Ar), 5.58 (s, 1H,-PhCH), 5.29 (d, J = 1.4 Hz, 1H,H-1), 4.88 (d, J = 11.9 Hz, 1H,-
CH2Bn), 4.82 – 4.74 (m, 1H), 4.71 (d, J = 12.0 Hz, 1H,-CH2Bn), 4.15 (dd, J = 9.8, 3.1 Hz, 
1H,H-3), 4.08 (d, J = 9.2 Hz, 1H,H-4), 3.94 – 3.89 (m, 1H,H-6a), 3.89 – 3.85 (m, 1H), 3.80 (dd, 
J = 3.2, 1.4 Hz, 1H,H-2), 2.66 – 2.52 (m, 2H,-SCH2), 1.27 – 1.25 (m, 3H,-CH3), 0.90 (s, 9H,-
(C(CH3)3), 0.09 (s, 3H,-Si(CH3), 0.05 (s, 3H,-Si(CH3). 
 
13C NMR (176 MHz, CDCl3) δ 128.96(-Ar), 128.93(-Ar), 128.55, 128.44, 128.40, 128.31, 
128.22, 128.18, 128.14, 128.06, 127.96, 127.90, 127.75, 127.69, 126.36, 126.22, 102.03(-







Step 3 – Procedure: Formation of sulfoxide 
This procedure maintained an inert atmosphere throughout. To 4 mmol of 6h (2.1 g), 27 mL 
of anhydrous DCM (final concentration: ~ 0.1M) and placed in an ice bath to cool down to 0oC. 
Then, m-CPBA (4 mmol, 0.7 g) was weighed into a 100 mL round bottom flask and purged 
with argon for several minutes before adding DCM (~ 10 mL), and added into the reaction 
flask dropwise via a dropping funnel. The reaction was then allowed to stir on ice bath. After 
~ 1 hour, the reaction was quenched with Sat. aq. NaHCO3 (~ 10 mL) and poured into a 
separating funnel. The organic phase was then extracted, and washed with Brine (~ 100 mL, 
2x). The combined organic phase was dried with MgSO4, concentrated and subjected to 
purification.  
Step 3 – Purification 
The crude material was purified by flash chromatography with Tol/EA as eluents. (9:1 6:1 
4:1). Product eluted at 4:1. The product fractions were collected, concentrated and dried 
under high vacuum to give 0.104g of pure BB 10.  
Step 3 – Analysis 
TLC: Rf = 0.6 (Tol/EA 3:1) 
1H NMR (400 MHz, CDCl3) δ 7.49 – 7.34 (m, 11H,-Ar), 5.58 (s, 1H,-Ar), 4.97 (d, J = 11.4 Hz, 
1H,-CH2Bn), 4.69 (d, J = 11.4 Hz, 1H,-CH2Bn), 4.62 (d, J = 1.2 Hz, 1H,H-1), 4.35 – 4.31 (m, 
2H), 4.20 – 4.11 (m, 2H), 3.79 – 3.68 (m, 2H), 2.91 (dq, J = 13.5, 7.5 Hz, 1H), 2.64 (dq, J = 
13.5, 7.4 Hz, 1H), 1.36 (t, J = 7.5 Hz, 3H), 0.90 (s, 9H), 0.11 (s, 3H), 0.07 (d, J = 3.8 Hz, 3H). 
 
13C NMR (101 MHz, CDCl3) δ 137.97(-Ar), 137.24(-Ar), 128.60(-Ar), 128.29(-Ar), 128.27(-Ar), 
128.09, 126.29, 102.16(-PhCH), 93.24(C-1), 78.15, 76.02, 75.06, 70.70, 68.28, 44.31, 25.98, 


















Procedure: This procedure maintained an inert atmosphere throughout. To 4mmol of 
Compound_ (2g), 15mL of anhydrous DCM (final concentration: ~ 0.3M) were added under 
argon atmosphere and placed in an ice bath to cool down to 0oC. Then, FMOC-Cl (8mmol, 
2.1g) were added, followed by addition of pyridine (13mmol, 1mL). The colour of the reaction 
mixture changed from yellow to orange upon addition of pyridine. After the addition, the 
reaction flask was removed from the ice bath, and allowed to stir at room temperature for ~ 12 
hours. Then, the reaction was quenched with 1N HCl, and poured into a separating funnel. 
The organic layer was then extracted, and washed with Sat. aq. NaHCO3(~80mL,2x) and Brine 
(~80mL,2x). The combined organic phase was then dried with MgSO4, concentrated and dried 
under high vacuum.  
Purification: The crude material was subjected to purification by column chromatography 
with Hex/EA as solvents. (Hex/EA 6:1, 4:1, 2:1). The product fractions were collected, 
concentrated and dried under high vacuum.  
Analysis: 







8.3 Synthesis of β-mannose containing  




Procedure: Donor (0.4mmol, 0.2g) and acceptor (0.6mmol, 0.354g) were co-evaporated with 
Toluene (~5mL,3x) and dried under high vacuum overnight. Then, the donor was dissolved in 
(~ 7mL) and poured into a 100 mL 3-necked round botton flask (pre-dried in the oven and 
cooled under Ar), and the reaction flask was placed in a cooling bath and the temperature was 
set to -78oC using dry ice and acetone. Then, DTBMP (0.8mmol, 0.166g) was added, and the 
reaction mixture was stirred for ~ 10 minutes. Then, Tf2O (0.4mmol, 0.061mL) were added 
dropwise. Then, the reaction was strirred for ~ minutes, and the acceptor (dissolved in 7mL 
DCM) was added dropwise into the reaction flask. Then, the reaction was allowed to stir on 
the cooling bath overnight. Then, the reaction was quenched with Sat. Aq. NaHCO3(~30mL) 
and poured into a separting funnel. The organic phase was extracted and washed with Brine 
(~ 50mL,2x). The combined organic phase was dried with MgSO4, concentrated and dried 
under high vacuum.  
 




1H NMR (500 MHz, CDCl3) δ 7.49 – 7.46 (m, 1H), 7.42 – 7.26 (m, 15H), 6.91 (d, J = 0.7 Hz, 
2H,H-1), 5.64 (s, 1H,-PhCH), 4.92 – 4.89 (m, 1H), 4.89 – 4.82 (m, 1H), 4.81 – 4.74 (m, 2H,H-
1(GlcNAc (H-1)), 4.70 (dd, J = 15.2, 11.8 Hz, 1H), 4.62 (d, J = 1.4 Hz, 1H,H-1 (alpha)), 4.60 – 
4.55 (m, 1H), 4.52 (dd, J = 3.4, 1.5 Hz, 1H), 4.35 (dd, J = 10.1, 9.2 Hz, 1H), 4.20 (dd, J = 10.2, 
4.6 Hz, 1H), 4.13 (dd, J = 10.0, 3.4 Hz, 1H), 3.92 – 3.87 (m, 1H), 3.85 – 3.77 (m, 2H), 3.72 
(dd, J = 4.9, 0.7 Hz, 1H), 3.56 (dt, J = 9.7, 4.9 Hz, 0H), 2.94 – 2.86 (m, 1H), 2.76 – 2.60 (m, 
2H), 0.98 (t, J = 7.9 Hz, 3H). 
13C NMR (126 MHz, CDCl3) δ 167.54, 146.55, 138.24, 137.72, 137.30, 129.15, 128.74, 
128.66, 128.65, 128.60, 128.48, 128.36, 128.25, 128.23, 128.15, 128.12, 128.07, 127.94, 
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127.80, 127.77, 126.17, 116.32, 101.75, 92.90, 82.91, 82.77, 81.48, 81.35, 78.05, 77.94, 
76.31, 74.96, 74.22, 73.94, 73.68, 73.32, 73.22, 70.85, 70.22, 68.33, 57.10, 44.18, 37.54, 
24.60, 24.37, 21.60, 15.24, 6.79, 6.02, 4.35. 
 
 
8.4  General procedures for pre-automation steps 
8.4.1   Attachment of Lenz linker to Merrifield resin 
The resin (2g, loading: 0.5mmol/g) was weighed into a filter syringe, and swollen in DCM for 
1 hour. Then, Lenz linker (441mg, 1.104mmol) was weighed into a 100 mL round bottom flask, 
and dissolved in EtOH (2mL) and deionized H2O (0.55mL). The pH was then adjusted to 7 by 
adding 2M Cs2CO3 (~ 0.5mL). The solution was then evaporated to dryness. Then, it was co-
evaporated with anhydrous 1,4-Dioxane (3x) and dried under high vacuum for ~ 30 minutes. 
DCM was then drained from the resin and allowed to sit on DMF for ~ 15-20 minutes. The Cs 
salt of the Lenz linker was then taken off from the high vacuum and dissolved in 10mL DMF. 
Then, NaI (0.092mmol, 0.014g) was added into it. DMF was then drained out of the filter 
syringe containing resin. Then, a needle was fiited to the syringe and the Cs salf was drwan 
up into the syringe. The needle was taken out, and the syringe was capped. It was then kept 
in a 1L conical flask, and covered with parafilm. The flask was kept at 50oC in the oven 
overnight.  
 
8.4.2   Attachment of FMOC carbonate to Lenz resin/photocleavable resin 
~ 150mg Lenz resin was weighed into a filter syringe, and swollen in DCM for 1 hour on a 
shaker. Meanwhile, 550mg FMOC-Cl was weighed into a round bottom flask, and dissolved 
in 5mL DCM. Then, 0.5mL pyridine was added into it. Then, the filter syringe was removed 
from the shaker, and the FMOC solution was drawn up the syringe using a needle. Upon 
complete addition, the needle was removed, and the syringe was capped. Then, the syringe 
was the left on the shaker overnight. The syringe was then removed from the shaker, and the 
solution was drained out of the syringe. The resin was then washed with DCM and MeOH (~ 









8.4.3  Loading determination of Linker loaded resin(Lenz resin/photocleavable 
resin) 
 
For the loading determination, three independent samples of Lenz/photocleavable resin with 
FMOC carbonate attached were prepared. Approximately,  50 mg of dried resin were weighed 
into a grdauated 100 mL flask and 20mL DMF (using the 25 mL graduated pipette) were 
added. The suspension was left to sit for 30 minutes under occassional gentle swirling and 
then 400 μL of DBU were added (using the 1 mL volumetric pipette) , affording a final 
concentration of 2% DBU (v/v). This mixture was left to sit under occassional swirling for 
another 30 minutes. After 30 min, ACN was added to make up the final volume to 100 mL. 
Then, 2 mL of this solution was transferred to a graduated 25mL flask and diluted with ACN 
to 25mL. The reference solution was prepared similarly without the resin. Then, the UV 
absorption maxima of the reference and the three independent samples were measured at 
304 or 294 nm. Three measurements were prformed for each of the resin sample and 
reference.  
The data were recorded and imported into Excel. The raw data was then “corrected” by 
subtracting the average of teh three refernce measurements from each of the individual 
samples. The loading was then calculated using the following formula: 
      























Commands Function Parameters 
P1 P2 P3 P4 P5 
Argon Mix Mixes the 
contents of the 
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via bubbling 
Bubble on(s) Bubble off 
(s) 
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8.6   Automated Glycan Assembly using the Glyconeer 
 
8.6.1   General methods and Materials 
Anhydrous* solvents used to prepare building block as well as activator, TMSOTf and capping 
stock solutions were taken from a solvent drying system (jcmeyer-solvent systems). HPLC 
Grade DCM was used for washing. All other washing solvents (DMF, THF, Dioxane and 
MeOH) were reagent grade. Building blocks are dried by co-evaporation with Toluene (3x) 
and drying under high vacuum for approximately 1 to 2 hours. All synthesis were carried out 
on a scale of 0.0125 mmol using a Merrifield Resin modified with a photocleavable linker 
(Loading = 0.41 mmol/g).  
 
The polymer matrix is Copoly(stryol-1% divinylbenzol)    






Stock Solutions  
Activator solution:   150 mM NIS/15mM TfOH in DCM*:Dioxane* 
Acid wash solution:   62 mM TMSOTf in DCM* 
Capping solution:   10% (v/v) Ac2O/2% (v/v) MeSO3H in DCM* 
Pyridine “pre-wash” solution:  10% (v/v) pyridine in DMF  
FMOC deprotection solution:  20% (v/v) Piperidine in DMF 
Automation Modules  
Module A: Initial Resin Swelling/Beginning of Synthesis Wash 
The resin is washed with DCM, DMF and THF (3x, 2 mL, 25 s each) before swelling in DCM 
(2 mL) for 30 mins with occasional mixing using pulsed Argon bubbling. 
Module B: Acidic Wash with 62 mM TMSOTf 
DCM (2 mL) is delivered into the reaction vessel, and the temperature is adjusted to -20 °C. 
The DCM is drained and replaced by another 2 mL of DCM before TMSOTf solution (1 mL) is 
added dropwise. The mixture is incubated for 1.5 mins under Ar bubbling before draining 
washing with 2 mL DCM for 25 s.  
 
Module C: Thioglycoside coupling 
Building Block stock solutions and glycosylation parameters: 
 Building Block Excess c (mM) T1 (°C) T2 (°C) 
A BB1, BB2, BB4, BB6, 
BB7, BB8 
6.5 eq. 81 -20 0 
B BB3 10 eq. 125 -40 -20 
 
Glycosylation cycle: 
DCM (2 mL) is added to the resin and the temperature is set to the activation temperature T1-
2 K. While cooling down, the building block solution is delivered to the reaction vessel. After 
the set temperature has stabilized at T1 - 2 K, the reaction is started by adding 1 mL of 
activator solution. The mixture is kept at T1 for 5 minutes before a second 20 minute incubation 
cycle is started during which the temperature is raised to a temperature T2. Upon completion 
Action Cycles Reagent Amount T(oC) Incubation Time 
Cooling - - - -20 - 
Deliver 2 DCM 2 mL -20 - 
Deliver TMSOTf 1 mL -20 1.5 min 
Wash DCM 2 mL -20 25 s 
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of the incubation cycle the reaction mixture is drained and the resin is washed once each with 
DCM/Dioxane 1:1 (2 mL) and DCM (2mL). The module finishes by raising the temperature to 
25 °C while performing two additional DCM washes (2 mL). 
Action Cycles Solution Amount T(oC) Incubation Time 
Cooling - - - T1 - 2 - 
Deliver 2  
 




Incubation    T1 5 min 
Incubation    T2 20 min 
Wash 1 DCM:Dioxane 
1:1 
2mL T2 25 s 
Wash 1 DCM 2mL 0 25 s 
Heating - - - 25 - 
Wash 2 DCM 2mL 25 25 s 
 
 
Module D: Capping  
The resin is washed with DMF (2x, 25 s) and the temperature of the reaction vessel was set 
to 25 °C. 2 mL of 10 % Pyridine in DMF is delivered into the reaction vessel. After 1 min, the 
solution is drained and the resin is washed with DCM (3x, 2 mL, 25 s). Then, 4 mL of capping 
solution is delivered into the reaction vessel and incubated for 20 mins under Argon bubbling. 
The cycle concludes by draining the reaction mixture washing the resin with DCM (3x, 2mL, 
25 s).  
 
Module E: FMOC Deprotection 
The resin is washed with DMF (3x, 2 mL, 25s) and the temperature of the reaction vessel is 
adjusted to 25 °C. 2 mL of FMOC deprotection solution is delivered into the reaction vessel. 
After 5 mins, the solution was drained through the UV-sensor and the resin is washed with 
DMF (3x, 2 mL) and DCM (5x, 2mL, 60 s each). The temperature of the reaction vessel was 
decreased to -20 °C in preparation of the next cycle.  
Action Cycles Solution Amount T(oC) Incubation Time 
Heating - - - 25  
Wash 2 DMF 2 mL 25 25s 
Deliver 1 10% Py in 
DMF 
2 mL 25 1 min 
Wash 3 DCM 2 mL 25 25s 
Deliver 1 Capping 
Solution 
4 mL 25 20 mins 




8.7    General procedure for post automation steps 
 
8.7.1   Photo-induced cleavage of the product from the solid support 
The sample (resin loaded with target oligosaccharide) was taken up in 20 mL DCM (stabilized 
with amylene, HPLC grade) and injected into the reactor (Wavelength = 300 nm) at the rate 
of 2.0 mL/min. When all of the resin was inside the reactor, it was allowed to incubate inside 
the reactor for ~ 20 mins. After this, fresh DCM (20 mL) was injected to retrieve the 
photocleaved resin. The filtrate so obtained was concentrated in-vacuo and subjected to 
HPLC analysis and purification.  
 
8.7.2   Quantification of 1st building block  
The building block was co-evaporated with Toluene (~ 5 mL, 3x) and dried under high vacuum 
for ~ 2 hours. It was then dissolved in DCM (anhydrous) (2mL) and put in the BB vials. The 
photoresin was then added into the reaction vessel of the Glyconeer, and the synthetic 
modules were programmed as follows: Initial resin swelling            Thioglycoside Glycosylation 
Ac2O capping       FMOC deprotection. The discharge solution upon FMOC cleavage was 
collected in the fraction collector, and pooled into 100 mL volumetric flask. The tubes were 
washed down with ACN several times, and added into the volumetric flask. Then, the volume 
was made upto 100 mL with ACN. The reference solution was prepared in the same way, 
without addition of the resin. Then, 2ml of this solution was taken in a 25 mL volumetric flask, 
and diluted with ACN to make up the volume to 25 mL. This solution was then subjected to 






Action Cycles Solution Amount T(oC) Incubation Time 
Heating - - - 25  
Wash 3 DMF 2 mL 25 25 s 
Deliver 1 FMOC Deprotection Solution 2 mL 25 5 mins 
Wash 1 DMF 2 mL   
Cooling - - - -20 - 
Wash 3 DMF 2 mL  25 s 
Wash 5 DCM 2 mL  25  
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8.8 General procedure for global deprotection of glycans 
8.8.1   Global deprotection of Lewisx 
The starting material (protected Lewisx epitope structure) was dissolved in DCM/MeOH 1:1 
and 0.1 mL NaOMe in MeOH (0.5M) was added into it via a syringe. The reaction was then 
allowed to stir at room temperature overnight. Thereafter, the reaction mixture was analysed 
using MALDI to monitor the progress of reaction. Then, the crude mixture was neutralized 
using amberlite resin till PH reached 7. The filtrate thus obtained was concentrated, and 
subjected to hydrogenation.  The debenzoylated crude sample was dissolved in EtOAc/t-
BuOH/H2O 2:1:1 (4 mL). Then Pd(OH)2 on C (10%) was added into it, and H2 (1 atm)was 
purged through the reaction mixture for ~ 10 mins. Then, two H2 balloons were attached to the 
septum, and the reaction mixture was allowed to stir at r.t for 24 hours. Then, the reaction 
mixture was added to a filter syringe attached to a syringe filter. The catalyst was then washed 
with EA (2x), t-BuOH (2x) and finally with H2O (6-8x). The filtrate so obtained was concentrated 
and analysed by MALDI and HPLC.   
 
8.8.2    Global deprotection of PNAG oligomers 
 The crude samples (PNAG tetramer, pentamer and hexamer) were dissolved in EtOAc/t-
BuOH/H2O 2:1:1 (4 mL). Then Pd on C (10%) was added into it, and H2 (1 atm) was purged 
through the reaction mixture for ~ 10 mins. Then, two H2 balloons were attached to the septum, 
and the reaction mixture was allowed to stir at r.t for 24 hours. Then, the reaction mixture was 
added to a filter syringe attached to a syringe filter. The catalyst was then washed with EA 
(2x), t-BuOH (2x) and finally with H2O (6-8x).  The filtrate so obtained was concentrated and 













8.9   Analytical Data for target glycans 
 






1H NMR (600 MHz, Chloroform-d) δ 7.96 – 7.93 (m, 1H), 7.60 – 7.56 (m, 1H), 7.44 (t, J = 7.8 
Hz, 1H), 7.41 – 7.27 (m, 14H), 7.26 – 7.20 (m, 3H), 5.18 – 5.16 (m, 1H, H-1’’), 4.75 (d, J = 2.6 
Hz, 1H), 4.72 (dd, J = 4.9, 1.6 Hz, 2H), 4.69 (d, J = 7.7 Hz, 1H, H-1), 4.67 (d, J = 7.9 Hz, 1H, 
H-1’), 4.45 (d, J = 12.2 Hz, 1H), 4.40 (q, J = 11.8 Hz, 1H), 4.28 (d, J = 11.4 Hz, 1H), 4.07 (t, J 
= 8.2 Hz, 1H), 4.01 (dd, J = 10.2, 3.7 Hz, 1H), 3.90 (dd, J = 10.2, 2.8 Hz, 1H), 3.83 (dd, J = 
10.9, 3.2 Hz, 1H), 3.74 – 3.68 (m, 2H), 3.68 – 3.64 (m, 1H), 3.60 (dd, J = 10.1, 3.5 Hz, 1H), 
3.43 (d, J = 2.8 Hz, 1H), 3.12 (q, J = 6.9 Hz, 1H), 2.05 (s, 1H), 1.46 (dp, J = 30.2, 7.0, 6.6 Hz, 
2H), 1.28 – 1.23 (m, 2H). 
HRMS (ESI-QTOF): calcd for  C82H89Cl3N2O18  [M+Na]+: 1517.5176 Found: 1517.5109 
NMR in agreement with Literature27 






1H NMR (600 MHz, Chloroform-d) δ 7.94 (dd, J = 19.9, 7.7 Hz, 6H), 7.35 – 7.28 (m, 18H), 
7.24 – 7.16 (m, 7H), 5.14 (d, J = 3.6 Hz, 1H), 5.05 (d, J = 8.4 Hz, 5H), 4.90 (d, J = 11.1 Hz, 
1H), 4.78 – 4.72 (m, 3H), 4.35 – 4.25 (m, 7H), 4.21 – 4.16 (m, 2H), 4.09 – 3.98 (m, 3H), 3.92 
– 3.86 (m, 2H), 3.79 (ddd, J = 10.2, 7.5, 2.5 Hz, 2H), 3.76 – 3.64 (m, 4H), 3.54 (ddd, J = 22.2, 
10.9, 6.4 Hz, 4H), 3.44 (td, J = 13.3, 9.2 Hz, 2H), 3.34 (ddd, J = 21.7, 9.0, 5.0 Hz, 2H), 3.16 
(d, J = 14.8 Hz, 2H), 2.86 (d, J = 12.0 Hz, 5H), 2.35 (t, J = 7.8 Hz, 1H), 2.23 (t, J = 7.8 Hz, 1H), 
1.17 – 1.02 (m, 4H). 
HRMS (ESI-QTOF): calcd for C163H171Cl3N2O33    [M+2Na]2+= 1417.5307 Found: 1417.5304 
NMR in agreement with Literature27 
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1H NMR (600 MHz, Chloroform-d) δ 7.99 – 7.96 (m, 1H), 7.44 – 7.37 (m, 4H), 7.37 – 7.25 
(m, 18H), 7.24 – 7.12 (m, 8H), 5.19 (d, J = 3.5 Hz, 1H), 5.10 (d, J = 3.9 Hz, 1H), 4.92 (dd, J = 
11.5, 2.6 Hz, 1H), 4.75 – 4.68 (m, 2H), 4.66 – 4.62 (m, 1H), 4.61 – 4.57 (m, 3H), 4.53 – 4.49 
(m, 2H), 4.37 (d, J = 7.1 Hz, 1H), 4.24 – 4.20 (m, 1H), 4.06 (t, J = 3.6 Hz, 1H), 4.01 – 3.95 (m, 
2H), 3.89 (q, J = 6.5 Hz, 1H), 3.83 (dt, J = 10.0, 3.8 Hz, 2H), 3.77 (dd, J = 9.9, 6.1 Hz, 1H), 
3.58 (d, J = 3.0 Hz, 1H), 3.30 (dtd, J = 9.6, 6.8, 3.8 Hz, 1H), 3.26 – 3.17 (m, 1H), 3.13 – 3.06 
(m, 1H), 2.23 (td, J = 7.7, 2.6 Hz, 1H), 2.11 – 2.02 (m, 1H), 1.82 (dddd, J = 19.6, 16.2, 12.4, 
7.6 Hz, 1H), 1.72 – 1.60 (m, 4H), 1.58 – 1.43 (m, 2H), 1.38 – 1.27 (m, 1H), 1.08 (d, J = 6.4 Hz, 
2H). 
HRMS (ESI-QTOF): calcd for C89H93Cl3N2O19 [M+Na]+= 1621.5438 Found: 1621.5266 
 






1H NMR (600 MHz, Deuterium Oxide) δ 7.46 – 7.37 (m, 3H), 5.83 (d, J = 8.7 Hz, 1H), 4.59 – 
4.48 (m, 4H), 4.24 – 4.10 (m, 5H), 3.94 (dd, J = 12.1, 8.0 Hz, 3H), 3.80 – 3.72 (m, 5H), 3.71 
(q, J = 5.1, 4.1 Hz, 2H), 3.68 – 3.53 (m, 9H), 3.47 (d, J = 5.0 Hz, 3H), 3.48 – 3.37 (m, 3H), 
3.01 (q, J = 7.7 Hz, 4H), 2.12 (s, 13H), 2.09 (d, J = 5.4 Hz, 2H), 2.06 (dd, J = 12.1, 4.8 Hz, 






8.9.5   PNAG 








1H NMR (600 MHz, Deuterium Oxide) δ 4.60 – 4.50 (m, 6H), 4.27 – 4.17 (m, 8H), 3.97 (d, J 
= 12.1 Hz, 2H), 3.90 (tt, J = 12.6, 6.5 Hz, 2H), 3.84 – 3.72 (m, 12H), 3.03 (td, J = 8.3, 7.9, 2.8 
Hz, 5H), 2.11 – 2.03 (m, 20H), 1.76 – 1.67 (m, 6H), 1.62 (q, J = 7.6 Hz, 5H), 1.45 (dt, J = 15.1, 








1H NMR (600 MHz, Chloroform-d) δ 7.40 – 7.26 (m, 14H), 7.24 – 7.13 (m, 4H), 5.06 (s, 2H), 
5.03 (dd, J = 9.8, 8.8 Hz, 1H), 4.98 (d, J = 8.1 Hz, 1H, H-1), 4.73 (d, J = 7.7 Hz, 1H, H-1’), 4.64 
(d, J = 11.1 Hz, 1H), 4.55 (d, J = 11.1 Hz, 1H), 4.52 – 4.50 (m, 6H), 4.31 (dd, J = 10.3, 8.9 Hz, 
1H), 3.88 (dt, J = 9.6, 6.1 Hz, 1H), 3.64 (ddd, J = 9.6, 5.1, 4.0 Hz, 1H), 3.58 – 3.54 (m, 2H), 
3.48 (dt, J = 9.4, 6.4 Hz, 1H), 3.41 (dt, J = 10.4, 7.7 Hz, 1H), 3.15 (qq, J = 13.3, 6.4 Hz, 3H), 
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